<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>LipiFlow for the treatment of dry eye disease - Pucker, AD - 2024 | Cochrane Library</title> <meta content="LipiFlow for the treatment of dry eye disease - Pucker, AD - 2024 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015448.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="LipiFlow for the treatment of dry eye disease - Pucker, AD - 2024 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015448.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD015448.pub2" name="dc.identifier" scheme="DOI"/> <meta content="LipiFlow for the treatment of dry eye disease" name="citation_title"/> <meta content="Andrew D Pucker&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Lexitas Pharma Services" name="citation_author_institution"/> <meta content="andrewpucker@hotmail.com" name="citation_author_email"/> <meta content="Tsz Wing Yim&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Colorado Anschutz Medical Campus" name="citation_author_institution"/> <meta content="Erin Rueff" name="citation_author"/> <meta content="Marshall B. Ketchum University" name="citation_author_institution"/> <meta content="William Ngo" name="citation_author"/> <meta content="University of Waterloo" name="citation_author_institution"/> <meta content="Anna A Tichenor" name="citation_author"/> <meta content="Indiana University School of Optometry" name="citation_author_institution"/> <meta content="John E Conto" name="citation_author"/> <meta content="Medical College of Wisconsin" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD015448.pub2" name="citation_doi"/> <meta content="2024" name="citation_date"/> <meta content="2024/02/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015448.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015448.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015448.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Dry Eye Syndromes [therapy]; Hyperthermia, Induced [instrumentation, methods]; Meibomian Gland Dysfunction [therapy]; *Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015448.pub2&amp;doi=10.1002/14651858.CD015448.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015448.pub2&amp;doi=10.1002/14651858.CD015448.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015448.pub2&amp;doi=10.1002/14651858.CD015448.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015448.pub2&amp;doi=10.1002/14651858.CD015448.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015448.pub2&amp;doi=10.1002/14651858.CD015448.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015448.pub2&amp;doi=10.1002/14651858.CD015448.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015448.pub2&amp;doi=10.1002/14651858.CD015448.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015448.pub2&amp;doi=10.1002/14651858.CD015448.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015448.pub2&amp;doi=10.1002/14651858.CD015448.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015448.pub2&amp;doi=10.1002/14651858.CD015448.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015448.pub2&amp;doi=10.1002/14651858.CD015448.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015448.pub2&amp;doi=10.1002/14651858.CD015448.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015448.pub2&amp;doi=10.1002/14651858.CD015448.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015448.pub2&amp;doi=10.1002/14651858.CD015448.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015448.pub2&amp;doi=10.1002/14651858.CD015448.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015448.pub2&amp;doi=10.1002/14651858.CD015448.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015448.pub2&amp;doi=10.1002/14651858.CD015448.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015448.pub2&amp;doi=10.1002/14651858.CD015448.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015448.pub2&amp;doi=10.1002/14651858.CD015448.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015448.pub2&amp;doi=10.1002/14651858.CD015448.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015448.pub2&amp;doi=10.1002/14651858.CD015448.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015448.pub2&amp;doi=10.1002/14651858.CD015448.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015448.pub2&amp;doi=10.1002/14651858.CD015448.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="EBp84H4P";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD015448\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD015448\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015448\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015448\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","ko","ms","hr","fr","zh_HANS","zh_HANT","th","fa","pl","ro"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD015448.pub2",title:"LipiFlow for the treatment of dry eye disease",firstPublishedDate:"Feb 5, 2024 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=EBp84H4P&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015448.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015448.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD015448.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD015448.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015448.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD015448.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ro&quot;,&quot;title&quot;:&quot;Sumar&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;riskOfBias2&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of Bias&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD015448.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD015448.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD015448.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD015448.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1260 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD015448.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/full#CD015448-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/full#CD015448-sec-0130"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/full#CD015448-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/full#CD015448-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/full#CD015448-sec-0017"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/full#CD015448-sec-0018"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/full#CD015448-sec-0042"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/full#CD015448-sec-0124"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/appendices#CD015448-sec-0137"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#riskOfBias2"> Risk of bias </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/supinfo/CD015448-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/supinfo/CD015448-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2024 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">LipiFlow for the treatment of dry eye disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="These authors should be considered joint first author"><a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/information#CD015448-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Andrew D Pucker</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors should be considered joint first author"><a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/information#CD015448-cr-0005">Tsz Wing Yim</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/information#CD015448-cr-0006">Erin Rueff</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/information#CD015448-cr-0007">William Ngo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/information#CD015448-cr-0008">Anna A Tichenor</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015448.pub2/information#CD015448-cr-0009">John E Conto</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/information/en#CD015448-sec-0147">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 February 2024 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD015448.pub2">https://doi.org/10.1002/14651858.CD015448.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD015448-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015448-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD015448-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015448-abs-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015448-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD015448-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD015448-abs-0016">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015448-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD015448-abs-0001" lang="en"> <section id="CD015448-sec-0001"> <h3 class="title" id="CD015448-sec-0001">Background</h3> <p>Meibomian gland dysfunction (MGD) is the most common underlying cause of dry eye disease (DED). MGD leads to pathological alteration of the composition or quantity of meibum, or both, which subsequently results in tear evaporation and the typical signs and symptoms associated with DED. The LipiFlow Thermal Pulsation System (LipiFlow) is a medical device used to treat MGD in office; however, it is unclear if LipiFlow can outperform other DED treatments. </p> </section> <section id="CD015448-sec-0002"> <h3 class="title" id="CD015448-sec-0002">Objectives</h3> <p>To evaluate the effectiveness of LipiFlow for treating DED signs and symptoms and the safety of LipiFlow compared with sham or other available treatments for MGD in adults. </p> </section> <section id="CD015448-sec-0003"> <h3 class="title" id="CD015448-sec-0003">Search methods</h3> <p>The Cochrane Eyes and Vision Information Specialist searched the electronic databases for randomized controlled trials. There were no restrictions on language or date of publication. We searched the Cochrane Central Register of Controlled Trials (CENTRAL, including the Cochrane Eyes and Vision Trials Register; 2022, Issue 6), MEDLINE Ovid, Embase.com, PubMed, LILACS (Latin American and Caribbean Health Science Information database), ClinicalTrials.gov, and World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) electronic databases. We also examined the reference lists of identified trials, review articles, and guidelines for information about relevant trials that may not have been identified by our search strategy. We contacted investigators regarding ongoing trials. The last database search was performed on 24 October 2022. </p> </section> <section id="CD015448-sec-0004"> <h3 class="title" id="CD015448-sec-0004">Selection criteria</h3> <p>We included studies conducted in adults (over 18 years of age) with DED or MGD as defined by the primary trial investigators. We imposed no restrictions on race, ethnicity, or sex. We considered trials involving contact lens wearers if they were equally represented between groups. </p> </section> <section id="CD015448-sec-0005"> <h3 class="title" id="CD015448-sec-0005">Data collection and analysis</h3> <p>We applied standard Cochrane methodology.</p> </section> <section id="CD015448-sec-0006"> <h3 class="title" id="CD015448-sec-0006">Main results</h3> <p>We included 13 trials that randomized a total of 1155 participants (28 to 236 participants randomized per study). Six trials were conducted in the USA, three in China, two in Thailand, one in France, and one in Italy. Eight trials were of single‐center design, while four trials were of multicenter design; one trial did not report the number of participating centers. </p> <p><b>Study characteristics</b> </p> <p>The study population of the included trials was 66% female (range 48% to 80%), with an age range of 19 to 86 years. LipiFlow, used as a stand‐alone intervention, was compared with basic warm compresses in five studies, thermostatic device in five studies, oral intervention in one trial, and topical dry eye medications in one trial. LipiFlow was also evaluated together with eyelid hygiene product versus eyelid hygiene products alone in one trial. </p> <p><b>Findings</b> </p> <p>Five trials compared LipiFlow with a basic warm compress applied for varying durations and frequencies during the trial period; only one of these trials combined a warm compress with eyelid massage. Analyzing symptom scores by different questionnaires (Ocular Surface Disease Index [OSDI] and Standard Patient Evaluation of Eye Dryness [SPEED]) yielded conflicting evidence of a difference in symptoms between LipiFlow and basic warm compresses after four weeks. There was no evidence of a difference in meibomian gland expression, meibum quality, or tear breakup time when comparing LipiFlow with basic warm compresses. Another five trials compared LipiFlow with thermostatic devices. Analysis of symptom scores at four weeks showed that thermostatic devices had reduced OSDI scores by a mean difference (MD) of 4.59 (95% confidence interval [CI] 1.23 to 7.95; I<sup>2</sup> = 0, P = 0.007; 553 participants; very low certainty evidence) as compared with LipiFlow. When we compared LipiFlow plus eyelid hygiene with eyelid hygiene alone, there was no evidence of difference in signs or symptoms at any time point evaluated. </p> <p>Only one trial compared LipiFlow with a topical DED medication (lifitegrast 5%). The single‐trial estimate suggested that 5% lifitegrast may increase meibomian gland expression scores compared with LipiFlow at day 42 (MD −1.21, 95% CI −2.37 to −0.05; 50 participants; low certainty evidence) by using a meibomian gland expression scale of 0 to 8. One trial compared LipiFlow with an oral intervention (doxycycline), finding that LipiFlow may result in significantly better SPEED scores than doxycycline at three months (MD −4.00, 95% CI −7.33 to −0.67; 24 participants; very low certainty evidence). No other significant differences in signs or symptoms were found between LipiFlow and doxycycline at three months. We did not find any other statistically significant differences in symptoms or signs for any other analysis performed in this review at the one‐ to four‐week time point. </p> <p><b>Adverse events</b> </p> <p>No trial reported any intervention‐related, vision‐threatening adverse events.</p> </section> <section id="CD015448-sec-0007"> <h3 class="title" id="CD015448-sec-0007">Authors' conclusions</h3> <p>LipiFlow performs similarly to other commonly used DED treatments with regard to DED signs and symptoms. The best available evidence was deemed to have a high level of bias, leading to low or very low certainty evidence. Additional research with adequate masking, a standardized testing methodology, and a sample representative of the MGD population is therefore needed before any firm conclusions can be drawn regarding comparative benefits and harms. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD015448-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015448-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD015448-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD015448-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015448-abs-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015448-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD015448-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD015448-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD015448-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD015448-abs-0020">Polski</a> </li> <li class="section-language"> <a class="" href="full/ro#CD015448-abs-0021">Română</a> </li> <li class="section-language"> <a class="" href="full/ru#CD015448-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD015448-abs-0017">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015448-abs-0014">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD015448-abs-0015">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD015448-abs-0002" lang="en"> <h3>Is LipiFlow more effective than other dry eye disease treatments?</h3> <p><b>Key messages</b> </p> <p>• LipiFlow performs similarly to other commonly used DED treatments with regard to DED signs and symptoms, but the evidence is very uncertain. </p> <p>• LipiFlow did not appear to cause any adverse events.</p> <p><b>What is dry eye disease?</b> </p> <p>Dry eye disease is a common condition with several risk factors, including patient age, sex, race, hormonal imbalances, digital device use, and meibomian gland dysfunction. Meibomian gland dysfunction is the primary cause of dry eye disease. Meibomian glands in the eyelids, when functioning normally, secrete oil that promotes stable tears on the surface of the eye. When meibomian glands are not functioning properly because they have become clogged or inflamed, the result is dry eye symptoms (e.g. burning, stinging, watering) and signs (e.g. eye surface damage, redness). </p> <p><b>What is LipiFlow?</b> </p> <p>The LipiFlow Thermal Pulsation System is a medical device that provides controlled, repeatable, heated compression to the eyelids and meibomian glands with the aim of resulting in expression and unclogging of the meibomian glands. LipiFlow is primarily intended for treating people who have meibomian gland dysfunction and not other forms of dry eye disease. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out if LipiFlow is as effective or more effective than other common dry eye disease treatments. We also wanted to find out if LipiFlow is safe and if it causes any unwanted side effects. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that investigated LipiFlow compared to other common dry eye disease treatments (e.g. warm compresses, thermostatic devices, eyelid hygiene product, topical medications, oral interventions) and looked at how patient‐reported symptoms (e.g. eye dryness) and signs (e.g. meibomian gland function, tear breakup time) differed between LipiFlow and other treatments. We analyzed and summarized the results of the trials and rated our confidence in the evidence. </p> <p><b>What did we find?</b> </p> <p>We found 13 trials with a total of 1155 participants (1720 eyes) with dry eye disease.</p> <p>When comparing LipiFlow to basic warm compresses, eyelid hygiene products, or dry eye disease medications, there was no clear evidence of a difference in improvement in symptom scores obtained using questionnaires or in signs by eye surface tests. Thermostatic devices decreased symptom scores compared with LipiFlow based on one questionnaire, but this result was not found with other questionnaires. LipiFlow may improve symptom scores based on one questionnaire compared with oral intervention. </p> <p>We found no evidence that LipiFlow is unsafe or causes any unwanted side effects.</p> <p><b>What are the limitations of the evidence?</b> </p> <p>Our confidence in the evidence is low to very low because the people in the trials were aware of the treatment they were receiving, which may have influenced their symptoms responses, and because of differences across the included studies, including in testing regimens. This uncertainty in the evidence makes it challenging to evaluate the advantages and disadvantages of LipiFlow compared with other treatments. Limitations related to lack of masking of participants could be addressed in future trials by including a control group who undergoes a sham LipiFlow treatment without thermal pulsation. </p> <p><b>How up‐to‐date is the evidence?</b> </p> <p>The evidence is current to October 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD015448-sec-0130" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD015448-sec-0130"></div> <h3 class="title" id="CD015448-sec-0131">Implications for practice</h3> <section id="CD015448-sec-0131"> <p>This systemic review reveals that the current clinical trial evidence regarding the comparative effectiveness and safety of LipiFlow for treating meibomian gland dysfunction (MGD) and dry eye disease (DED) of other etiologies is limited and inconclusive. However, the available data suggest that LipiFlow performs similarly to other commonly used DED treatments with regard to DED signs and symptoms. Of the trials reviewed, estimates of outcomes relating to symptoms, meibum expression score, quality of meibum, and meibomian gland atrophy provided evidence of very low to low certainty. Given the nature of the LipiFlow thermopulsation device, a major shortcoming was the failure to mask both the examiner and the participant to the assigned treatment. Additionally, due to a lack of comprehensive reporting of adverse events, the safety profile of LipiFlow in people with MGD remains unclear, although none of the trials reported sight‐threatening complications relating to the procedure. At the time of this review, no included trials had reported long‐term effects of LipiFlow beyond one year. </p> <p>Comparative trials between LipiFlow and other established treatments for MGD, such as topical and systemic medications, other thermal devices, and radio frequency, are still lacking in number and quality. We assessed the evidence from trials that compared LipiFlow to thermostatic devices, eyelid hygiene products, and topical DED medication as of very low to low certainty. More double‐masked comparative clinical trials are needed to determine how LipiFlow compares in terms of effectiveness and safety with other treatment modalities. Double‐masked trials with LipiFlow could be accomplished by including a control group who undergoes a sham LipiFlow treatment without thermal pulsation. This treatment would have to be administered by an investigator who was not involved in evaluating trial outcomes. </p> <p>The limited research on LipiFlow creates uncertainty for practitioners in advising patients on expectations of outcomes and adverse effects. Without stronger evidence, providers may find it difficult to determine whether and when to recommend thermopulsation as a first‐line or adjunctive treatment for MGD, especially given that LipiFlow often results in a high cost to the patient. The weaknesses of the few comparative trials against traditional treatments further increase the challenge of providing evidence‐based guidance regarding the benefits and risks of LipiFlow against other current therapeutic options. </p> </section> <h3 class="title" id="CD015448-sec-0132">Implications for research</h3> <section id="CD015448-sec-0132"> <p>Further research is needed to establish the effectiveness and safety of LipiFlow as a single therapy and in combination with other current and evolving therapeutic modalities. The mechanism of action for how LipiFlow affects MGD also requires more investigation. </p> <p>The current systematic review identified several issues with the existing randomized controlled trials, including sample sizes and trial design limitations, such as the lack of double‐masked comparisons, that may have introduced bias. While most studies recorded age and sex, only four trials recorded race (<a href="./references#CD015448-bbs2-0003" title="GuptaPK , HollandEJ , HovanesianJ , LohJ , JacksonMA , KarpeckiPM , et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea2022;41(4):417‐26. ">Gupta 2022</a>; <a href="./references#CD015448-bbs2-0006" title="BloomensteinM , LohJ , DhamdhereK . Effectiveness of TearCare system in improvement dry eye disease symptoms in meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2022;63(7):1567-A0292. HollandEJ , LohJ , BloomensteinM , ThompsonV , WirtaD , DhamdhereK . A comparison of TearCare and Lipiflow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clinical Ophthalmology (Auckland, NZ)2022;16:2861‐71. NCT03857919. TearCare system to treat dry eye disease. clinicaltrials.gov/show/NCT03857919 (first received 28 February 2019). ">Holland 2022</a>; <a href="./references#CD015448-bbs2-0012" title="TauberJ . A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction. Cornea2020;39(4):403‐7. ">Tauber 2020b</a>; <a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a>). Expanding the diversity of trial populations enrolled in all future studies is important to determine efficacy among different patient subgroups, especially given that Asian individuals have a higher risk of developing DED than people of other ancestry. </p> <p>Further study of the impact LipiFlow and other treatments may have on the progression of DED is also required. None of the trials included in this review reported on this outcome. Six ongoing trials may address some of the shortcomings of the reviewed trials. Additionally, independence from funders in the design, conduct, and reporting of trials is desirable; we noted that several of the included trials were supported by industry or had investigators with financial interest (<a href="./references#CD015448-bbs2-0003" title="GuptaPK , HollandEJ , HovanesianJ , LohJ , JacksonMA , KarpeckiPM , et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea2022;41(4):417‐26. ">Gupta 2022</a>; <a href="./references#CD015448-bbs2-0006" title="BloomensteinM , LohJ , DhamdhereK . Effectiveness of TearCare system in improvement dry eye disease symptoms in meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2022;63(7):1567-A0292. HollandEJ , LohJ , BloomensteinM , ThompsonV , WirtaD , DhamdhereK . A comparison of TearCare and Lipiflow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clinical Ophthalmology (Auckland, NZ)2022;16:2861‐71. NCT03857919. TearCare system to treat dry eye disease. clinicaltrials.gov/show/NCT03857919 (first received 28 February 2019). ">Holland 2022</a>; <a href="./references#CD015448-bbs2-0011" title="NCT03055832. Comparison Between iLux™ and LipiFlow® in the treatment of meibomian gland dysfunction. clinicaltrials.gov/show/NCT03055832 (first received 16 February 2017). TauberJ , OwenJ , BloomensteinM , HovanesianJ , BullimoreMA . Comparison of the iLUX and the LipiFlow for the treatment of meibomian gland dysfunction and symptoms: a randomized clinical trial. Clinical Ophthalmology (Auckland, NZ)2020;14:405‐18. ">Tauber 2020a</a>; <a href="./references#CD015448-bbs2-0012" title="TauberJ . A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction. Cornea2020;39(4):403‐7. ">Tauber 2020b</a>; <a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a>). Of these, the two largest cohorts, <a href="./references#CD015448-bbs2-0006" title="BloomensteinM , LohJ , DhamdhereK . Effectiveness of TearCare system in improvement dry eye disease symptoms in meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2022;63(7):1567-A0292. HollandEJ , LohJ , BloomensteinM , ThompsonV , WirtaD , DhamdhereK . A comparison of TearCare and Lipiflow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clinical Ophthalmology (Auckland, NZ)2022;16:2861‐71. NCT03857919. TearCare system to treat dry eye disease. clinicaltrials.gov/show/NCT03857919 (first received 28 February 2019). ">Holland 2022</a> (235 participants) and <a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a> (236 participants), were industry‐sponsored. Another consideration for future research is the development of centers to participate in multicenter trials. Most of the trials in this review were conducted at single sites, a design that reduces the diversity of trial populations and external validity of findings, as promoted by best‐practice guidelines. </p> <p>Trial durations of one year or longer would be beneficial to determine the proper intervention period and to investigate any cumulative effects of LipiFlow treatment. Only 5 of the 13 included trials reported findings longer than 6 months, and a single trial reported at 12 months (<a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a>). </p> <p>As other systematic reviews have discussed with DED treatments, standardization of data collection and outcome sets is critical to enable more accurate analysis and conclusions regarding the efficacy and safety of newer DED interventions. This can be partially accomplished by having future trials include the common MGD outcomes analyzed in this study in addition to any other novel outcomes such as lipid layer thickness, which could also be considered in future reviews if these metrics become standard of care across clinical practice. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD015448-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD015448-sec-0008"></div> <div class="table" id="CD015448-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">LipiFlow compared with basic warm compresses</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>LipiFlow compared with basic warm compresses for dry eye disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with dry eye </p> <p><b>Settings:</b> hospitals or eye clinic </p> <p><b>Intervention:</b> LipiFlow </p> <p><b>Comparison:</b> local eyelid manipulation (EyeGiene, MeiboPatch, warm compresses, warm compresses with eyelid massages) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Local eyelid manipulation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>LipiFlow</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mean change from baseline in symptom scores at 1 to 4 weeks</b> </p> <p>(lower is favored)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>OSDI questionnaire</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mean change in symptom scores in LipiFlow groups was on average 16.62 (29.41 to 3.83) lower than in the basic warm compresses groups at week 4. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD −16.62</b> </p> <p>(−29.41 to −3.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 eyes/30 participants</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015448-bbs2-0005" title="HeJZ , ZhongM . Comparative study between the meibomian pulsation system and the warm compress treatment for MGD. International Eye Science2018;18(7):1324‐8. ">He 2018</a> (90 eyes in 45 participants) reported this outcome at the eye level, with an MD of −0.43 (95% CI −2.39 to 1.53) at week 4. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>SPEED questionnaire</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mean change in symptom scores in LipiFlow groups was on average 2.12 (4.09 to 0.14) lower than in the basic warm compresses groups at week 4. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD −2.12</b> </p> <p>(−4.09 to −0.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 eyes/76 participants</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015448-bbs2-0002" title="BooranapongW , PrabhasawatP , ChotikavanichS , TongsaiS , NaranunnP , ThaweerattanasilpW , et al. Comparison of an automated thermodynamic treatment system (LipiFlow) and warm compresses for the treatment of moderate severity of meibomian gland dysfunction. Siriraj Medical Journal2019;72(1):79-86. TCTR20170905001. Comparison of an automated thermodynamic treatment system (LipiFlow®) and eyelid warm compress for the treatment of meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20170905001 (first received 05 September 2017). ">Booranapong 2019</a> (56 eyes in 56 participants; paired‐eye design) and <a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a> (100 eyes in 50 participants) reported this outcome at the eye level, with an MD of −0.12 (95% CI −0.21 to −0.03) at week 4. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change from baseline in meibomian gland expression scores at 1 to 4 weeks</b> </p> <p>(higher is favored)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mean change in meibomian gland expression scores in LipiFlow groups was on average 1.31 SMD (−0.21 to 2.83) higher than in the basic warm compresses groups at week 4. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD 1.31</b> </p> <p>(−0.21 to 2.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 eyes/76 participants</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015448-bbs2-0005" title="HeJZ , ZhongM . Comparative study between the meibomian pulsation system and the warm compress treatment for MGD. International Eye Science2018;18(7):1324‐8. ">He 2018</a> (90 eyes in 45 participants), <a href="./references#CD015448-bbs2-0002" title="BooranapongW , PrabhasawatP , ChotikavanichS , TongsaiS , NaranunnP , ThaweerattanasilpW , et al. Comparison of an automated thermodynamic treatment system (LipiFlow) and warm compresses for the treatment of moderate severity of meibomian gland dysfunction. Siriraj Medical Journal2019;72(1):79-86. TCTR20170905001. Comparison of an automated thermodynamic treatment system (LipiFlow®) and eyelid warm compress for the treatment of meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20170905001 (first received 05 September 2017). ">Booranapong 2019</a> (56 eyes in 56 participants; paired‐eye design), and <a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a> (100 eyes in 50 participants) reported this outcome at the eye level, with an SMD of 0.17 (95% CI −0.08 to 0.42) at week 4. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change from baseline in meibum quality scores at 1 to 4 weeks</b> </p> <p>(higher is favored)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mean change in meibum quality scores in LipiFlow groups was on average 0.65 SMD (1.25 to 0.06) lower than in the basic warm compresses groups at week 4. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD −0.65</b> </p> <p>(−1.25 to −0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 eyes/46 participants</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a> (100 eyes in 50 participants) reported this outcome at the eye level, with an SMD of 0.27 (95% CI −0.12 to 0.67) at week 4. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change from baseline in meibomian gland atrophy scores at 1 to 4 weeks</b> </p> <p>(lower is favored)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a> (100 eyes in 50 participants) reported mean change from baseline in meibomian gland atrophy scores at 3 months, with an MD of 0.03 (95% CI −0.02 to 0.08). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with intervention‐related, vision‐threatening adverse events at 1 to 4 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000 at week 4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000 at week 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>197 participants</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean baseline risk from the studies in the meta‐analysis; the total number of events in the control group divided by the total number of participants in the control groups, scaled to 1000. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>MD</b> : mean difference; <b>OSDI</b> : Ocular Surface Disease Index; <b>RCT:</b> randomized controlled trial; <b>SMD</b> : standardized mean difference; <b>SPEED</b>: Standard Patient Evaluation of Eye Dryness </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for inconsistency (−1).<br/><sup>b</sup>Downgraded for risk of bias (−1).<br/><sup>c</sup>Downgraded for imprecision (−1).<br/><sup>d</sup>Downgraded for very serious imprecision (−2). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015448-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">LipiFlow compared with thermostatic devices</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>LipiFlow compared with thermostatic devices for dry eye disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with dry eye </p> <p><b>Settings:</b> hospitals or eye clinics </p> <p><b>Intervention:</b> LipiFlow </p> <p><b>Comparison:</b> thermostatic device (iLux, MiBoFlo, TearCare) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Thermostatic device</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>LipiFlow</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Mean change from baseline in symptom scores at 1 to 4 weeks</b> </p> <p>(lower is favored)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>OSDI questionnaire</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mean change in symptom scores in LipiFlow groups was on average 4.59 (1.23 to 7.95) higher than in the thermostatic device groups at week 4. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 4.59</b> </p> <p>(1.23 to 7.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>553 participants</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>SANDE questionnaire</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mean change in symptom scores in LipiFlow groups was on average 1.22 lower (6.97 lower to 4.54 higher) than in the thermostatic device groups at week 4. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD −1.22</b> </p> <p>(−6.97 to 4.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>370 participants</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>IDEEL‐SB questionnaire</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mean change in symptom scores in LipiFlow group was on average 0.10 higher (0.32 lower to 0.52 higher) than in the thermostatic device group at week 4. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.10</b> </p> <p>(−0.32 to 0.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227 participants</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change from baseline in meibomian gland expression scores at 1 to 4 weeks</b> </p> <p>(higher is favored)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mean change in meibomian gland expression scores in LipiFlow groups was on average 0.02 SMD lower (0.16 lower to 0.11 higher) than in the thermostatic device groups at week 4. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD −0.02</b> </p> <p>(−0.16 to 0.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>820 eyes/410 participants</p> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All included trials reported at the eye level.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change from baseline in meibum quality scores at 1 to 4 weeks</b> </p> <p>(higher is favored)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mean change in meibum quality scores in LipiFlow groups was on average 0.11 SMD higher (0.20 lower to 0.42 higher) than in the thermostatic device groups at week 4. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD 0.11</b> (−0.20 to 0.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>354 eyes/177 participants</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All included trials reported at the eye level.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change from baseline in meibomian gland atrophy scores at 1 to 4 weeks</b> </p> <p>(lower is favored)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015448-bbs2-0008" title="LiS , YangK , WangJ , ZhuL , FengJ , TianL , et al. Effect of a novel thermostatic device on meibomian gland dysfunction: a randomized controlled trial in Chinese patients. Ophthalmology and Therapy2022;11(1):261‐70. NCT04310969. Clinical effect of MiboFlo in dry eye patients. clinicaltrials.gov/show/NCT04310969 (first received 17 March 2020). ">Li 2022</a> (84 eyes) reported mean change from baseline in meibomian gland atrophy scores to 2 months, with an MD of 0.05 (95% CI −0.01 to 0.11) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with intervention‐related, vision‐threatening adverse events at 1 to 4 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000 at week 4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000 at week 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>445 participants</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean baseline risk from the studies in the meta‐analysis; the total number of events in the control group divided by the total number of participants in the control groups, scaled to 1000. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IDEEL‐SB:</b> Impact of Dry Eye on Everyday Life—Symptom Bother; <b>MD:</b> mean difference; <b>OSDI:</b> Ocular Surface Disease Index; <b>RCT:</b> randomized controlled trial; <b>SANDE:</b> Symptom Assessment iN Dry Eye; <b>SMD</b>: standardized mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for inconsistency (−1)<br/><sup>b</sup>Downgraded for risk of bias (−1)<br/><sup>c</sup>Downgraded for high risk of bias (−2)<br/><sup>d</sup>Downgraded for imprecision (−1)<br/><sup>e</sup>Downgraded for very serious imprecision (−2) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD015448-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD015448-sec-0009"></div> <section id="CD015448-sec-0010"> <h3 class="title" id="CD015448-sec-0010">Description of the condition</h3> <section id="CD015448-sec-0011"> <h4 class="title">Description of dry eye disease and meibomian gland dysfunction</h4> <p>Dry eye disease (DED) is a common condition that causes significant discomfort and negatively impacts quality of life (<a href="./references#CD015448-bbs2-0077" title="StapletonF , AlvesM , BunyaVY , JalbertI , LekhanontK , MaletF , et al. TFOS DEWS II epidemiology report. Ocular Surface2017;15(3):334-65.">Stapleton 2017</a>; <a href="./references#CD015448-bbs2-0080" title="UchinoM , SchaumbergDA . Dry eye disease: impact on quality of life and vision. Current Ophthalmology Reports2013;1(2):51-7.">Uchino 2013</a>). DED can result from a lack of tear production (aqueous deficiency DED), excessive tear evaporation (evaporative DED), or a combination of both (<a href="./references#CD015448-bbs2-0081" title="WolffsohnJS , AritaR , ChalmersR , DjalilianA , DogruM , DumbletonK , et al. TFOS DEWS II diagnostic methodology report. Ocular Surface2017;15(3):539-74.">Wolffsohn 2017</a>). Evaporative DED most commonly stems from meibomian gland dysfunction (MGD), and MGD is the most common form of DED, with MGD estimated to be present in over 80% of all people with DED (<a href="./references#CD015448-bbs2-0059" title="LempMA , CrewsLA , BronAJ , FoulksGN , SullivanBD . Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea2012;31(5):472-8.">Lemp 2012</a>). </p> <p>Meibomian glands, situated within the upper and lower eyelid, secrete oils (meibum) through openings at the eyelid margins (<a href="./references#CD015448-bbs2-0051" title="KnopE , KnopN , MillarT , ObataH , SullivanDA . The International Workshop on Meibomian Gland Dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Investigative Ophthalmology and Visual Science2011;52(4):1938-78.">Knop 2011</a>). Meibum mixes with tears to form a thin oil layer on top of the tear film, which functions to prevent evaporation of the aqueous tears while stabilizing the thin spreading of the tear film during blinking (<a href="./references#CD015448-bbs2-0043" title="GeorgievGA , EftimovP , YokoiN . Structure-function relationship of tear film lipid layer: a contemporary perspective. Experimental Eye Research2017;163:17-28.">Georgiev 2017</a>). However, in MGD, the composition and quantity of meibum are pathologically altered, reducing its ability to retard evaporation and stabilize the tear film, resulting in evaporative DED (<a href="./references#CD015448-bbs2-0051" title="KnopE , KnopN , MillarT , ObataH , SullivanDA . The International Workshop on Meibomian Gland Dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Investigative Ophthalmology and Visual Science2011;52(4):1938-78.">Knop 2011</a>). MGD tends to result in chronic ocular symptoms and ocular surface irritation (e.g. corneal staining) that require lifelong treatment. </p> </section> <section id="CD015448-sec-0012"> <h4 class="title">Epidemiology of dry eye disease and meibomian gland dysfunction</h4> <p>Several trials have evaluated the prevalence of DED; a recent meta‐analysis estimated that the prevalence of DED is 8.1% (<a href="./references#CD015448-bbs2-0062" title="McCannP , AbrahamAG , MukhopadhyayA , PanagiotopoulouK , ChenH , RittiphairojT , et al. Prevalence and incidence of dry eye and meibomian gland dysfunction in the United States: a systematic review and meta-analysis. JAMA Ophthalmology2022;140(12):1181-92.">McCann 2022</a>; <a href="./references#CD015448-bbs2-0068" title="PapasEB . The global prevalence of dry eye disease: a Bayesian view. Ophthalmic and Physiological Optics2021;41(6):1254-66.">Papas 2021</a>; <a href="./references#CD015448-bbs2-0077" title="StapletonF , AlvesM , BunyaVY , JalbertI , LekhanontK , MaletF , et al. TFOS DEWS II epidemiology report. Ocular Surface2017;15(3):334-65.">Stapleton 2017</a>). MGD was found in this same meta‐analysis to have a prevalence of 21.2% among people with DED. The literature also suggests a global DED distribution that impacts all ages, sexes, and racial groups (<a href="./references#CD015448-bbs2-0068" title="PapasEB . The global prevalence of dry eye disease: a Bayesian view. Ophthalmic and Physiological Optics2021;41(6):1254-66.">Papas 2021</a>; <a href="./references#CD015448-bbs2-0077" title="StapletonF , AlvesM , BunyaVY , JalbertI , LekhanontK , MaletF , et al. TFOS DEWS II epidemiology report. Ocular Surface2017;15(3):334-65.">Stapleton 2017</a>). Risk factors for DED include female sex, advancing age (over 50 years), and Asian ethnicity (<a href="./references#CD015448-bbs2-0039" title="FarrandKF , FridmanM , StillmanIO , SchaumbergDA . Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. American Journal of Ophthalmology2017;182:90-8.">Farrand 2017</a>; <a href="./references#CD015448-bbs2-0070" title="RapoportY , SingerJM , LingJD , GregoryA , KohanimS . A comprehensive review of sex disparities in symptoms, pathophysiology, and epidemiology of dry eye syndrome. Seminars in Ophthalmology2016;31(4):325-36.">Rapoport 2016</a>; <a href="./references#CD015448-bbs2-0072" title="SchaumbergDA , SullivanDA , BuringJE , DanaMR . Prevalence of dry eye syndrome among US women. American Journal of Ophthalmology2003;136(2):318-26.">Schaumberg 2003</a>; <a href="./references#CD015448-bbs2-0073" title="SchaumbergDA , DanaR , BuringJE , SullivanDA . Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies. American Journal of Ophthalmology2009;127(6):763-8.">Schaumberg 2009</a>). There are few trials on the prevalence of DED in children, but the current research indicates that children with certain conditions, including Sjögren's syndrome, graft‐versus‐host disease, or environmental allergies, are likely to have the condition (<a href="./references#CD015448-bbs2-0031" title="AlvesM , DiasAC , RochaEM . Dry eye in childhood: epidemiological and clinical aspects. Ocular Surface2008;6(1):44-51.">Alves 2008</a>). </p> </section> <section id="CD015448-sec-0013"> <h4 class="title">Diagnosis of meibomian gland dysfunction</h4> <p>There are many different strategies to diagnose MGD. The International Workshop on MGD concluded that meibomian gland dropout (atrophy) quantification, and quality or expressibility of meibum assessments, are the most frequent and appropriate factors for diagnosing MGD (<a href="./references#CD015448-bbs2-0079" title="TomlinsonA , BronAJ , KorbDR , AmanoS , PaughJR , PearceEI , et al. The International Workshop on Meibomian Gland Dysfunction: report of the diagnosis subcommittee. Investigative Ophthalmology and Visual Science2011;52(4):2006-49.">Tomlinson 2011</a>). MGD can sometimes affect focal areas of the eyelid, but it has been suggested that there is a high correlation between disease severity across the upper and lower eyelids (<a href="./references#CD015448-bbs2-0061" title="McCannLC , TomlinsonA , PearceEI , DiaperC . Tear and meibomian gland function in blepharitis and normals. Eye and Contact Lens2009;35(4):203-8.">McCann 2009</a>), so some diagnostic protocols allow diagnosis based on the lower eyelid evaluation alone. </p> <p>Meibomian gland expression is typically performed by applying digital pressure to the outer eyelid surface. Some methods and devices have been designed to provide a standardized force (<a href="./references#CD015448-bbs2-0065" title="MeadowsJF , RamamoorthyP , NicholsJJ , NicholsKK . Development of the 4-3-2-1 meibum expressibility scale. Eye and Contact Lens2012;38(2):86-92.">Meadows 2012</a>). Meibum quality (clear, opaque, etc.) and ease of expressibility can be considered when grading gland expression. Meibomian gland morphology can likewise be evaluated with a digital imaging system called meibography. Various grading scales exist to quantify gland atrophy, expressibility, and meibum quality (<a href="./references#CD015448-bbs2-0079" title="TomlinsonA , BronAJ , KorbDR , AmanoS , PaughJR , PearceEI , et al. The International Workshop on Meibomian Gland Dysfunction: report of the diagnosis subcommittee. Investigative Ophthalmology and Visual Science2011;52(4):2006-49.">Tomlinson 2011</a>). </p> <p>Other clinical features may aid in diagnosing and evaluating the severity of DED and MGD. Symptom assessment using validated questionnaires is helpful in quantifying symptoms before and after treatment. Objective clinical assessments of tear osmolarity, tear volume, ocular surface staining, and grading of eyelid morphology may also be used in conjunction with gland atrophy and expressibility assessments to diagnose and grade MGD severity (<a href="./references#CD015448-bbs2-0079" title="TomlinsonA , BronAJ , KorbDR , AmanoS , PaughJR , PearceEI , et al. The International Workshop on Meibomian Gland Dysfunction: report of the diagnosis subcommittee. Investigative Ophthalmology and Visual Science2011;52(4):2006-49.">Tomlinson 2011</a>). </p> </section> </section> <section id="CD015448-sec-0014"> <h3 class="title" id="CD015448-sec-0014">Description of the intervention</h3> <p>The LipiFlow Thermal Pulsation System (LipiFlow) is a medical device used in the office by eye care professionals to treat MGD. It aims to provide controlled, repeatable heat and compression to the eyelid and meibomian glands. The device applies heat to the upper and lower palpebral conjunctival tissues that lie directly over the meibomian glands, while also applying graded pulsatile pressure to the outer eyelid to express the meibomian glands. The meibomian glands are massaged in the direction of the gland orifices, allowing expression during the heating procedure (<a href="./references#CD015448-bbs2-0055" title="LaneSS , DuBinerHB , EpsteinRJ , ErnestPH , GreinerJV , HardtenDR , et al. A new system, the LipiFlow, for the treatment of meibomian gland dysfunction. Cornea2012;31(4):396-404.">Lane 2012</a>). </p> <p>The system consists of disposable activator (the component that meets the eye and ocular surface) and the control system. The disposable activator consists of the eyelid warmer and the eyecup. The eyelid warmer is similar in size and shape to a scleral contact lens. The concave edges rest on the bulbar conjunctiva and the concave center vaults the cornea, shielding the cornea from direct heat exposure. On the convex eyelid warmer surface, a heater regulates the temperature administered to the inner eyelid surface and palpebral conjunctiva to between 41 °C and 43 °C. The eyecup component contains an inflatable air bladder that sits on the external eyelid surface and inflates, allowing compression of the eyelid (<a href="./references#CD015448-bbs2-0055" title="LaneSS , DuBinerHB , EpsteinRJ , ErnestPH , GreinerJV , HardtenDR , et al. A new system, the LipiFlow, for the treatment of meibomian gland dysfunction. Cornea2012;31(4):396-404.">Lane 2012</a>). </p> <p>Prior to insertion of the disposable, two drops of topical anesthetic may be applied to each eye. The disposable can be inserted, like a scleral contact lens or corneal surgical shield. The patient is instructed to close their eyes (<a href="./references#CD015448-bbs2-0055" title="LaneSS , DuBinerHB , EpsteinRJ , ErnestPH , GreinerJV , HardtenDR , et al. A new system, the LipiFlow, for the treatment of meibomian gland dysfunction. Cornea2012;31(4):396-404.">Lane 2012</a>). Once the disposable is properly inserted, the 12‐minute treatment begins. It consists of a programmed compression cadence that includes cycles of constant, increasing, and alternating pressure (maximum 6 pounds per square inch), which results in the eyelids being heated and massaged for the entire 12 minutes (<a href="./references#CD015448-bbs2-0040" title="FinisD , HayajnehJ , KonigC , BorrelliM , SchraderS , GeerlingG . Evaluation of an automated thermodynamic treatment (LipiFlow®) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial. Ocular Surface2014;12(2):146-54.">Finis 2014</a>). With LipiFlow’s known mechanism of action (mechanical/thermal), a treatment effect should be observed immediately. It is currently unclear if patients will benefit from repeat treatments with LipiFlow. </p> </section> <section id="CD015448-sec-0015"> <h3 class="title" id="CD015448-sec-0015">How the intervention might work</h3> <p>LipiFlow works by applying a combination of heat, which attempts to liquefy hardened meibum in MGD, and pressure, which pushes the meibum out of the meibomian glands; this combination alleviates gland obstruction and promotes normal tear film function (<a href="./references#CD015448-bbs2-0042" title="FriedlandBR , FlemingCP , BlackieCA , KorbDR . A novel thermodynamic treatment for meibomian gland dysfunction. Current Eye Research2011;36(2):79-87.">Friedland 2011</a>; <a href="./references#CD015448-bbs2-0060" title="LiB , FuH , LiuT , XuM . Comparison of the therapeutic effect of Meibomian Thermal Pulsation LipiFlow® on obstructive and hyposecretory meibomian gland dysfunction patients. International Ophthalmology2020;40(12):3469-79.">Li 2020</a>). </p> <p>Other treatments that aim to provide local heat and compression, such as manual warm compress techniques, heating pads, and goggles, may be less effective than LipiFlow, because of difficulties in maintaining a temperature that can diffuse from the outer eyelid to the location of the meibomian glands near the inner palpebral conjunctiva and/or apply the appropriate amount of pressure in the correct eyelid location (<a href="./references#CD015448-bbs2-0054" title="KorbDR , BlackieCA . Meibomian gland therapeutic expression: quantifying the applied pressure and the limitation of resulting pain. Eye and Contact Lens2011;37(5):298-301.">Korb 2011</a>). </p> </section> <section id="CD015448-sec-0016"> <h3 class="title" id="CD015448-sec-0016">Why it is important to do this review</h3> <p>MGD is one of the most common ocular conditions, therefore having effective treatments is vital (<a href="./references#CD015448-bbs2-0045" title="HassanzadehS , VarmaghaniM , Zarei-GhanavatiS , HeravianSJ , AzimiKA . Global prevalence of meibomian gland dysfunction: a systematic review and meta-analysis. Ocular Immunology and Inflammation2021;29(1):66-75.">Hassanzadeh 2021</a>). The LipiFlow Thermal Pulsation System has been touted as an effective treatment for alleviating obstructive MGD (<a href="./references#CD015448-bbs2-0055" title="LaneSS , DuBinerHB , EpsteinRJ , ErnestPH , GreinerJV , HardtenDR , et al. A new system, the LipiFlow, for the treatment of meibomian gland dysfunction. Cornea2012;31(4):396-404.">Lane 2012</a>). To date, only one systematic review has compared the LipiFlow with placebo or other commercially available DED treatments (<a href="./references#CD015448-bbs2-0049" title="HuJ , ZhuS , LiuX . Efficacy and safety of a vectored thermal pulsation system (Lipiflow®) in the treatment of meibomian gland dysfunction: a systematic review and meta-analysis. Graefe's Archive for Clinical and Experimental Ophthalmology2022;260(1):25-39.">Hu 2022</a>). This systematic review is therefore important as it will provide an updated, comprehensive review of the current research available on the efficacy and safety of the LipiFlow for the treatment of DED. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD015448-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD015448-sec-0017"></div> <p>To evaluate the effectiveness of LipiFlow for treating DED signs and symptoms and the safety of LipiFlow compared with sham or other available treatments for MGD in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD015448-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD015448-sec-0018"></div> <section id="CD015448-sec-0019"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD015448-sec-0020"> <h4 class="title">Types of studies</h4> <p>We included randomized controlled trials (RCTs). We excluded cross‐over trials because the LipiFlow Thermal Pulsation System is thought to have variable long‐term benefits with no consensus on the duration of potential carry‐over effects. </p> </section> <section id="CD015448-sec-0021"> <h4 class="title">Types of participants</h4> <p>We included trials conducted in adults over 18 years of age with DED or MGD, as defined by the primary trial investigators. We imposed no restrictions on race, ethnicity, or sex. We considered studies involving contact lens wearers if they were equally represented between groups. </p> </section> <section id="CD015448-sec-0022"> <h4 class="title">Types of interventions</h4> <p>We included studies comparing LipiFlow with no treatment, sham (e.g. non‐activated device), or any DED treatment, including: </p> <p> <ul id="CD015448-list-0001"> <li> <p>artificial tears;</p> </li> <li> <p>topical dry eye medications (e.g. corticosteroids, ciclosporin, lifitegrast);</p> </li> <li> <p>oral intervention (e.g. doxycycline, azithromycin, omega‐3, omega‐6);</p> </li> <li> <p>local eyelid manipulation (e.g. warm compresses, Meibopatch, EyeGiene);</p> </li> <li> <p>eyelid hygiene products (e.g. eyelid scrubs); and</p> </li> <li> <p>other devices for MGD (e.g. iLux, Mibo Thermoflo, TearCare).</p> </li> </ul> </p> <p>We included trials that combined LipiFlow with other treatments if clear distinctions in treatment effects could be determined. </p> </section> <section id="CD015448-sec-0023"> <h4 class="title">Types of outcome measures</h4> <section id="CD015448-sec-0024"> <h5 class="title">Critical outcomes</h5> <p>The critical outcome was the mean change from baseline in patient‐reported symptom scores as measured by validated questionnaires such as the Standard Patient Evaluation of Eye Dryness Questionnaire (SPEED; <a href="./references#CD015448-bbs2-0053" title="KorbDR , HermanJP , GreinerJV , ScaffidiRC , FinnemoreVM , ExfordJM , et al. Lid wiper epitheliopathy and dry eye symptoms. Eye and Contact Lens2005;31(1):2-8.">Korb 2005</a>), Ocular Surface Disease Index (OSDI; <a href="./references#CD015448-bbs2-0074" title="SchiffmanRM , ChristiansonMD , JacobsenG , HirschJD , ReisBL . Reliability and validity of the Ocular Surface Disease Index. American Journal of Ophthalmology2000;118(5):615-21.">Schiffman 2000</a>), or Dry Eye Questionnaire 5 (DEQ‐5; <a href="./references#CD015448-bbs2-0033" title="BegleyCG , ChalmersRL , MitchellGL , NicholsKK , CafferyB , SimpsonT , et al. Characterization of ocular surface symptoms from optometric practices in North America. Cornea2001;20(6):610-8.">Begley 2001</a>), at one to four weeks post‐treatment, with the longest time point within this time frame being used in the analysis. This time frame was chosen based upon a pre‐review of the literature, which found that one to four weeks was commonly included in the trials of interest. This time frame was likewise chosen given LipiFlow’s mechanism of action (mechanical/thermal), which should have an immediate effect. Longer post‐treatment evaluations (e.g. 6 to 12 months) were performed when assessed in an included trial. </p> </section> <section id="CD015448-sec-0025"> <h5 class="title">Important outcomes</h5> <p>We evaluated the following outcomes, measured as the mean change from baseline (see <a href="#CD015448-sec-0151">Differences between protocol and review</a>) at one to four weeks post‐treatment, with the longest time point within this time frame being used in the analysis: </p> <p> <ul id="CD015448-list-0002"> <li> <p>meibomian gland expression, assessed by any integer scale with a grade of 1 or more classified as clinically meaningful (<a href="./references#CD015448-bbs2-0034" title="BronAJ , BenjaminL , SnibsonGR . Meibomian gland disease. Classification and grading of lid changes. Eye1991;5 (Pt 4):395-411.">Bron 1991</a>; <a href="./references#CD015448-bbs2-0041" title="FoulksGN , BronAJ . Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocular Surface2003;1(3):107-26.">Foulks 2003</a>; <a href="./references#CD015448-bbs2-0065" title="MeadowsJF , RamamoorthyP , NicholsJJ , NicholsKK . Development of the 4-3-2-1 meibum expressibility scale. Eye and Contact Lens2012;38(2):86-92.">Meadows 2012</a>); </p> </li> <li> <p>meibum quality, assessed by any integer scale with a grade of 1 or more classified as clinically meaningful (<a href="./references#CD015448-bbs2-0034" title="BronAJ , BenjaminL , SnibsonGR . Meibomian gland disease. Classification and grading of lid changes. Eye1991;5 (Pt 4):395-411.">Bron 1991</a>; <a href="./references#CD015448-bbs2-0065" title="MeadowsJF , RamamoorthyP , NicholsJJ , NicholsKK . Development of the 4-3-2-1 meibum expressibility scale. Eye and Contact Lens2012;38(2):86-92.">Meadows 2012</a>; <a href="./references#CD015448-bbs2-0076" title="ShimazakiJ , GotoE , OnoM , ShimmuraS , TsubotaK . Meibomian gland dysfunction in patients with Sjögren syndrome. Ophthalmology1998;105(8):1485-8.">Shimazaki 1998</a>); </p> </li> <li> <p>meibomian gland atrophy, as determined with meibography and assessed by any integer scale with a grade of 2 or more classified as clinically meaningful (<a href="./references#CD015448-bbs2-0032" title="AritaR , ItohK , InoueK , AmanoS . Noncontact infrared meibography to document age-related changes of the meibomian glands in a normal population. Ophthalmology2008;115(5):911-5.">Arita 2008</a>; <a href="./references#CD015448-bbs2-0069" title="PultH , Riede-PultB . Comparison of subjective grading and objective assessment in meibography. Contact Lens and Anterior Eye2013;36(1):22-7.">Pult 2013</a>); </p> </li> <li> <p>tear breakup time, assessed in seconds with times less than 10 seconds classified as abnormal (<a href="./references#CD015448-bbs2-0052" title="KorbDR , GreinerJV , HermanJ . Comparison of fluorescein break-up time measurement reproducibility using standard fluorescein strips versus the Dry Eye Test (DET) method. Cornea2001;20(8):811-5.">Korb 2001</a>; <a href="./references#CD015448-bbs2-0057" title="LempMA , Hamill JR Jr. Factors affecting tear film breakup in normal eyes. Archives of Ophthalmology1973;89(2):103-5.">Lemp 1973</a>); </p> </li> <li> <p>adverse events:</p> <ul id="CD015448-list-0003"> <li> <p>intervention‐related, vision‐threatening adverse events that could potentially lead to permanent vision loss, such as microbial keratitis or corneal abrasions; </p> </li> <li> <p>progression of DED, as quantified by increases in corneal fluorescein staining compared to baseline using any validated scale (e.g. the National Eye Institute (NEI) scoring system (range 0 to 15) (<a href="./references#CD015448-bbs2-0058" title="LempMA . Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. CLAO Journal1995;21(4):221-32.">Lemp 1995</a>); the Oxford scales (range 0 to 5) (<a href="./references#CD015448-bbs2-0035" title="BronAJ . The Doyne Lecture. Reflections on the tears. Eye1997;11 (Pt 5):583-602.">Bron 1997</a>), with higher numbers being worse) with a grade increase by one compared to baseline classified as clinically meaningful. </p> </li> </ul> </li> </ul> </p> <p>We evaluated the following outcome, measured at between 6 months and 12 months, with the longest time point within this time frame used in the analysis: </p> <p> <ul id="CD015448-list-0004"> <li> <p>patient‐reported symptom scores as measured by validated questionnaires (<a href="./references#CD015448-bbs2-0033" title="BegleyCG , ChalmersRL , MitchellGL , NicholsKK , CafferyB , SimpsonT , et al. Characterization of ocular surface symptoms from optometric practices in North America. Cornea2001;20(6):610-8.">Begley 2001</a>; <a href="./references#CD015448-bbs2-0053" title="KorbDR , HermanJP , GreinerJV , ScaffidiRC , FinnemoreVM , ExfordJM , et al. Lid wiper epitheliopathy and dry eye symptoms. Eye and Contact Lens2005;31(1):2-8.">Korb 2005</a>; <a href="./references#CD015448-bbs2-0074" title="SchiffmanRM , ChristiansonMD , JacobsenG , HirschJD , ReisBL . Reliability and validity of the Ocular Surface Disease Index. American Journal of Ophthalmology2000;118(5):615-21.">Schiffman 2000</a>). </p> </li> </ul> </p> </section> </section> </section> <section id="CD015448-sec-0026"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD015448-sec-0027"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Eyes and Vision Information Specialist searched the following electronic databases without restrictions on language or date of publication. The date of the last database search was 24 October 2022. </p> <p> <ul id="CD015448-list-0005"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) in the Cochrane Library (2022; Issue 6) (<a href="./appendices#CD015448-sec-0138">Appendix 1</a>); </p> </li> <li> <p>MEDLINE Ovid (1946 to 24 October 2022) (<a href="./appendices#CD015448-sec-0139">Appendix 2</a>); </p> </li> <li> <p>Embase.com (1947 to 24 October 2022) (<a href="./appendices#CD015448-sec-0140">Appendix 3</a>); </p> </li> <li> <p>PubMed (1948 to 24 October 2022) (<a href="./appendices#CD015448-sec-0141">Appendix 4</a>); </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database) (1982 to 24 October 2022) (<a href="./appendices#CD015448-sec-0142">Appendix 5</a>); </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>) (<a href="./appendices#CD015448-sec-0143">Appendix 6</a>); and </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="https://www.who.int/clinical-trials-registry-platform" target="_blank">www.who.int/ictrp</a>) (<a href="./appendices#CD015448-sec-0144">Appendix 7</a>). </p> </li> </ul> </p> </section> <section id="CD015448-sec-0028"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of included studies and review articles to identify additional relevant studies that may not have been identified by our primary search. We imposed no restrictions on language or date of publication. We also contacted experts in the field regarding information about any ongoing trials of LipiFlow. </p> </section> </section> <section id="CD015448-sec-0029"> <h3 class="title" id="CD015448-sec-0029">Data collection and analysis</h3> <section id="CD015448-sec-0030"> <h4 class="title">Selection of studies</h4> <p>After removal of duplicate records, two review authors independently screened the titles and abstracts of studies identified by the search using the internet‐based review management software <a href="./references#CD015448-bbs2-0036" title="Covidence. Version accessed 22 March 2022. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a> (<a href="./references#CD015448-bbs2-0036" title="Covidence. Version accessed 22 March 2022. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a>). We classified each record as 'definitely relevant,' 'possibly relevant,' or 'not relevant' for full‐text review. We retrieved the full‐text reports of records classified as 'definitely relevant' or 'possibly relevant.' Two review authors then independently reviewed the full‐text articles for eligibility, excluding ineligible studies. We recorded the reasons for exclusion for each report deemed ineligible after full‐text assessment (see <a href="./references#CD015448-sec-0154" title="">Characteristics of excluded studies</a>). When there were questions regarding study eligibility, we contacted the study investigators to obtain further information. If the study investigators did not respond within two weeks, we used the information available from publications and trial registers to determine study eligibility. We categorized trials that met the eligibility criteria but have not yet been completed as 'ongoing', and any relevant trial that was completed but for which results were unavailable as 'awaiting classification.' Any disagreements between review authors at each stage of the screening process were resolved by discussion and consensus. </p> </section> <section id="CD015448-sec-0031"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted data from the included studies using a data collection form developed and piloted in <a href="./references#CD015448-bbs2-0036" title="Covidence. Version accessed 22 March 2022. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a> (<a href="./references#CD015448-bbs2-0036" title="Covidence. Version accessed 22 March 2022. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a>). One review author (TWY) exported data from <a href="./references#CD015448-bbs2-0036" title="Covidence. Version accessed 22 March 2022. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.">Covidence</a> into Review Manager Web (<a href="./references#CD015448-bbs2-0071" title="Review Manager Web (RevMan Web). Version 7.1.3. The Cochrane Collaboration, 2023. Available at revman.cochrane.org.">RevMan Web 2023</a>), and a second review author (WN) verified all data entries to ensure that data were consistent and error‐free. We extracted the following information: </p> <p> <ul id="CD015448-list-0006"> <li> <p>methods: trial design, trial setting, location, sample size, trial duration;</p> </li> <li> <p>participants: number of participants, age, sex, race, ethnicity, inclusion criteria and exclusion criteria; </p> </li> <li> <p>interventions: intervention, comparison interventions, co‐intervention;</p> </li> <li> <p>outcomes: primary, secondary, time points; and</p> </li> <li> <p>other: sources of funding, and potential conflicts of interest.</p> </li> </ul> </p> <p>We collected and used the most detailed numerical data available from the included trials to facilitate analysis. We contacted the trial investigators or organizations to obtain missing data or for clarification. If the investigators did not respond within two weeks, we proceeded with the existing information. We planned that if data were available only in graphical displays, we would extract the data digitally with an appropriate program such as <a href="./references#CD015448-bbs2-0050" title="ImageJ: Image Processing and Analysis in Java. Version 1.8.0. Bethesda, MD: US National Institutes of Health, 2018. Available at imagej.nih.gov/ij/.">ImageJ</a> (<a href="./references#CD015448-bbs2-0050" title="ImageJ: Image Processing and Analysis in Java. Version 1.8.0. Bethesda, MD: US National Institutes of Health, 2018. Available at imagej.nih.gov/ij/.">ImageJ</a>). In the case of discrepancies in data extraction between review authors, consensus was reached through discussion or by consulting a third review author. </p> </section> <section id="CD015448-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the risk of bias in the critical outcome, symptom scores at one to four weeks post‐treatment, for each of the included studies using RoB 2, as described in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015448-bbs2-0047" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch V, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.">Higgins 2022a</a>). We considered the following domains of bias: </p> <p> <ul id="CD015448-list-0007"> <li> <p>bias arising from the randomization process;</p> </li> <li> <p>bias due to deviations from intended interventions;</p> </li> <li> <p>bias due to missing outcome data;</p> </li> <li> <p>bias in measurement of the outcome; and</p> </li> <li> <p>bias in selection of the reported result.</p> </li> </ul> </p> <p>We evaluated the risk of bias in every bias domain as well as the overall risk of bias as 'low risk of bias,' 'high risk of bias,' or 'some concerns.' The assessment of each domain was guided by signaling questions (<a href="./references#CD015448-bbs2-0078" title="SterneJA , SavovićJ , PageMJ , ElbersRG , BlencoweNS , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019;366:l4898. [DOI: 10.1136/bmj.l4898]">Sterne 2019</a>). </p> <p>Regarding overall risk of bias, we considered a trial to have:</p> <p> <ul id="CD015448-list-0008"> <li> <p>low risk of bias if it was of low risk of bias for all domains for the result;</p> </li> <li> <p>some concerns if the trial was judged to raise some concerns in at least one domain for the result, but was not at high risk of bias for any domain; and </p> </li> <li> <p>high risk of bias if the trial was judged to be at high risk of bias in at least one domain, or to have some concerns for multiple domains such that confidence in the result was substantially lowered. </p> </li> </ul> </p> <p>In the case of disagreement or discrepancy between review authors, consensus was reached through discussion or by consulting a third review author. </p> </section> <section id="CD015448-sec-0033"> <h4 class="title">Measures of treatment effect</h4> <p>For continuous outcomes measured using the same scales, we calculated mean differences (MDs) with 95% confidence intervals (CIs) where outcomes were normally distributed. Where trials measured continuous outcomes using different scales, we calculated standardized mean differences (SMDs). While some included trials reported symptom scores by using two different validated questionnaires, we calculated MDs instead of SMDs to prevent duplication of eye or participant counts. </p> <p>For dichotomous outcomes, we did not calculate risk ratios (RR) with 95% CIs for the proportion of participants with an adverse event due to insufficient data provided. None of the included trials reported skewed data, so we did not check the data for skewness (<a href="./references#CD015448-bbs2-0037" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch V, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.">Deeks 2022</a>). </p> </section> <section id="CD015448-sec-0034"> <h4 class="title">Unit of analysis issues</h4> <p>The participant was the primary unit of analysis; however, results were analyzed by eye when contralateral eye trials were being evaluated. When the trial reported symptom scores using two different valid questionnaires, and we wished to integrate both participant‐ and eye‐level data, we utilized a generic inverse‐variance (GIV) method to calculate MDs. Additionally, we applied the GIV method when the trial authors reported data on differences between eyes, rather than changes from baseline or end values at the arm‐level. We separated trials into different subgroups that involved both participant and eye‐level data when calculating both MDs and SMDs. None of the included trials had more than two groups, so we did not evaluate each relevant comparison separately, and did not select one pair‐wise comparison that was relevant to the review to avoid double counting the trials in the analysis (<a href="./references#CD015448-bbs2-0048" title="HigginsJP , LiT , DeeksJJ . Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch V, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.">Higgins 2022b</a>). </p> </section> <section id="CD015448-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the trial authors in the case of missing outcome data; we used the best information available to analyze data when we received no response within two weeks. We only analyzed available data and did not impute missing data for the purposes of this review. When performing the GIV method, standard errors were imputed from the reported P values for two‐sample t‐test, as described in Chapter 6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015448-bbs2-0048" title="HigginsJP , LiT , DeeksJJ . Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch V, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.">Higgins 2022b</a>). </p> </section> <section id="CD015448-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical and methodological heterogeneity among studies by evaluating the potential differences in participant characteristics, interventions compared (LipiFlow versus other DED treatments or placebo), and trial design features. We also assessed statistical heterogeneity among outcomes by examining the overlap of CIs in forest plots and by using the Chi<sup>2</sup> and I<sup>2</sup> statistics to determine the proportion of total variation due to statistical heterogeneity (<a href="./references#CD015448-bbs2-0046" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327:557-60.">Higgins 2003</a>), as described in Chapter 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015448-bbs2-0037" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch V, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.">Deeks 2022</a>). We interpreted the I<sup>2</sup> statistic as follows: </p> <p> <ul id="CD015448-list-0009"> <li> <p>0% to 40%: may not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity; and</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> </section> <section id="CD015448-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed selective result reporting for ocular symptoms guided by the signaling questions in the RoB 2 tool (<a href="./references#CD015448-bbs2-0047" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch V, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.">Higgins 2022a</a>). We assessed selective outcome reporting for each trial using methods outlined in Chapter 13 of the <i>Cochrane Handbook</i> (<a href="./references#CD015448-bbs2-0067" title="PageMJ , HigginsJPT , SterneJAC . Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch V, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Available from training.cochrane.org/handbook/archive/v6.3.">Page 2022</a>). We did not use a funnel plot to assess small‐trial effects because none of the meta‐analyses involved 10 more trials (<a href="./references#CD015448-bbs2-0038" title="EggerM , SmithGD , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34. [PMID: 9310563]">Egger 1997</a>). </p> </section> <section id="CD015448-sec-0038"> <h4 class="title">Data synthesis</h4> <p>We synthesized and analyzed data following the guidelines in Chapter 9, <a href="./references#CD015448-bbs2-0063" title="McKenzieJE , BrennanSE , RyanRE , ThomsonHJ , JohnstonRV . Chapter 9: Summarizing study characteristics and preparing for synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch V, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.">McKenzie 2022a</a>, and Chapter 10, <a href="./references#CD015448-bbs2-0037" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch V, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.">Deeks 2022</a>, of the <i>Cochrane Handbook</i> . When more than two studies contributed data to the same outcome, and where there was statistical or clinical heterogeneity, we used a random‐effects model to estimate intervention effects. When the direction of treatment effects was inconsistent across trials, or we detected the presence of substantial or considerable statistical heterogeneity, we did not combine results in a meta‐analysis, but instead provided a narrative summary of results, following guidance in Chapter 12 of the <i>Cochrane Handbook</i> (<a href="./references#CD015448-bbs2-0064" title="McKenzieJE , BrennanSE . Chapter 12: Synthesizing and presenting findings using other methods. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch V, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.">McKenzie 2022b</a>). </p> </section> <section id="CD015448-sec-0039"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to conduct subgroup analysis on the following two outcomes: changes in symptom scores at post‐treatment weeks 1 to 4, and changes in symptom scores at post‐treatment months 6 to 12, by the following factors, depending on the availability of data: </p> <p> <ul id="CD015448-list-0010"> <li> <p>comparison interventions;</p> </li> <li> <p>sex;</p> </li> <li> <p>race and ethnicity; and</p> </li> <li> <p>number of LipiFlow treatment sessions performed.</p> </li> </ul> </p> <p>However, subgroup analysis was precluded by insufficient data.</p> </section> <section id="CD015448-sec-0040"> <h4 class="title">Sensitivity analysis</h4> <p>Insufficient data precluded sensitivity analysis excluding trials with an overall high risk of bias and trials that failed to handle the unit of analysis issue properly. </p> </section> <section id="CD015448-sec-0041"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We prepared a summary of findings table according to the methods described in Chapter 14 of the <i>Cochrane Handbook</i> (<a href="./references#CD015448-bbs2-0075" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch V, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.">Schünemann 2022</a>), and presented the estimated effects of the LipiFlow at one to four weeks, with the longest time point within this time frame being used in analysis. We included the following outcomes (see <a href="#CD015448-sec-0151">Differences between protocol and review</a>): </p> <p> <ul id="CD015448-list-0011"> <li> <p>mean change from baseline in symptom scores, as measured with any validated symptom questionnaire (e.g. SPEED, OSDI, DEQ‐5); </p> </li> <li> <p>mean change from baseline in meibomian gland expression, assessed by any integer scale (e.g. 0 to 3, with higher numbers being worse) with a grade of 1 or more classified as clinically meaningful; </p> </li> <li> <p>mean change from baseline in meibum quality, assessed by any integer scale (e.g. 0 to 3, 0 to 4, with higher numbers being worse) with a grade of 1 or more classified as clinically meaningful; </p> </li> <li> <p>mean change from baseline in meibomian gland atrophy, as determined with meibography and assessed by any integer scale (e.g. 0 to 3, 0 to 4, with higher numbers being worse) with a grade of 2 or more classified as clinically meaningful; and </p> </li> <li> <p>proportion of participants with intervention‐related, vision‐threatening adverse events that could potentially lead to permanent vision loss, such as microbial keratitis or corneal abrasions. </p> </li> </ul> </p> <p>Two review authors independently judged the certainty of the evidence for each outcome using the GRADE approach. We judged the certainty of evidence as high, moderate, low, or very low (<a href="./references#CD015448-bbs2-0075" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch V, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.3.">Schünemann 2022</a>). Any disagreements were resolved by discussion or consultation with a third review author. For outcomes that we did not assess using the complete RoB 2 tool, we judged trial‐level risk of bias based on domains 1, 2, and 3 of the RoB 2 tool. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD015448-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD015448-sec-0042"></div> <section id="CD015448-sec-0043"> <h3 class="title">Description of studies</h3> <section id="CD015448-sec-0044"> <h4 class="title">Results of the search</h4> <p>Our searches of the electronic databases in October 2022 yielded 1388 records. We added one record through handsearching other sources. After removal of duplicates, we screened 1092 titles and abstracts (<a href="#CD015448-fig-0001">Figure 1</a>). We retrieved 41 full‐text reports for further screening and excluded 10 trials (12 records), with reasons provided (see <a href="./references#CD015448-sec-0154" title="">Characteristics of excluded studies</a>). We included 13 trials (22 records), identified 6 ongoing trials (<a href="./references#CD015448-bbs2-0025" title="ChiCTR2100048758. Effects and safety of LipiFlow on meibomian gland dysfunction for patients with ocular graft-versus-host diseases. chictr.org.cn/showproj.aspx?proj=130238 (first received 16 July 2021). ">ChiCTR2100048758</a>; <a href="./references#CD015448-bbs2-0026" title="ChiCTR2100050323. Vectored thermal pulsation, intense pulsed light, and eyelid warm compress (VIEW) therapies for meibomian gland dysfunction—a randomized, assessor-masked, active-controlled clinical trial. chictr.org.cn/showproj.aspx?proj=132588 (first received 26 August 2021). ">ChiCTR2100050323</a>; <a href="./references#CD015448-bbs2-0027" title="NCT04322656. Stability of biometry in meibomian gland dysfunction. clinicaltrials.gov/show/NCT04322656 (first received 26 March 2020). ">NCT04322656</a>; <a href="./references#CD015448-bbs2-0028" title="Evaluation of the efficacy of intense pulse light combined with LipiFlow in the treatment of meibomian gland dysfunction. clinicaltrials.gov/show/NCT04633798 (first received 18 November 2020). ">NCT04633798</a>; <a href="./references#CD015448-bbs2-0029" title="NCT05162261. To evaluate the effectiveness and safety of the Tixel®, vs LipiFlow® in the treatment of meibomian gland dysfunction. clinicaltrials.gov/show/NCT05162261 (first received 17 December 2021). ">NCT05162261</a>; <a href="./references#CD015448-bbs2-0030" title="NCT05577910. Vectored thermal pulsation, intense pulsed light, and eyelid warm compress therapies for MGD. clinicaltrials.gov/ct2/show/NCT05577910 (first received 13 October 2022). ">NCT05577910</a>), and assessed 1 trial as awaiting classification (<a href="./references#CD015448-bbs2-0024" title="ChiCTR-INR-17013856. Evaluation of the effectiveness of LipiFlow in the treatment of MGD. chictr.org.cn/showproj.aspx?proj=23844 (first received 12 December 2017). ">ChiCTR‐INR‐17013856</a>). </p> <div class="figure" id="CD015448-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD015448-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD015448-sec-0045"> <h4 class="title">Included studies</h4> <section id="CD015448-sec-0046"> <h5 class="title">Types of studies</h5> <p>All 13 included trials had a parallel‐group RCT design and compared the effectiveness of LipiFlow with basic warm compresses (<a href="./references#CD015448-bbs2-0001" title="BaumannA , CochenerB . Meibomian gland dysfunction: a comparative study of modern treatments. Journal Français d'Ophtalmologie2014;37(4):303‐12. ">Baumann 2014</a>; <a href="./references#CD015448-bbs2-0002" title="BooranapongW , PrabhasawatP , ChotikavanichS , TongsaiS , NaranunnP , ThaweerattanasilpW , et al. Comparison of an automated thermodynamic treatment system (LipiFlow) and warm compresses for the treatment of moderate severity of meibomian gland dysfunction. Siriraj Medical Journal2019;72(1):79-86. TCTR20170905001. Comparison of an automated thermodynamic treatment system (LipiFlow®) and eyelid warm compress for the treatment of meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20170905001 (first received 05 September 2017). ">Booranapong 2019</a>; <a href="./references#CD015448-bbs2-0005" title="HeJZ , ZhongM . Comparative study between the meibomian pulsation system and the warm compress treatment for MGD. International Eye Science2018;18(7):1324‐8. ">He 2018</a>; <a href="./references#CD015448-bbs2-0009" title="MencucciR , MercuriS , CennamoM , MorelliA , FavuzzaE . Efficacy of Vector Thermal Pulsation treatment in reducing post-cataract surgery dry eye disease in patients affected by meibomian gland dysfunction. Journal of Cataract &amp; Refractive Surgery2022;49(4):423-9. NCT05062564. Efficacy of LipiFlow in patients affected by meibomian gland dysfunction in reducing post-cataract surgery dry eye. clinicaltrials.gov/show/NCT05062564 (first received 30 September 2021). ">Mencucci 2022</a>; <a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a>), thermostatic devices (<a href="./references#CD015448-bbs2-0003" title="GuptaPK , HollandEJ , HovanesianJ , LohJ , JacksonMA , KarpeckiPM , et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea2022;41(4):417‐26. ">Gupta 2022</a>; <a href="./references#CD015448-bbs2-0006" title="BloomensteinM , LohJ , DhamdhereK . Effectiveness of TearCare system in improvement dry eye disease symptoms in meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2022;63(7):1567-A0292. HollandEJ , LohJ , BloomensteinM , ThompsonV , WirtaD , DhamdhereK . A comparison of TearCare and Lipiflow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clinical Ophthalmology (Auckland, NZ)2022;16:2861‐71. NCT03857919. TearCare system to treat dry eye disease. clinicaltrials.gov/show/NCT03857919 (first received 28 February 2019). ">Holland 2022</a>; <a href="./references#CD015448-bbs2-0008" title="LiS , YangK , WangJ , ZhuL , FengJ , TianL , et al. Effect of a novel thermostatic device on meibomian gland dysfunction: a randomized controlled trial in Chinese patients. Ophthalmology and Therapy2022;11(1):261‐70. NCT04310969. Clinical effect of MiboFlo in dry eye patients. clinicaltrials.gov/show/NCT04310969 (first received 17 March 2020). ">Li 2022</a>; <a href="./references#CD015448-bbs2-0012" title="TauberJ . A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction. Cornea2020;39(4):403‐7. ">Tauber 2020b</a>; <a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a>), eyelid hygiene products (<a href="./references#CD015448-bbs2-0007" title="KasetsuwanN , SuwajanakornD , TantipatC , ReinprayoonU . The efficacy between conventional lid hygiene and additional thermal pulsatile system in meibomian gland dysfunction patients treated with long-term anti-glaucoma medications in a randomized controlled trial. Clinical Ophthalmology (Auckland, NZ)2020;14:2891‐902. TCTR20150919001. Comparison of efficacy between thermal pulsatile system (Lipiflow®) And conventional lid hygiene In anti-glaucoma agent related meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20150919001 (first received 19 September 2015). ">Kasetsuwan 2020</a>), topical DED medications (<a href="./references#CD015448-bbs2-0011" title="NCT03055832. Comparison Between iLux™ and LipiFlow® in the treatment of meibomian gland dysfunction. clinicaltrials.gov/show/NCT03055832 (first received 16 February 2017). TauberJ , OwenJ , BloomensteinM , HovanesianJ , BullimoreMA . Comparison of the iLUX and the LipiFlow for the treatment of meibomian gland dysfunction and symptoms: a randomized clinical trial. Clinical Ophthalmology (Auckland, NZ)2020;14:405‐18. ">Tauber 2020a</a>), or oral interventions in people with DED (<a href="./references#CD015448-bbs2-0004" title="HagenKB , BediR , BlackieCA , Christenson-AkagiKJ . Comparison of a single-dose vectored thermal pulsation procedure with a 3-month course of daily oral doxycycline for moderate-to-severe meibomian gland dysfunction. Clinical Ophthalmology (Auckland, NZ)2018;12:161‐8. ">Hagen 2018</a>). Six trials were conducted in the USA (<a href="./references#CD015448-bbs2-0003" title="GuptaPK , HollandEJ , HovanesianJ , LohJ , JacksonMA , KarpeckiPM , et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea2022;41(4):417‐26. ">Gupta 2022</a>; <a href="./references#CD015448-bbs2-0004" title="HagenKB , BediR , BlackieCA , Christenson-AkagiKJ . Comparison of a single-dose vectored thermal pulsation procedure with a 3-month course of daily oral doxycycline for moderate-to-severe meibomian gland dysfunction. Clinical Ophthalmology (Auckland, NZ)2018;12:161‐8. ">Hagen 2018</a>; <a href="./references#CD015448-bbs2-0006" title="BloomensteinM , LohJ , DhamdhereK . Effectiveness of TearCare system in improvement dry eye disease symptoms in meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2022;63(7):1567-A0292. HollandEJ , LohJ , BloomensteinM , ThompsonV , WirtaD , DhamdhereK . A comparison of TearCare and Lipiflow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clinical Ophthalmology (Auckland, NZ)2022;16:2861‐71. NCT03857919. TearCare system to treat dry eye disease. clinicaltrials.gov/show/NCT03857919 (first received 28 February 2019). ">Holland 2022</a>; <a href="./references#CD015448-bbs2-0011" title="NCT03055832. Comparison Between iLux™ and LipiFlow® in the treatment of meibomian gland dysfunction. clinicaltrials.gov/show/NCT03055832 (first received 16 February 2017). TauberJ , OwenJ , BloomensteinM , HovanesianJ , BullimoreMA . Comparison of the iLUX and the LipiFlow for the treatment of meibomian gland dysfunction and symptoms: a randomized clinical trial. Clinical Ophthalmology (Auckland, NZ)2020;14:405‐18. ">Tauber 2020a</a>; <a href="./references#CD015448-bbs2-0012" title="TauberJ . A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction. Cornea2020;39(4):403‐7. ">Tauber 2020b</a>; <a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a>), three in China (<a href="./references#CD015448-bbs2-0005" title="HeJZ , ZhongM . Comparative study between the meibomian pulsation system and the warm compress treatment for MGD. International Eye Science2018;18(7):1324‐8. ">He 2018</a>; <a href="./references#CD015448-bbs2-0008" title="LiS , YangK , WangJ , ZhuL , FengJ , TianL , et al. Effect of a novel thermostatic device on meibomian gland dysfunction: a randomized controlled trial in Chinese patients. Ophthalmology and Therapy2022;11(1):261‐70. NCT04310969. Clinical effect of MiboFlo in dry eye patients. clinicaltrials.gov/show/NCT04310969 (first received 17 March 2020). ">Li 2022</a>; <a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a>), two in Thailand (<a href="./references#CD015448-bbs2-0002" title="BooranapongW , PrabhasawatP , ChotikavanichS , TongsaiS , NaranunnP , ThaweerattanasilpW , et al. Comparison of an automated thermodynamic treatment system (LipiFlow) and warm compresses for the treatment of moderate severity of meibomian gland dysfunction. Siriraj Medical Journal2019;72(1):79-86. TCTR20170905001. Comparison of an automated thermodynamic treatment system (LipiFlow®) and eyelid warm compress for the treatment of meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20170905001 (first received 05 September 2017). ">Booranapong 2019</a>; <a href="./references#CD015448-bbs2-0007" title="KasetsuwanN , SuwajanakornD , TantipatC , ReinprayoonU . The efficacy between conventional lid hygiene and additional thermal pulsatile system in meibomian gland dysfunction patients treated with long-term anti-glaucoma medications in a randomized controlled trial. Clinical Ophthalmology (Auckland, NZ)2020;14:2891‐902. TCTR20150919001. Comparison of efficacy between thermal pulsatile system (Lipiflow®) And conventional lid hygiene In anti-glaucoma agent related meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20150919001 (first received 19 September 2015). ">Kasetsuwan 2020</a>), one in France (<a href="./references#CD015448-bbs2-0001" title="BaumannA , CochenerB . Meibomian gland dysfunction: a comparative study of modern treatments. Journal Français d'Ophtalmologie2014;37(4):303‐12. ">Baumann 2014</a>), and one in Italy (<a href="./references#CD015448-bbs2-0009" title="MencucciR , MercuriS , CennamoM , MorelliA , FavuzzaE . Efficacy of Vector Thermal Pulsation treatment in reducing post-cataract surgery dry eye disease in patients affected by meibomian gland dysfunction. Journal of Cataract &amp; Refractive Surgery2022;49(4):423-9. NCT05062564. Efficacy of LipiFlow in patients affected by meibomian gland dysfunction in reducing post-cataract surgery dry eye. clinicaltrials.gov/show/NCT05062564 (first received 30 September 2021). ">Mencucci 2022</a>). Eleven trials were published in English, and two trials were published in other languages (one each in Chinese and French). Twelve trials were published between 2018 and 2022, and one trial was published in 2014 (<a href="./references#CD015448-bbs2-0001" title="BaumannA , CochenerB . Meibomian gland dysfunction: a comparative study of modern treatments. Journal Français d'Ophtalmologie2014;37(4):303‐12. ">Baumann 2014</a>). Seven trials were registered on trial registries, but only two trials had publicly available protocols (<a href="./references#CD015448-bbs2-0012" title="TauberJ . A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction. Cornea2020;39(4):403‐7. ">Tauber 2020b</a>; <a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a>). Eight trials provided power and sample size calculations. </p> <p>Eight trials had a single‐center design, while four trials were multicenter (<a href="./references#CD015448-bbs2-0003" title="GuptaPK , HollandEJ , HovanesianJ , LohJ , JacksonMA , KarpeckiPM , et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea2022;41(4):417‐26. ">Gupta 2022</a>; <a href="./references#CD015448-bbs2-0006" title="BloomensteinM , LohJ , DhamdhereK . Effectiveness of TearCare system in improvement dry eye disease symptoms in meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2022;63(7):1567-A0292. HollandEJ , LohJ , BloomensteinM , ThompsonV , WirtaD , DhamdhereK . A comparison of TearCare and Lipiflow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clinical Ophthalmology (Auckland, NZ)2022;16:2861‐71. NCT03857919. TearCare system to treat dry eye disease. clinicaltrials.gov/show/NCT03857919 (first received 28 February 2019). ">Holland 2022</a>; <a href="./references#CD015448-bbs2-0012" title="TauberJ . A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction. Cornea2020;39(4):403‐7. ">Tauber 2020b</a>; <a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a>). One trial did not report the number of participating centers (<a href="./references#CD015448-bbs2-0004" title="HagenKB , BediR , BlackieCA , Christenson-AkagiKJ . Comparison of a single-dose vectored thermal pulsation procedure with a 3-month course of daily oral doxycycline for moderate-to-severe meibomian gland dysfunction. Clinical Ophthalmology (Auckland, NZ)2018;12:161‐8. ">Hagen 2018</a>). Only one trial reported having received no funding (<a href="./references#CD015448-bbs2-0009" title="MencucciR , MercuriS , CennamoM , MorelliA , FavuzzaE . Efficacy of Vector Thermal Pulsation treatment in reducing post-cataract surgery dry eye disease in patients affected by meibomian gland dysfunction. Journal of Cataract &amp; Refractive Surgery2022;49(4):423-9. NCT05062564. Efficacy of LipiFlow in patients affected by meibomian gland dysfunction in reducing post-cataract surgery dry eye. clinicaltrials.gov/show/NCT05062564 (first received 30 September 2021). ">Mencucci 2022</a>). Two trials reported dual funding sources from the affiliated institution and government (<a href="./references#CD015448-bbs2-0008" title="LiS , YangK , WangJ , ZhuL , FengJ , TianL , et al. Effect of a novel thermostatic device on meibomian gland dysfunction: a randomized controlled trial in Chinese patients. Ophthalmology and Therapy2022;11(1):261‐70. NCT04310969. Clinical effect of MiboFlo in dry eye patients. clinicaltrials.gov/show/NCT04310969 (first received 17 March 2020). ">Li 2022</a>; <a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a>). Five trials received industry funding (<a href="./references#CD015448-bbs2-0003" title="GuptaPK , HollandEJ , HovanesianJ , LohJ , JacksonMA , KarpeckiPM , et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea2022;41(4):417‐26. ">Gupta 2022</a>; <a href="./references#CD015448-bbs2-0006" title="BloomensteinM , LohJ , DhamdhereK . Effectiveness of TearCare system in improvement dry eye disease symptoms in meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2022;63(7):1567-A0292. HollandEJ , LohJ , BloomensteinM , ThompsonV , WirtaD , DhamdhereK . A comparison of TearCare and Lipiflow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clinical Ophthalmology (Auckland, NZ)2022;16:2861‐71. NCT03857919. TearCare system to treat dry eye disease. clinicaltrials.gov/show/NCT03857919 (first received 28 February 2019). ">Holland 2022</a>; <a href="./references#CD015448-bbs2-0011" title="NCT03055832. Comparison Between iLux™ and LipiFlow® in the treatment of meibomian gland dysfunction. clinicaltrials.gov/show/NCT03055832 (first received 16 February 2017). TauberJ , OwenJ , BloomensteinM , HovanesianJ , BullimoreMA . Comparison of the iLUX and the LipiFlow for the treatment of meibomian gland dysfunction and symptoms: a randomized clinical trial. Clinical Ophthalmology (Auckland, NZ)2020;14:405‐18. ">Tauber 2020a</a>; <a href="./references#CD015448-bbs2-0012" title="TauberJ . A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction. Cornea2020;39(4):403‐7. ">Tauber 2020b</a>; <a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a>), while one trial only received funding from the affiliated institution (<a href="./references#CD015448-bbs2-0002" title="BooranapongW , PrabhasawatP , ChotikavanichS , TongsaiS , NaranunnP , ThaweerattanasilpW , et al. Comparison of an automated thermodynamic treatment system (LipiFlow) and warm compresses for the treatment of moderate severity of meibomian gland dysfunction. Siriraj Medical Journal2019;72(1):79-86. TCTR20170905001. Comparison of an automated thermodynamic treatment system (LipiFlow®) and eyelid warm compress for the treatment of meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20170905001 (first received 05 September 2017). ">Booranapong 2019</a>). </p> <p>Five trials randomized the interventions and analyzed all outcomes at the participant level (<a href="./references#CD015448-bbs2-0001" title="BaumannA , CochenerB . Meibomian gland dysfunction: a comparative study of modern treatments. Journal Français d'Ophtalmologie2014;37(4):303‐12. ">Baumann 2014</a>; <a href="./references#CD015448-bbs2-0006" title="BloomensteinM , LohJ , DhamdhereK . Effectiveness of TearCare system in improvement dry eye disease symptoms in meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2022;63(7):1567-A0292. HollandEJ , LohJ , BloomensteinM , ThompsonV , WirtaD , DhamdhereK . A comparison of TearCare and Lipiflow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clinical Ophthalmology (Auckland, NZ)2022;16:2861‐71. NCT03857919. TearCare system to treat dry eye disease. clinicaltrials.gov/show/NCT03857919 (first received 28 February 2019). ">Holland 2022</a>; <a href="./references#CD015448-bbs2-0007" title="KasetsuwanN , SuwajanakornD , TantipatC , ReinprayoonU . The efficacy between conventional lid hygiene and additional thermal pulsatile system in meibomian gland dysfunction patients treated with long-term anti-glaucoma medications in a randomized controlled trial. Clinical Ophthalmology (Auckland, NZ)2020;14:2891‐902. TCTR20150919001. Comparison of efficacy between thermal pulsatile system (Lipiflow®) And conventional lid hygiene In anti-glaucoma agent related meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20150919001 (first received 19 September 2015). ">Kasetsuwan 2020</a>; <a href="./references#CD015448-bbs2-0009" title="MencucciR , MercuriS , CennamoM , MorelliA , FavuzzaE . Efficacy of Vector Thermal Pulsation treatment in reducing post-cataract surgery dry eye disease in patients affected by meibomian gland dysfunction. Journal of Cataract &amp; Refractive Surgery2022;49(4):423-9. NCT05062564. Efficacy of LipiFlow in patients affected by meibomian gland dysfunction in reducing post-cataract surgery dry eye. clinicaltrials.gov/show/NCT05062564 (first received 30 September 2021). ">Mencucci 2022</a>; <a href="./references#CD015448-bbs2-0011" title="NCT03055832. Comparison Between iLux™ and LipiFlow® in the treatment of meibomian gland dysfunction. clinicaltrials.gov/show/NCT03055832 (first received 16 February 2017). TauberJ , OwenJ , BloomensteinM , HovanesianJ , BullimoreMA . Comparison of the iLUX and the LipiFlow for the treatment of meibomian gland dysfunction and symptoms: a randomized clinical trial. Clinical Ophthalmology (Auckland, NZ)2020;14:405‐18. ">Tauber 2020a</a>). Another six trials randomized the intervention at the participant level but analyzed the outcomes at the eye level, with the exception of symptoms score outcomes (<a href="./references#CD015448-bbs2-0003" title="GuptaPK , HollandEJ , HovanesianJ , LohJ , JacksonMA , KarpeckiPM , et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea2022;41(4):417‐26. ">Gupta 2022</a>; <a href="./references#CD015448-bbs2-0004" title="HagenKB , BediR , BlackieCA , Christenson-AkagiKJ . Comparison of a single-dose vectored thermal pulsation procedure with a 3-month course of daily oral doxycycline for moderate-to-severe meibomian gland dysfunction. Clinical Ophthalmology (Auckland, NZ)2018;12:161‐8. ">Hagen 2018</a>; <a href="./references#CD015448-bbs2-0005" title="HeJZ , ZhongM . Comparative study between the meibomian pulsation system and the warm compress treatment for MGD. International Eye Science2018;18(7):1324‐8. ">He 2018</a>; <a href="./references#CD015448-bbs2-0008" title="LiS , YangK , WangJ , ZhuL , FengJ , TianL , et al. Effect of a novel thermostatic device on meibomian gland dysfunction: a randomized controlled trial in Chinese patients. Ophthalmology and Therapy2022;11(1):261‐70. NCT04310969. Clinical effect of MiboFlo in dry eye patients. clinicaltrials.gov/show/NCT04310969 (first received 17 March 2020). ">Li 2022</a>; <a href="./references#CD015448-bbs2-0012" title="TauberJ . A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction. Cornea2020;39(4):403‐7. ">Tauber 2020b</a>; <a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a>). The other two trials randomized the interventions at the eye level and analyzed all outcomes accordingly at the same level (<a href="./references#CD015448-bbs2-0002" title="BooranapongW , PrabhasawatP , ChotikavanichS , TongsaiS , NaranunnP , ThaweerattanasilpW , et al. Comparison of an automated thermodynamic treatment system (LipiFlow) and warm compresses for the treatment of moderate severity of meibomian gland dysfunction. Siriraj Medical Journal2019;72(1):79-86. TCTR20170905001. Comparison of an automated thermodynamic treatment system (LipiFlow®) and eyelid warm compress for the treatment of meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20170905001 (first received 05 September 2017). ">Booranapong 2019</a>; <a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a>). </p> <p>For further details, see <a href="./references#CD015448-sec-0153" title="">Characteristics of included studies</a>. </p> </section> <section id="CD015448-sec-0047"> <h5 class="title">Types of participants</h5> <p>The included trials enrolled a total of 1155 participants (1720 eyes), with 28 to 236 participants enrolled per study. The majority (66%) of participants were women (range 48% to 80%), with participants aged from 19 to 86 years; <a href="./references#CD015448-bbs2-0004" title="HagenKB , BediR , BlackieCA , Christenson-AkagiKJ . Comparison of a single-dose vectored thermal pulsation procedure with a 3-month course of daily oral doxycycline for moderate-to-severe meibomian gland dysfunction. Clinical Ophthalmology (Auckland, NZ)2018;12:161‐8. ">Hagen 2018</a> did not provide any sex or age information. Of the four trials that reported race and ethnicity of participants, the majority of them identified as white, <a href="./references#CD015448-bbs2-0003" title="GuptaPK , HollandEJ , HovanesianJ , LohJ , JacksonMA , KarpeckiPM , et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea2022;41(4):417‐26. ">Gupta 2022</a>; <a href="./references#CD015448-bbs2-0012" title="TauberJ . A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction. Cornea2020;39(4):403‐7. ">Tauber 2020b</a>; <a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a>, or non‐Hispanic, <a href="./references#CD015448-bbs2-0006" title="BloomensteinM , LohJ , DhamdhereK . Effectiveness of TearCare system in improvement dry eye disease symptoms in meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2022;63(7):1567-A0292. HollandEJ , LohJ , BloomensteinM , ThompsonV , WirtaD , DhamdhereK . A comparison of TearCare and Lipiflow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clinical Ophthalmology (Auckland, NZ)2022;16:2861‐71. NCT03857919. TearCare system to treat dry eye disease. clinicaltrials.gov/show/NCT03857919 (first received 28 February 2019). ">Holland 2022</a>; <a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a>; the remaining trials did not provide any race or ethnicity information. All enrolled participants were required to meet the criterion of the trial investigators or having either MGD or DED. Two studies had an additional inclusion criterion that participants had to be receiving antiglaucoma medications in both eyes (<a href="./references#CD015448-bbs2-0007" title="KasetsuwanN , SuwajanakornD , TantipatC , ReinprayoonU . The efficacy between conventional lid hygiene and additional thermal pulsatile system in meibomian gland dysfunction patients treated with long-term anti-glaucoma medications in a randomized controlled trial. Clinical Ophthalmology (Auckland, NZ)2020;14:2891‐902. TCTR20150919001. Comparison of efficacy between thermal pulsatile system (Lipiflow®) And conventional lid hygiene In anti-glaucoma agent related meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20150919001 (first received 19 September 2015). ">Kasetsuwan 2020</a>), or participants were within five weeks of cataract surgery and intraocular lens implantation (<a href="./references#CD015448-bbs2-0009" title="MencucciR , MercuriS , CennamoM , MorelliA , FavuzzaE . Efficacy of Vector Thermal Pulsation treatment in reducing post-cataract surgery dry eye disease in patients affected by meibomian gland dysfunction. Journal of Cataract &amp; Refractive Surgery2022;49(4):423-9. NCT05062564. Efficacy of LipiFlow in patients affected by meibomian gland dysfunction in reducing post-cataract surgery dry eye. clinicaltrials.gov/show/NCT05062564 (first received 30 September 2021). ">Mencucci 2022</a>). </p> </section> <section id="CD015448-sec-0048"> <h5 class="title">Types of interventions</h5> <p>LipiFlow was used as a stand‐alone intervention and compared with four different types of interventions, with the exception of one trial that combined LipiFlow with another intervention and compared the combination of the two to that intervention alone. </p> <p>Five trials compared LipiFlow with basic warm compresses; two trials used warm compresses for one 5‐minute session, <a href="./references#CD015448-bbs2-0002" title="BooranapongW , PrabhasawatP , ChotikavanichS , TongsaiS , NaranunnP , ThaweerattanasilpW , et al. Comparison of an automated thermodynamic treatment system (LipiFlow) and warm compresses for the treatment of moderate severity of meibomian gland dysfunction. Siriraj Medical Journal2019;72(1):79-86. TCTR20170905001. Comparison of an automated thermodynamic treatment system (LipiFlow®) and eyelid warm compress for the treatment of meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20170905001 (first received 05 September 2017). ">Booranapong 2019</a>, or 15 minutes per day over a two‐week period, <a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a>; one trial used warm compresses in combination with eyelid massage for one 5‐minute session (<a href="./references#CD015448-bbs2-0009" title="MencucciR , MercuriS , CennamoM , MorelliA , FavuzzaE . Efficacy of Vector Thermal Pulsation treatment in reducing post-cataract surgery dry eye disease in patients affected by meibomian gland dysfunction. Journal of Cataract &amp; Refractive Surgery2022;49(4):423-9. NCT05062564. Efficacy of LipiFlow in patients affected by meibomian gland dysfunction in reducing post-cataract surgery dry eye. clinicaltrials.gov/show/NCT05062564 (first received 30 September 2021). ">Mencucci 2022</a>); one trial used MeiboPatch for 10 minutes daily over a three‐month period (<a href="./references#CD015448-bbs2-0001" title="BaumannA , CochenerB . Meibomian gland dysfunction: a comparative study of modern treatments. Journal Français d'Ophtalmologie2014;37(4):303‐12. ">Baumann 2014</a>); and one trial used EyeGiene for 15 minutes per day over a two‐week period (<a href="./references#CD015448-bbs2-0005" title="HeJZ , ZhongM . Comparative study between the meibomian pulsation system and the warm compress treatment for MGD. International Eye Science2018;18(7):1324‐8. ">He 2018</a>). </p> <p>Another five trials compared LipiFlow with a thermostatic device. Two of these trials used TearCare for a single 15‐minute treatment (<a href="./references#CD015448-bbs2-0003" title="GuptaPK , HollandEJ , HovanesianJ , LohJ , JacksonMA , KarpeckiPM , et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea2022;41(4):417‐26. ">Gupta 2022</a>; <a href="./references#CD015448-bbs2-0006" title="BloomensteinM , LohJ , DhamdhereK . Effectiveness of TearCare system in improvement dry eye disease symptoms in meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2022;63(7):1567-A0292. HollandEJ , LohJ , BloomensteinM , ThompsonV , WirtaD , DhamdhereK . A comparison of TearCare and Lipiflow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clinical Ophthalmology (Auckland, NZ)2022;16:2861‐71. NCT03857919. TearCare system to treat dry eye disease. clinicaltrials.gov/show/NCT03857919 (first received 28 February 2019). ">Holland 2022</a>); two trials used iLux for a single treatment lasting 8 to 12 minutes (<a href="./references#CD015448-bbs2-0012" title="TauberJ . A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction. Cornea2020;39(4):403‐7. ">Tauber 2020b</a>; <a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a>); and one trial used MiBoFlo for three 10‐minute treatments every two weeks (<a href="./references#CD015448-bbs2-0008" title="LiS , YangK , WangJ , ZhuL , FengJ , TianL , et al. Effect of a novel thermostatic device on meibomian gland dysfunction: a randomized controlled trial in Chinese patients. Ophthalmology and Therapy2022;11(1):261‐70. NCT04310969. Clinical effect of MiboFlo in dry eye patients. clinicaltrials.gov/show/NCT04310969 (first received 17 March 2020). ">Li 2022</a>). </p> <p><a href="./references#CD015448-bbs2-0007" title="KasetsuwanN , SuwajanakornD , TantipatC , ReinprayoonU . The efficacy between conventional lid hygiene and additional thermal pulsatile system in meibomian gland dysfunction patients treated with long-term anti-glaucoma medications in a randomized controlled trial. Clinical Ophthalmology (Auckland, NZ)2020;14:2891‐902. TCTR20150919001. Comparison of efficacy between thermal pulsatile system (Lipiflow®) And conventional lid hygiene In anti-glaucoma agent related meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20150919001 (first received 19 September 2015). ">Kasetsuwan 2020</a> combined the intervention of eyelid hygiene with LipiFlow and compared them with eyelid hygiene alone. <a href="./references#CD015448-bbs2-0011" title="NCT03055832. Comparison Between iLux™ and LipiFlow® in the treatment of meibomian gland dysfunction. clinicaltrials.gov/show/NCT03055832 (first received 16 February 2017). TauberJ , OwenJ , BloomensteinM , HovanesianJ , BullimoreMA . Comparison of the iLUX and the LipiFlow for the treatment of meibomian gland dysfunction and symptoms: a randomized clinical trial. Clinical Ophthalmology (Auckland, NZ)2020;14:405‐18. ">Tauber 2020a</a> used a topical dry eye medication for comparison: participants received 5% lifitegrast ophthalmic solution, applying one drop per eye twice per day for a duration of 42 days. <a href="./references#CD015448-bbs2-0004" title="HagenKB , BediR , BlackieCA , Christenson-AkagiKJ . Comparison of a single-dose vectored thermal pulsation procedure with a 3-month course of daily oral doxycycline for moderate-to-severe meibomian gland dysfunction. Clinical Ophthalmology (Auckland, NZ)2018;12:161‐8. ">Hagen 2018</a> used an oral intervention for comparison: participants were required to take 100 mg of doxycycline twice per day for 14 days, followed by a dosage of 100 mg once per day for days 15 to 90. </p> </section> <section id="CD015448-sec-0049"> <h5 class="title">Types of outcomes</h5> <section id="CD015448-sec-0050"> <h6 class="title">Critical outcome</h6> <section id="CD015448-sec-0051"> <p><b>Mean change from baseline in symptom scores at one to four weeks</b></p> <p>Eleven of the 13 included trials reported changes in patient‐reported symptom scores at one to four weeks post‐treatment, while one trial reported this outcome on day 42. Three trials measured the change in symptoms score by two different questionnaires (<a href="./references#CD015448-bbs2-0001" title="BaumannA , CochenerB . Meibomian gland dysfunction: a comparative study of modern treatments. Journal Français d'Ophtalmologie2014;37(4):303‐12. ">Baumann 2014</a>; <a href="./references#CD015448-bbs2-0003" title="GuptaPK , HollandEJ , HovanesianJ , LohJ , JacksonMA , KarpeckiPM , et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea2022;41(4):417‐26. ">Gupta 2022</a>; <a href="./references#CD015448-bbs2-0006" title="BloomensteinM , LohJ , DhamdhereK . Effectiveness of TearCare system in improvement dry eye disease symptoms in meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2022;63(7):1567-A0292. HollandEJ , LohJ , BloomensteinM , ThompsonV , WirtaD , DhamdhereK . A comparison of TearCare and Lipiflow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clinical Ophthalmology (Auckland, NZ)2022;16:2861‐71. NCT03857919. TearCare system to treat dry eye disease. clinicaltrials.gov/show/NCT03857919 (first received 28 February 2019). ">Holland 2022</a>). Seven trials used the Ocular Surface Disease Index (OSDI) (<a href="./references#CD015448-bbs2-0001" title="BaumannA , CochenerB . Meibomian gland dysfunction: a comparative study of modern treatments. Journal Français d'Ophtalmologie2014;37(4):303‐12. ">Baumann 2014</a>; <a href="./references#CD015448-bbs2-0003" title="GuptaPK , HollandEJ , HovanesianJ , LohJ , JacksonMA , KarpeckiPM , et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea2022;41(4):417‐26. ">Gupta 2022</a>; <a href="./references#CD015448-bbs2-0005" title="HeJZ , ZhongM . Comparative study between the meibomian pulsation system and the warm compress treatment for MGD. International Eye Science2018;18(7):1324‐8. ">He 2018</a>; <a href="./references#CD015448-bbs2-0006" title="BloomensteinM , LohJ , DhamdhereK . Effectiveness of TearCare system in improvement dry eye disease symptoms in meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2022;63(7):1567-A0292. HollandEJ , LohJ , BloomensteinM , ThompsonV , WirtaD , DhamdhereK . A comparison of TearCare and Lipiflow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clinical Ophthalmology (Auckland, NZ)2022;16:2861‐71. NCT03857919. TearCare system to treat dry eye disease. clinicaltrials.gov/show/NCT03857919 (first received 28 February 2019). ">Holland 2022</a>; <a href="./references#CD015448-bbs2-0007" title="KasetsuwanN , SuwajanakornD , TantipatC , ReinprayoonU . The efficacy between conventional lid hygiene and additional thermal pulsatile system in meibomian gland dysfunction patients treated with long-term anti-glaucoma medications in a randomized controlled trial. Clinical Ophthalmology (Auckland, NZ)2020;14:2891‐902. TCTR20150919001. Comparison of efficacy between thermal pulsatile system (Lipiflow®) And conventional lid hygiene In anti-glaucoma agent related meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20150919001 (first received 19 September 2015). ">Kasetsuwan 2020</a>; <a href="./references#CD015448-bbs2-0008" title="LiS , YangK , WangJ , ZhuL , FengJ , TianL , et al. Effect of a novel thermostatic device on meibomian gland dysfunction: a randomized controlled trial in Chinese patients. Ophthalmology and Therapy2022;11(1):261‐70. NCT04310969. Clinical effect of MiboFlo in dry eye patients. clinicaltrials.gov/show/NCT04310969 (first received 17 March 2020). ">Li 2022</a>; <a href="./references#CD015448-bbs2-0012" title="TauberJ . A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction. Cornea2020;39(4):403‐7. ">Tauber 2020b</a>); four trials used the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire (<a href="./references#CD015448-bbs2-0001" title="BaumannA , CochenerB . Meibomian gland dysfunction: a comparative study of modern treatments. Journal Français d'Ophtalmologie2014;37(4):303‐12. ">Baumann 2014</a>; <a href="./references#CD015448-bbs2-0002" title="BooranapongW , PrabhasawatP , ChotikavanichS , TongsaiS , NaranunnP , ThaweerattanasilpW , et al. Comparison of an automated thermodynamic treatment system (LipiFlow) and warm compresses for the treatment of moderate severity of meibomian gland dysfunction. Siriraj Medical Journal2019;72(1):79-86. TCTR20170905001. Comparison of an automated thermodynamic treatment system (LipiFlow®) and eyelid warm compress for the treatment of meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20170905001 (first received 05 September 2017). ">Booranapong 2019</a>; <a href="./references#CD015448-bbs2-0009" title="MencucciR , MercuriS , CennamoM , MorelliA , FavuzzaE . Efficacy of Vector Thermal Pulsation treatment in reducing post-cataract surgery dry eye disease in patients affected by meibomian gland dysfunction. Journal of Cataract &amp; Refractive Surgery2022;49(4):423-9. NCT05062564. Efficacy of LipiFlow in patients affected by meibomian gland dysfunction in reducing post-cataract surgery dry eye. clinicaltrials.gov/show/NCT05062564 (first received 30 September 2021). ">Mencucci 2022</a>; <a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a>); two trials used the Symptom Assessment iN Dry Eye (SANDE) (<a href="./references#CD015448-bbs2-0003" title="GuptaPK , HollandEJ , HovanesianJ , LohJ , JacksonMA , KarpeckiPM , et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea2022;41(4):417‐26. ">Gupta 2022</a>; <a href="./references#CD015448-bbs2-0006" title="BloomensteinM , LohJ , DhamdhereK . Effectiveness of TearCare system in improvement dry eye disease symptoms in meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2022;63(7):1567-A0292. HollandEJ , LohJ , BloomensteinM , ThompsonV , WirtaD , DhamdhereK . A comparison of TearCare and Lipiflow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clinical Ophthalmology (Auckland, NZ)2022;16:2861‐71. NCT03857919. TearCare system to treat dry eye disease. clinicaltrials.gov/show/NCT03857919 (first received 28 February 2019). ">Holland 2022</a>); one trial used Impact of Dry Eye on Everyday Life—Symptom Bother (IDEEL‐SB) (<a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a>); and one trial administered a visual analog scale (VAS) (<a href="./references#CD015448-bbs2-0011" title="NCT03055832. Comparison Between iLux™ and LipiFlow® in the treatment of meibomian gland dysfunction. clinicaltrials.gov/show/NCT03055832 (first received 16 February 2017). TauberJ , OwenJ , BloomensteinM , HovanesianJ , BullimoreMA . Comparison of the iLUX and the LipiFlow for the treatment of meibomian gland dysfunction and symptoms: a randomized clinical trial. Clinical Ophthalmology (Auckland, NZ)2020;14:405‐18. ">Tauber 2020a</a>). All questionnaires were completed by participants. Four trials reported symptom score results referring to one eye (<a href="./references#CD015448-bbs2-0001" title="BaumannA , CochenerB . Meibomian gland dysfunction: a comparative study of modern treatments. Journal Français d'Ophtalmologie2014;37(4):303‐12. ">Baumann 2014</a>; <a href="./references#CD015448-bbs2-0007" title="KasetsuwanN , SuwajanakornD , TantipatC , ReinprayoonU . The efficacy between conventional lid hygiene and additional thermal pulsatile system in meibomian gland dysfunction patients treated with long-term anti-glaucoma medications in a randomized controlled trial. Clinical Ophthalmology (Auckland, NZ)2020;14:2891‐902. TCTR20150919001. Comparison of efficacy between thermal pulsatile system (Lipiflow®) And conventional lid hygiene In anti-glaucoma agent related meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20150919001 (first received 19 September 2015). ">Kasetsuwan 2020</a>; <a href="./references#CD015448-bbs2-0009" title="MencucciR , MercuriS , CennamoM , MorelliA , FavuzzaE . Efficacy of Vector Thermal Pulsation treatment in reducing post-cataract surgery dry eye disease in patients affected by meibomian gland dysfunction. Journal of Cataract &amp; Refractive Surgery2022;49(4):423-9. NCT05062564. Efficacy of LipiFlow in patients affected by meibomian gland dysfunction in reducing post-cataract surgery dry eye. clinicaltrials.gov/show/NCT05062564 (first received 30 September 2021). ">Mencucci 2022</a>; <a href="./references#CD015448-bbs2-0011" title="NCT03055832. Comparison Between iLux™ and LipiFlow® in the treatment of meibomian gland dysfunction. clinicaltrials.gov/show/NCT03055832 (first received 16 February 2017). TauberJ , OwenJ , BloomensteinM , HovanesianJ , BullimoreMA . Comparison of the iLUX and the LipiFlow for the treatment of meibomian gland dysfunction and symptoms: a randomized clinical trial. Clinical Ophthalmology (Auckland, NZ)2020;14:405‐18. ">Tauber 2020a</a>); eight trials reported results for both eyes with the same intervention (<a href="./references#CD015448-bbs2-0003" title="GuptaPK , HollandEJ , HovanesianJ , LohJ , JacksonMA , KarpeckiPM , et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea2022;41(4):417‐26. ">Gupta 2022</a>; <a href="./references#CD015448-bbs2-0004" title="HagenKB , BediR , BlackieCA , Christenson-AkagiKJ . Comparison of a single-dose vectored thermal pulsation procedure with a 3-month course of daily oral doxycycline for moderate-to-severe meibomian gland dysfunction. Clinical Ophthalmology (Auckland, NZ)2018;12:161‐8. ">Hagen 2018</a>; <a href="./references#CD015448-bbs2-0005" title="HeJZ , ZhongM . Comparative study between the meibomian pulsation system and the warm compress treatment for MGD. International Eye Science2018;18(7):1324‐8. ">He 2018</a>; <a href="./references#CD015448-bbs2-0006" title="BloomensteinM , LohJ , DhamdhereK . Effectiveness of TearCare system in improvement dry eye disease symptoms in meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2022;63(7):1567-A0292. HollandEJ , LohJ , BloomensteinM , ThompsonV , WirtaD , DhamdhereK . A comparison of TearCare and Lipiflow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clinical Ophthalmology (Auckland, NZ)2022;16:2861‐71. NCT03857919. TearCare system to treat dry eye disease. clinicaltrials.gov/show/NCT03857919 (first received 28 February 2019). ">Holland 2022</a>; <a href="./references#CD015448-bbs2-0008" title="LiS , YangK , WangJ , ZhuL , FengJ , TianL , et al. Effect of a novel thermostatic device on meibomian gland dysfunction: a randomized controlled trial in Chinese patients. Ophthalmology and Therapy2022;11(1):261‐70. NCT04310969. Clinical effect of MiboFlo in dry eye patients. clinicaltrials.gov/show/NCT04310969 (first received 17 March 2020). ">Li 2022</a>; <a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a>; <a href="./references#CD015448-bbs2-0012" title="TauberJ . A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction. Cornea2020;39(4):403‐7. ">Tauber 2020b</a>; <a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a>); and one trial reported results for both eyes with different interventions (<a href="./references#CD015448-bbs2-0002" title="BooranapongW , PrabhasawatP , ChotikavanichS , TongsaiS , NaranunnP , ThaweerattanasilpW , et al. Comparison of an automated thermodynamic treatment system (LipiFlow) and warm compresses for the treatment of moderate severity of meibomian gland dysfunction. Siriraj Medical Journal2019;72(1):79-86. TCTR20170905001. Comparison of an automated thermodynamic treatment system (LipiFlow®) and eyelid warm compress for the treatment of meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20170905001 (first received 05 September 2017). ">Booranapong 2019</a>). </p> </section> </section> <section id="CD015448-sec-0052"> <h6 class="title">Important outcomes</h6> <section id="CD015448-sec-0053"> <p><b>Mean change from baseline in symptom scores at between 6 months and 12 months</b></p> <p>Three trials reported changes in symptom scores between 6 months and 12 months: two trials reported at month 6 (<a href="./references#CD015448-bbs2-0002" title="BooranapongW , PrabhasawatP , ChotikavanichS , TongsaiS , NaranunnP , ThaweerattanasilpW , et al. Comparison of an automated thermodynamic treatment system (LipiFlow) and warm compresses for the treatment of moderate severity of meibomian gland dysfunction. Siriraj Medical Journal2019;72(1):79-86. TCTR20170905001. Comparison of an automated thermodynamic treatment system (LipiFlow®) and eyelid warm compress for the treatment of meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20170905001 (first received 05 September 2017). ">Booranapong 2019</a>; <a href="./references#CD015448-bbs2-0007" title="KasetsuwanN , SuwajanakornD , TantipatC , ReinprayoonU . The efficacy between conventional lid hygiene and additional thermal pulsatile system in meibomian gland dysfunction patients treated with long-term anti-glaucoma medications in a randomized controlled trial. Clinical Ophthalmology (Auckland, NZ)2020;14:2891‐902. TCTR20150919001. Comparison of efficacy between thermal pulsatile system (Lipiflow®) And conventional lid hygiene In anti-glaucoma agent related meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20150919001 (first received 19 September 2015). ">Kasetsuwan 2020</a>), and one trial reported at month 12 (<a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a>). The OSDI, SPEED, and IDEEL‐SB questionnaires were used. </p> </section> <section id="CD015448-sec-0054"> <p><b>Mean change from baseline in meibomian gland expression at one to four weeks</b></p> <p>Nine trials reported changes in meibomian gland expression at one to four weeks, and one trial reported this outcome on day 42. Four trials reported the meibomian gland expression score using a 0‐to‐3 scale, with a total score range of 0 to 45 when 15 glands were evaluated (<a href="./references#CD015448-bbs2-0007" title="KasetsuwanN , SuwajanakornD , TantipatC , ReinprayoonU . The efficacy between conventional lid hygiene and additional thermal pulsatile system in meibomian gland dysfunction patients treated with long-term anti-glaucoma medications in a randomized controlled trial. Clinical Ophthalmology (Auckland, NZ)2020;14:2891‐902. TCTR20150919001. Comparison of efficacy between thermal pulsatile system (Lipiflow®) And conventional lid hygiene In anti-glaucoma agent related meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20150919001 (first received 19 September 2015). ">Kasetsuwan 2020</a>; <a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a>; <a href="./references#CD015448-bbs2-0012" title="TauberJ . A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction. Cornea2020;39(4):403‐7. ">Tauber 2020b</a>; <a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a>). <a href="./references#CD015448-bbs2-0008" title="LiS , YangK , WangJ , ZhuL , FengJ , TianL , et al. Effect of a novel thermostatic device on meibomian gland dysfunction: a randomized controlled trial in Chinese patients. Ophthalmology and Therapy2022;11(1):261‐70. NCT04310969. Clinical effect of MiboFlo in dry eye patients. clinicaltrials.gov/show/NCT04310969 (first received 17 March 2020). ">Li 2022</a> also used a 0‐to‐3 scale, but the total score range was 0 to 18 because six glands were evaluated. <a href="./references#CD015448-bbs2-0011" title="NCT03055832. Comparison Between iLux™ and LipiFlow® in the treatment of meibomian gland dysfunction. clinicaltrials.gov/show/NCT03055832 (first received 16 February 2017). TauberJ , OwenJ , BloomensteinM , HovanesianJ , BullimoreMA . Comparison of the iLUX and the LipiFlow for the treatment of meibomian gland dysfunction and symptoms: a randomized clinical trial. Clinical Ophthalmology (Auckland, NZ)2020;14:405‐18. ">Tauber 2020a</a> used a 0‐to‐8 scale to evaluate the patency of the central eight glands on the lower eyelid. The remaining three trials did not specify the score scale system used (<a href="./references#CD015448-bbs2-0001" title="BaumannA , CochenerB . Meibomian gland dysfunction: a comparative study of modern treatments. Journal Français d'Ophtalmologie2014;37(4):303‐12. ">Baumann 2014</a>; <a href="./references#CD015448-bbs2-0002" title="BooranapongW , PrabhasawatP , ChotikavanichS , TongsaiS , NaranunnP , ThaweerattanasilpW , et al. Comparison of an automated thermodynamic treatment system (LipiFlow) and warm compresses for the treatment of moderate severity of meibomian gland dysfunction. Siriraj Medical Journal2019;72(1):79-86. TCTR20170905001. Comparison of an automated thermodynamic treatment system (LipiFlow®) and eyelid warm compress for the treatment of meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20170905001 (first received 05 September 2017). ">Booranapong 2019</a>; <a href="./references#CD015448-bbs2-0006" title="BloomensteinM , LohJ , DhamdhereK . Effectiveness of TearCare system in improvement dry eye disease symptoms in meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2022;63(7):1567-A0292. HollandEJ , LohJ , BloomensteinM , ThompsonV , WirtaD , DhamdhereK . A comparison of TearCare and Lipiflow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clinical Ophthalmology (Auckland, NZ)2022;16:2861‐71. NCT03857919. TearCare system to treat dry eye disease. clinicaltrials.gov/show/NCT03857919 (first received 28 February 2019). ">Holland 2022</a>). </p> </section> <section id="CD015448-sec-0055"> <p><b>Mean change from baseline in meibum quality at one to four weeks</b></p> <p>Four trials reported changes in meibum quality at one to four weeks, and one trial reported this outcome on day 42. Two trials reported the meibum quality score using a 0‐to‐3 scale, with a total score range of 0 to 45 when 15 glands were evaluated (<a href="./references#CD015448-bbs2-0003" title="GuptaPK , HollandEJ , HovanesianJ , LohJ , JacksonMA , KarpeckiPM , et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea2022;41(4):417‐26. ">Gupta 2022</a>; <a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a>). Another two trials also used a 0‐to‐3 scale, with no total score range provided (<a href="./references#CD015448-bbs2-0008" title="LiS , YangK , WangJ , ZhuL , FengJ , TianL , et al. Effect of a novel thermostatic device on meibomian gland dysfunction: a randomized controlled trial in Chinese patients. Ophthalmology and Therapy2022;11(1):261‐70. NCT04310969. Clinical effect of MiboFlo in dry eye patients. clinicaltrials.gov/show/NCT04310969 (first received 17 March 2020). ">Li 2022</a>; <a href="./references#CD015448-bbs2-0011" title="NCT03055832. Comparison Between iLux™ and LipiFlow® in the treatment of meibomian gland dysfunction. clinicaltrials.gov/show/NCT03055832 (first received 16 February 2017). TauberJ , OwenJ , BloomensteinM , HovanesianJ , BullimoreMA . Comparison of the iLUX and the LipiFlow for the treatment of meibomian gland dysfunction and symptoms: a randomized clinical trial. Clinical Ophthalmology (Auckland, NZ)2020;14:405‐18. ">Tauber 2020a</a>). <a href="./references#CD015448-bbs2-0009" title="MencucciR , MercuriS , CennamoM , MorelliA , FavuzzaE . Efficacy of Vector Thermal Pulsation treatment in reducing post-cataract surgery dry eye disease in patients affected by meibomian gland dysfunction. Journal of Cataract &amp; Refractive Surgery2022;49(4):423-9. NCT05062564. Efficacy of LipiFlow in patients affected by meibomian gland dysfunction in reducing post-cataract surgery dry eye. clinicaltrials.gov/show/NCT05062564 (first received 30 September 2021). ">Mencucci 2022</a> did not specify the score scale system used. </p> </section> <section id="CD015448-sec-0056"> <p><b>Mean change from baseline in meibomian gland atrophy at one to four weeks</b></p> <p>None of the included trials reported this outcome at one to four weeks. <a href="./references#CD015448-bbs2-0008" title="LiS , YangK , WangJ , ZhuL , FengJ , TianL , et al. Effect of a novel thermostatic device on meibomian gland dysfunction: a randomized controlled trial in Chinese patients. Ophthalmology and Therapy2022;11(1):261‐70. NCT04310969. Clinical effect of MiboFlo in dry eye patients. clinicaltrials.gov/show/NCT04310969 (first received 17 March 2020). ">Li 2022</a> reported meibomian gland atrophy at month 2, while <a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a> reported it at month 3. </p> </section> <section id="CD015448-sec-0057"> <p><b>Mean change from baseline in tear breakup time at one to four weeks</b></p> <p>Six trials reported changes in invasive tear breakup time (TBUT) with sodium fluorescein (<a href="./references#CD015448-bbs2-0001" title="BaumannA , CochenerB . Meibomian gland dysfunction: a comparative study of modern treatments. Journal Français d'Ophtalmologie2014;37(4):303‐12. ">Baumann 2014</a>; <a href="./references#CD015448-bbs2-0003" title="GuptaPK , HollandEJ , HovanesianJ , LohJ , JacksonMA , KarpeckiPM , et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea2022;41(4):417‐26. ">Gupta 2022</a>; <a href="./references#CD015448-bbs2-0005" title="HeJZ , ZhongM . Comparative study between the meibomian pulsation system and the warm compress treatment for MGD. International Eye Science2018;18(7):1324‐8. ">He 2018</a>; <a href="./references#CD015448-bbs2-0007" title="KasetsuwanN , SuwajanakornD , TantipatC , ReinprayoonU . The efficacy between conventional lid hygiene and additional thermal pulsatile system in meibomian gland dysfunction patients treated with long-term anti-glaucoma medications in a randomized controlled trial. Clinical Ophthalmology (Auckland, NZ)2020;14:2891‐902. TCTR20150919001. Comparison of efficacy between thermal pulsatile system (Lipiflow®) And conventional lid hygiene In anti-glaucoma agent related meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20150919001 (first received 19 September 2015). ">Kasetsuwan 2020</a>; <a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a>; <a href="./references#CD015448-bbs2-0012" title="TauberJ . A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction. Cornea2020;39(4):403‐7. ">Tauber 2020b</a>), while three trials reported changes in non‐invasive tear breakup time (NITBUT) at one to four weeks (<a href="./references#CD015448-bbs2-0008" title="LiS , YangK , WangJ , ZhuL , FengJ , TianL , et al. Effect of a novel thermostatic device on meibomian gland dysfunction: a randomized controlled trial in Chinese patients. Ophthalmology and Therapy2022;11(1):261‐70. NCT04310969. Clinical effect of MiboFlo in dry eye patients. clinicaltrials.gov/show/NCT04310969 (first received 17 March 2020). ">Li 2022</a>; <a href="./references#CD015448-bbs2-0009" title="MencucciR , MercuriS , CennamoM , MorelliA , FavuzzaE . Efficacy of Vector Thermal Pulsation treatment in reducing post-cataract surgery dry eye disease in patients affected by meibomian gland dysfunction. Journal of Cataract &amp; Refractive Surgery2022;49(4):423-9. NCT05062564. Efficacy of LipiFlow in patients affected by meibomian gland dysfunction in reducing post-cataract surgery dry eye. clinicaltrials.gov/show/NCT05062564 (first received 30 September 2021). ">Mencucci 2022</a>; <a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a>). </p> </section> <section id="CD015448-sec-0058"> <p><b>Adverse events: intervention‐related, vision‐threatening adverse event</b></p> <p>Ten trials reported no occurrence of intervention‐related, vision‐threatening adverse events during the treatment or follow‐up period (<a href="./references#CD015448-bbs2-0002" title="BooranapongW , PrabhasawatP , ChotikavanichS , TongsaiS , NaranunnP , ThaweerattanasilpW , et al. Comparison of an automated thermodynamic treatment system (LipiFlow) and warm compresses for the treatment of moderate severity of meibomian gland dysfunction. Siriraj Medical Journal2019;72(1):79-86. TCTR20170905001. Comparison of an automated thermodynamic treatment system (LipiFlow®) and eyelid warm compress for the treatment of meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20170905001 (first received 05 September 2017). ">Booranapong 2019</a>; <a href="./references#CD015448-bbs2-0003" title="GuptaPK , HollandEJ , HovanesianJ , LohJ , JacksonMA , KarpeckiPM , et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea2022;41(4):417‐26. ">Gupta 2022</a>; <a href="./references#CD015448-bbs2-0004" title="HagenKB , BediR , BlackieCA , Christenson-AkagiKJ . Comparison of a single-dose vectored thermal pulsation procedure with a 3-month course of daily oral doxycycline for moderate-to-severe meibomian gland dysfunction. Clinical Ophthalmology (Auckland, NZ)2018;12:161‐8. ">Hagen 2018</a>; <a href="./references#CD015448-bbs2-0005" title="HeJZ , ZhongM . Comparative study between the meibomian pulsation system and the warm compress treatment for MGD. International Eye Science2018;18(7):1324‐8. ">He 2018</a>; <a href="./references#CD015448-bbs2-0008" title="LiS , YangK , WangJ , ZhuL , FengJ , TianL , et al. Effect of a novel thermostatic device on meibomian gland dysfunction: a randomized controlled trial in Chinese patients. Ophthalmology and Therapy2022;11(1):261‐70. NCT04310969. Clinical effect of MiboFlo in dry eye patients. clinicaltrials.gov/show/NCT04310969 (first received 17 March 2020). ">Li 2022</a>; <a href="./references#CD015448-bbs2-0009" title="MencucciR , MercuriS , CennamoM , MorelliA , FavuzzaE . Efficacy of Vector Thermal Pulsation treatment in reducing post-cataract surgery dry eye disease in patients affected by meibomian gland dysfunction. Journal of Cataract &amp; Refractive Surgery2022;49(4):423-9. NCT05062564. Efficacy of LipiFlow in patients affected by meibomian gland dysfunction in reducing post-cataract surgery dry eye. clinicaltrials.gov/show/NCT05062564 (first received 30 September 2021). ">Mencucci 2022</a>; <a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a>; <a href="./references#CD015448-bbs2-0011" title="NCT03055832. Comparison Between iLux™ and LipiFlow® in the treatment of meibomian gland dysfunction. clinicaltrials.gov/show/NCT03055832 (first received 16 February 2017). TauberJ , OwenJ , BloomensteinM , HovanesianJ , BullimoreMA . Comparison of the iLUX and the LipiFlow for the treatment of meibomian gland dysfunction and symptoms: a randomized clinical trial. Clinical Ophthalmology (Auckland, NZ)2020;14:405‐18. ">Tauber 2020a</a>; <a href="./references#CD015448-bbs2-0012" title="TauberJ . A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction. Cornea2020;39(4):403‐7. ">Tauber 2020b</a>; <a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a>). Three trials did not report or measure adverse events (<a href="./references#CD015448-bbs2-0001" title="BaumannA , CochenerB . Meibomian gland dysfunction: a comparative study of modern treatments. Journal Français d'Ophtalmologie2014;37(4):303‐12. ">Baumann 2014</a>; <a href="./references#CD015448-bbs2-0006" title="BloomensteinM , LohJ , DhamdhereK . Effectiveness of TearCare system in improvement dry eye disease symptoms in meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2022;63(7):1567-A0292. HollandEJ , LohJ , BloomensteinM , ThompsonV , WirtaD , DhamdhereK . A comparison of TearCare and Lipiflow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clinical Ophthalmology (Auckland, NZ)2022;16:2861‐71. NCT03857919. TearCare system to treat dry eye disease. clinicaltrials.gov/show/NCT03857919 (first received 28 February 2019). ">Holland 2022</a>; <a href="./references#CD015448-bbs2-0007" title="KasetsuwanN , SuwajanakornD , TantipatC , ReinprayoonU . The efficacy between conventional lid hygiene and additional thermal pulsatile system in meibomian gland dysfunction patients treated with long-term anti-glaucoma medications in a randomized controlled trial. Clinical Ophthalmology (Auckland, NZ)2020;14:2891‐902. TCTR20150919001. Comparison of efficacy between thermal pulsatile system (Lipiflow®) And conventional lid hygiene In anti-glaucoma agent related meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20150919001 (first received 19 September 2015). ">Kasetsuwan 2020</a>). </p> </section> <section id="CD015448-sec-0059"> <p><b>Progression of dry eye</b></p> <p>None of the included trials reported this outcome.</p> </section> </section> </section> </section> <section id="CD015448-sec-0060"> <h4 class="title">Excluded studies</h4> <p>We excluded 10 trials after evaluating the full‐text reports or trial registry records. Eight studies had an ineligible trial design; one study did not enroll the population of interest; and one study had an ineligible intervention or comparator. See <a href="./references#CD015448-sec-0154" title="">Characteristics of excluded studies</a>. </p> </section> <section id="CD015448-sec-0061"> <h4 class="title">Ongoing studies and studies awaiting classification</h4> <p>We identified six ongoing trials (<a href="./references#CD015448-bbs2-0025" title="ChiCTR2100048758. Effects and safety of LipiFlow on meibomian gland dysfunction for patients with ocular graft-versus-host diseases. chictr.org.cn/showproj.aspx?proj=130238 (first received 16 July 2021). ">ChiCTR2100048758</a>; <a href="./references#CD015448-bbs2-0026" title="ChiCTR2100050323. Vectored thermal pulsation, intense pulsed light, and eyelid warm compress (VIEW) therapies for meibomian gland dysfunction—a randomized, assessor-masked, active-controlled clinical trial. chictr.org.cn/showproj.aspx?proj=132588 (first received 26 August 2021). ">ChiCTR2100050323</a>; <a href="./references#CD015448-bbs2-0027" title="NCT04322656. Stability of biometry in meibomian gland dysfunction. clinicaltrials.gov/show/NCT04322656 (first received 26 March 2020). ">NCT04322656</a>; <a href="./references#CD015448-bbs2-0028" title="Evaluation of the efficacy of intense pulse light combined with LipiFlow in the treatment of meibomian gland dysfunction. clinicaltrials.gov/show/NCT04633798 (first received 18 November 2020). ">NCT04633798</a>; <a href="./references#CD015448-bbs2-0029" title="NCT05162261. To evaluate the effectiveness and safety of the Tixel®, vs LipiFlow® in the treatment of meibomian gland dysfunction. clinicaltrials.gov/show/NCT05162261 (first received 17 December 2021). ">NCT05162261</a>; <a href="./references#CD015448-bbs2-0030" title="NCT05577910. Vectored thermal pulsation, intense pulsed light, and eyelid warm compress therapies for MGD. clinicaltrials.gov/ct2/show/NCT05577910 (first received 13 October 2022). ">NCT05577910</a>). We assessed one eligible trial that was completed but for which trial results were unavailable as awaiting classification (<a href="./references#CD015448-bbs2-0024" title="ChiCTR-INR-17013856. Evaluation of the effectiveness of LipiFlow in the treatment of MGD. chictr.org.cn/showproj.aspx?proj=23844 (first received 12 December 2017). ">ChiCTR‐INR‐17013856</a>). </p> </section> </section> <section id="CD015448-sec-0062"> <h3 class="title">Risk of bias in included studies</h3> <p>We applied the RoB 2 tool to assess risk of bias for symptom scores that were measured with any validated symptom questionnaire at one to four weeks post‐treatment (<a href="#CD015448-fig-0002">Figure 2</a>). Of the 13 included trials, 11 reported symptom scores at one to four weeks post‐treatment. We judged the overall risk of bias as high for seven trials, and some concerns for the remaining four trials considering that patient‐reported outcomes could potentially be influenced by participant awareness of the intervention received. Detailed assessments for each trial's domain‐specific judgments and supporting statements can be found in the <a href="./references#CD015448-sec-0153" title="">Characteristics of included studies</a> section. </p> <div class="figure" id="CD015448-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: symptom scores at one to four weeks." data-id="CD015448-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-FIG-02.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: symptom scores at one to four weeks.</p> </div> </div> </div> <section id="CD015448-sec-0063"> <h4 class="title">Domain 1: Bias arising from the randomization process</h4> <p>We judged <a href="./references#CD015448-bbs2-0001" title="BaumannA , CochenerB . Meibomian gland dysfunction: a comparative study of modern treatments. Journal Français d'Ophtalmologie2014;37(4):303‐12. ">Baumann 2014</a> as at high risk of bias as there were significant baseline differences between the two intervention groups. Eight trials (72%) did not provide sufficient information about allocation sequence and were therefore deemed as having some concerns (<a href="./references#CD015448-bbs2-0002" title="BooranapongW , PrabhasawatP , ChotikavanichS , TongsaiS , NaranunnP , ThaweerattanasilpW , et al. Comparison of an automated thermodynamic treatment system (LipiFlow) and warm compresses for the treatment of moderate severity of meibomian gland dysfunction. Siriraj Medical Journal2019;72(1):79-86. TCTR20170905001. Comparison of an automated thermodynamic treatment system (LipiFlow®) and eyelid warm compress for the treatment of meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20170905001 (first received 05 September 2017). ">Booranapong 2019</a>; <a href="./references#CD015448-bbs2-0003" title="GuptaPK , HollandEJ , HovanesianJ , LohJ , JacksonMA , KarpeckiPM , et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea2022;41(4):417‐26. ">Gupta 2022</a>; <a href="./references#CD015448-bbs2-0005" title="HeJZ , ZhongM . Comparative study between the meibomian pulsation system and the warm compress treatment for MGD. International Eye Science2018;18(7):1324‐8. ">He 2018</a>; <a href="./references#CD015448-bbs2-0006" title="BloomensteinM , LohJ , DhamdhereK . Effectiveness of TearCare system in improvement dry eye disease symptoms in meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2022;63(7):1567-A0292. HollandEJ , LohJ , BloomensteinM , ThompsonV , WirtaD , DhamdhereK . A comparison of TearCare and Lipiflow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clinical Ophthalmology (Auckland, NZ)2022;16:2861‐71. NCT03857919. TearCare system to treat dry eye disease. clinicaltrials.gov/show/NCT03857919 (first received 28 February 2019). ">Holland 2022</a>; <a href="./references#CD015448-bbs2-0008" title="LiS , YangK , WangJ , ZhuL , FengJ , TianL , et al. Effect of a novel thermostatic device on meibomian gland dysfunction: a randomized controlled trial in Chinese patients. Ophthalmology and Therapy2022;11(1):261‐70. NCT04310969. Clinical effect of MiboFlo in dry eye patients. clinicaltrials.gov/show/NCT04310969 (first received 17 March 2020). ">Li 2022</a>; <a href="./references#CD015448-bbs2-0009" title="MencucciR , MercuriS , CennamoM , MorelliA , FavuzzaE . Efficacy of Vector Thermal Pulsation treatment in reducing post-cataract surgery dry eye disease in patients affected by meibomian gland dysfunction. Journal of Cataract &amp; Refractive Surgery2022;49(4):423-9. NCT05062564. Efficacy of LipiFlow in patients affected by meibomian gland dysfunction in reducing post-cataract surgery dry eye. clinicaltrials.gov/show/NCT05062564 (first received 30 September 2021). ">Mencucci 2022</a>; <a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a>; <a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a>). We judged the other two trials to be at low risk of bias for this domain (<a href="./references#CD015448-bbs2-0007" title="KasetsuwanN , SuwajanakornD , TantipatC , ReinprayoonU . The efficacy between conventional lid hygiene and additional thermal pulsatile system in meibomian gland dysfunction patients treated with long-term anti-glaucoma medications in a randomized controlled trial. Clinical Ophthalmology (Auckland, NZ)2020;14:2891‐902. TCTR20150919001. Comparison of efficacy between thermal pulsatile system (Lipiflow®) And conventional lid hygiene In anti-glaucoma agent related meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20150919001 (first received 19 September 2015). ">Kasetsuwan 2020</a>; <a href="./references#CD015448-bbs2-0012" title="TauberJ . A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction. Cornea2020;39(4):403‐7. ">Tauber 2020b</a>). </p> </section> <section id="CD015448-sec-0064"> <h4 class="title">Domain 2: Bias due to deviations from intended interventions</h4> <p>We judged two trials as having some concerns: <a href="./references#CD015448-bbs2-0003" title="GuptaPK , HollandEJ , HovanesianJ , LohJ , JacksonMA , KarpeckiPM , et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea2022;41(4):417‐26. ">Gupta 2022</a> used a per‐protocol analysis, and in <a href="./references#CD015448-bbs2-0006" title="BloomensteinM , LohJ , DhamdhereK . Effectiveness of TearCare system in improvement dry eye disease symptoms in meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2022;63(7):1567-A0292. HollandEJ , LohJ , BloomensteinM , ThompsonV , WirtaD , DhamdhereK . A comparison of TearCare and Lipiflow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clinical Ophthalmology (Auckland, NZ)2022;16:2861‐71. NCT03857919. TearCare system to treat dry eye disease. clinicaltrials.gov/show/NCT03857919 (first received 28 February 2019). ">Holland 2022</a> the analysis used for estimating the effect of assignment was unclear, and insufficient information was provided regarding the number of participants randomized. We judged the remaining nine trials (81%) to be at low risk of bias for this domain. </p> </section> <section id="CD015448-sec-0065"> <h4 class="title">Domain 3: Bias due to missing outcome data</h4> <p>We judged two trials to be at high risk of bias for this domain: <a href="./references#CD015448-bbs2-0006" title="BloomensteinM , LohJ , DhamdhereK . Effectiveness of TearCare system in improvement dry eye disease symptoms in meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2022;63(7):1567-A0292. HollandEJ , LohJ , BloomensteinM , ThompsonV , WirtaD , DhamdhereK . A comparison of TearCare and Lipiflow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clinical Ophthalmology (Auckland, NZ)2022;16:2861‐71. NCT03857919. TearCare system to treat dry eye disease. clinicaltrials.gov/show/NCT03857919 (first received 28 February 2019). ">Holland 2022</a> did not provide information on the number of participants randomized or lost to follow‐up, and the enrollment numbers differed between the published article and trial registry; and in <a href="./references#CD015448-bbs2-0007" title="KasetsuwanN , SuwajanakornD , TantipatC , ReinprayoonU . The efficacy between conventional lid hygiene and additional thermal pulsatile system in meibomian gland dysfunction patients treated with long-term anti-glaucoma medications in a randomized controlled trial. Clinical Ophthalmology (Auckland, NZ)2020;14:2891‐902. TCTR20150919001. Comparison of efficacy between thermal pulsatile system (Lipiflow®) And conventional lid hygiene In anti-glaucoma agent related meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20150919001 (first received 19 September 2015). ">Kasetsuwan 2020</a>, only 20% of outcome data were available for randomized participants (<a href="./references#CD015448-bbs2-0007" title="KasetsuwanN , SuwajanakornD , TantipatC , ReinprayoonU . The efficacy between conventional lid hygiene and additional thermal pulsatile system in meibomian gland dysfunction patients treated with long-term anti-glaucoma medications in a randomized controlled trial. Clinical Ophthalmology (Auckland, NZ)2020;14:2891‐902. TCTR20150919001. Comparison of efficacy between thermal pulsatile system (Lipiflow®) And conventional lid hygiene In anti-glaucoma agent related meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20150919001 (first received 19 September 2015). ">Kasetsuwan 2020</a>). We judged the remaining nine trials (82%) to be at low risk of bias for this domain. </p> </section> <section id="CD015448-sec-0066"> <h4 class="title">Domain 4: Bias in measurement of the outcome</h4> <p>We judged five trials to be at a high risk of bias due to their open‐label design (<a href="./references#CD015448-bbs2-0005" title="HeJZ , ZhongM . Comparative study between the meibomian pulsation system and the warm compress treatment for MGD. International Eye Science2018;18(7):1324‐8. ">He 2018</a>; <a href="./references#CD015448-bbs2-0009" title="MencucciR , MercuriS , CennamoM , MorelliA , FavuzzaE . Efficacy of Vector Thermal Pulsation treatment in reducing post-cataract surgery dry eye disease in patients affected by meibomian gland dysfunction. Journal of Cataract &amp; Refractive Surgery2022;49(4):423-9. NCT05062564. Efficacy of LipiFlow in patients affected by meibomian gland dysfunction in reducing post-cataract surgery dry eye. clinicaltrials.gov/show/NCT05062564 (first received 30 September 2021). ">Mencucci 2022</a>; <a href="./references#CD015448-bbs2-0012" title="TauberJ . A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction. Cornea2020;39(4):403‐7. ">Tauber 2020b</a>), paired‐eye approach (<a href="./references#CD015448-bbs2-0002" title="BooranapongW , PrabhasawatP , ChotikavanichS , TongsaiS , NaranunnP , ThaweerattanasilpW , et al. Comparison of an automated thermodynamic treatment system (LipiFlow) and warm compresses for the treatment of moderate severity of meibomian gland dysfunction. Siriraj Medical Journal2019;72(1):79-86. TCTR20170905001. Comparison of an automated thermodynamic treatment system (LipiFlow®) and eyelid warm compress for the treatment of meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20170905001 (first received 05 September 2017). ">Booranapong 2019</a>), or participants being aware of their assigned treatment (<a href="./references#CD015448-bbs2-0007" title="KasetsuwanN , SuwajanakornD , TantipatC , ReinprayoonU . The efficacy between conventional lid hygiene and additional thermal pulsatile system in meibomian gland dysfunction patients treated with long-term anti-glaucoma medications in a randomized controlled trial. Clinical Ophthalmology (Auckland, NZ)2020;14:2891‐902. TCTR20150919001. Comparison of efficacy between thermal pulsatile system (Lipiflow®) And conventional lid hygiene In anti-glaucoma agent related meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20150919001 (first received 19 September 2015). ">Kasetsuwan 2020</a>). We judged the other six trials as having some concerns because symptom scores were patient‐reported, and because participants were aware of their assigned treatment, which could have influenced the results. </p> </section> <section id="CD015448-sec-0067"> <h4 class="title">Domain 5: Bias in selective results reporting</h4> <p>We judged three trials to be at low risk of bias as symptom scores outcomes were analyzed according to specifications outlined in the trial protocol (<a href="./references#CD015448-bbs2-0012" title="TauberJ . A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction. Cornea2020;39(4):403‐7. ">Tauber 2020b</a>; <a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a>), or followed the description in the methods section of the trial report (<a href="./references#CD015448-bbs2-0003" title="GuptaPK , HollandEJ , HovanesianJ , LohJ , JacksonMA , KarpeckiPM , et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea2022;41(4):417‐26. ">Gupta 2022</a>). Eight trials (72%) did not have a statistical analysis plan or protocol available for assessment and were therefore judged as some concerns for this domain (<a href="./references#CD015448-bbs2-0001" title="BaumannA , CochenerB . Meibomian gland dysfunction: a comparative study of modern treatments. Journal Français d'Ophtalmologie2014;37(4):303‐12. ">Baumann 2014</a>; <a href="./references#CD015448-bbs2-0002" title="BooranapongW , PrabhasawatP , ChotikavanichS , TongsaiS , NaranunnP , ThaweerattanasilpW , et al. Comparison of an automated thermodynamic treatment system (LipiFlow) and warm compresses for the treatment of moderate severity of meibomian gland dysfunction. Siriraj Medical Journal2019;72(1):79-86. TCTR20170905001. Comparison of an automated thermodynamic treatment system (LipiFlow®) and eyelid warm compress for the treatment of meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20170905001 (first received 05 September 2017). ">Booranapong 2019</a>; <a href="./references#CD015448-bbs2-0005" title="HeJZ , ZhongM . Comparative study between the meibomian pulsation system and the warm compress treatment for MGD. International Eye Science2018;18(7):1324‐8. ">He 2018</a>; <a href="./references#CD015448-bbs2-0006" title="BloomensteinM , LohJ , DhamdhereK . Effectiveness of TearCare system in improvement dry eye disease symptoms in meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2022;63(7):1567-A0292. HollandEJ , LohJ , BloomensteinM , ThompsonV , WirtaD , DhamdhereK . A comparison of TearCare and Lipiflow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clinical Ophthalmology (Auckland, NZ)2022;16:2861‐71. NCT03857919. TearCare system to treat dry eye disease. clinicaltrials.gov/show/NCT03857919 (first received 28 February 2019). ">Holland 2022</a>; <a href="./references#CD015448-bbs2-0007" title="KasetsuwanN , SuwajanakornD , TantipatC , ReinprayoonU . The efficacy between conventional lid hygiene and additional thermal pulsatile system in meibomian gland dysfunction patients treated with long-term anti-glaucoma medications in a randomized controlled trial. Clinical Ophthalmology (Auckland, NZ)2020;14:2891‐902. TCTR20150919001. Comparison of efficacy between thermal pulsatile system (Lipiflow®) And conventional lid hygiene In anti-glaucoma agent related meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20150919001 (first received 19 September 2015). ">Kasetsuwan 2020</a>; <a href="./references#CD015448-bbs2-0008" title="LiS , YangK , WangJ , ZhuL , FengJ , TianL , et al. Effect of a novel thermostatic device on meibomian gland dysfunction: a randomized controlled trial in Chinese patients. Ophthalmology and Therapy2022;11(1):261‐70. NCT04310969. Clinical effect of MiboFlo in dry eye patients. clinicaltrials.gov/show/NCT04310969 (first received 17 March 2020). ">Li 2022</a>; <a href="./references#CD015448-bbs2-0009" title="MencucciR , MercuriS , CennamoM , MorelliA , FavuzzaE . Efficacy of Vector Thermal Pulsation treatment in reducing post-cataract surgery dry eye disease in patients affected by meibomian gland dysfunction. Journal of Cataract &amp; Refractive Surgery2022;49(4):423-9. NCT05062564. Efficacy of LipiFlow in patients affected by meibomian gland dysfunction in reducing post-cataract surgery dry eye. clinicaltrials.gov/show/NCT05062564 (first received 30 September 2021). ">Mencucci 2022</a>; <a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a>) </p> </section> </section> <section id="CD015448-sec-0068"> <h3 class="title" id="CD015448-sec-0068">Effects of interventions</h3> <p>See: <a href="./full#CD015448-tbl-0001"><b>Summary of findings 1</b> LipiFlow compared with basic warm compresses</a>; <a href="./full#CD015448-tbl-0002"><b>Summary of findings 2</b> LipiFlow compared with thermostatic devices</a> </p> <section id="CD015448-sec-0069"> <h4 class="title">Comparison 1: LipiFlow versus basic warm compresses</h4> <p>See <a href="./full#CD015448-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD015448-sec-0070"> <h5 class="title">Critical outcome</h5> <section id="CD015448-sec-0071"> <h6 class="title">Mean change from baseline in symptom scores at one to four weeks</h6> <p>Five trials reported this outcome at week 4 (<a href="#CD015448-fig-0003">Figure 3</a>). One trial measured this outcome with two different questionnaires, so we analyzed this outcome separately by type of questionnaire. The single participant‐level estimate from the OSDI suggested that LipiFlow reduced symptom scores when compared with the MeiboPatch (mean difference [MD] −16.62, 95% confidence interval [CI] −29.41 to −3.83; 30 eyes of 30 participants). When reported at the eye level, the single estimate indicated no evidence of a difference in symptom scores when comparing LipiFLow and EyeGiene responses to the OSDI (MD −0.43, 95% CI −2.39 to 1.53; 90 eyes of 45 participants). The combined estimate based on the SPEED questionnaire suggested that LipiFlow slightly reduced symptom scores compared with basic warm compresses whether reported at the participant level (MD −2.12, 95% CI −4.09 to −0.14; I<sup>2</sup> = 41%; 76 eyes of 76 participants) or at the eye level (MD −0.12, 95% CI −0.21 to −0.03; I<sup>2</sup> = 0%; 156 eyes of 106 participants). The combined eye‐level estimates from OSDI and SPEED questionnaires suggested the same results as above. Overall, we judged the certainty of the evidence to be very low because of inconsistency (−1), risk of bias associated with measurements (−1), and imprecision (−1). </p> <div class="figure" id="CD015448-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison 1: LipiFlow versus basic warm compresses, Outcome: 1.1 Mean change from baseline in symptom scores at 4 weeks." data-id="CD015448-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 1: LipiFlow versus basic warm compresses, Outcome: 1.1 Mean change from baseline in symptom scores at 4 weeks. </p> </div> </div> </div> </section> </section> <section id="CD015448-sec-0072"> <h5 class="title">Important outcomes</h5> <section id="CD015448-sec-0073"> <h6 class="title">Mean change from baseline in symptom scores at 6 to 12 months</h6> <p>Only one trial reported this outcome at month 6 (<a href="./references#CD015448-bbs2-0002" title="BooranapongW , PrabhasawatP , ChotikavanichS , TongsaiS , NaranunnP , ThaweerattanasilpW , et al. Comparison of an automated thermodynamic treatment system (LipiFlow) and warm compresses for the treatment of moderate severity of meibomian gland dysfunction. Siriraj Medical Journal2019;72(1):79-86. TCTR20170905001. Comparison of an automated thermodynamic treatment system (LipiFlow®) and eyelid warm compress for the treatment of meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20170905001 (first received 05 September 2017). ">Booranapong 2019</a>). The single‐trial estimate indicated no evidence of a difference in symptom score when comparing LipiFlow with warm compresses as measured by the SPEED questionnaire (MD −0.60, 95% CI −20.89 to 19.69; 56 eyes of 56 participants; <a href="./references#CD015448-fig-0010" title="">Analysis 1.2</a>). We judged the certainty of the evidence to be low because of very serious imprecision (−2). </p> </section> <section id="CD015448-sec-0074"> <h6 class="title">Mean change from baseline in meibomian gland expression at one to four weeks</h6> <p>Five trials reported meibomian gland expression at week 4 using a 0‐to‐3 scale, with a total score range of 0 to 45 (<a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a>), or with an unspecified scoring scale system (<a href="./references#CD015448-bbs2-0001" title="BaumannA , CochenerB . Meibomian gland dysfunction: a comparative study of modern treatments. Journal Français d'Ophtalmologie2014;37(4):303‐12. ">Baumann 2014</a>; <a href="./references#CD015448-bbs2-0002" title="BooranapongW , PrabhasawatP , ChotikavanichS , TongsaiS , NaranunnP , ThaweerattanasilpW , et al. Comparison of an automated thermodynamic treatment system (LipiFlow) and warm compresses for the treatment of moderate severity of meibomian gland dysfunction. Siriraj Medical Journal2019;72(1):79-86. TCTR20170905001. Comparison of an automated thermodynamic treatment system (LipiFlow®) and eyelid warm compress for the treatment of meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20170905001 (first received 05 September 2017). ">Booranapong 2019</a>; <a href="./references#CD015448-bbs2-0005" title="HeJZ , ZhongM . Comparative study between the meibomian pulsation system and the warm compress treatment for MGD. International Eye Science2018;18(7):1324‐8. ">He 2018</a>; <a href="./references#CD015448-bbs2-0009" title="MencucciR , MercuriS , CennamoM , MorelliA , FavuzzaE . Efficacy of Vector Thermal Pulsation treatment in reducing post-cataract surgery dry eye disease in patients affected by meibomian gland dysfunction. Journal of Cataract &amp; Refractive Surgery2022;49(4):423-9. NCT05062564. Efficacy of LipiFlow in patients affected by meibomian gland dysfunction in reducing post-cataract surgery dry eye. clinicaltrials.gov/show/NCT05062564 (first received 30 September 2021). ">Mencucci 2022</a>). The combined estimate indicated no evidence of a difference in meibomian gland expression when comparing LipiFlow with basic warm compresses, as reported at the participant level (standardized mean difference [SMD] 1.31, 95% CI −0.21 to 2.83; I<sup>2</sup> = 82%; 76 eyes of 76 participants) or the eye level (SMD 0.17, 95% CI −0.08 to 0.42; I<sup>2</sup> = 0%; 246 eyes of 151 participants) (<a href="#CD015448-fig-0004">Figure 4</a>). The substantial heterogeneity between the two trials in the participant‐level estimates may be attributable to high risk of bias in the randomization process (<a href="./references#CD015448-bbs2-0001" title="BaumannA , CochenerB . Meibomian gland dysfunction: a comparative study of modern treatments. Journal Français d'Ophtalmologie2014;37(4):303‐12. ">Baumann 2014</a>), in measurement of the outcome (<a href="./references#CD015448-bbs2-0009" title="MencucciR , MercuriS , CennamoM , MorelliA , FavuzzaE . Efficacy of Vector Thermal Pulsation treatment in reducing post-cataract surgery dry eye disease in patients affected by meibomian gland dysfunction. Journal of Cataract &amp; Refractive Surgery2022;49(4):423-9. NCT05062564. Efficacy of LipiFlow in patients affected by meibomian gland dysfunction in reducing post-cataract surgery dry eye. clinicaltrials.gov/show/NCT05062564 (first received 30 September 2021). ">Mencucci 2022</a>), or both. Overall, we judged the certainty of the evidence to be very low because of risk of bias (−1) and very serious imprecision (−2). </p> <div class="figure" id="CD015448-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison 1: LipiFlow versus basic warm compresses, Outcome: 1.3 Mean change from baseline in meibomian gland expression scores at 4 weeks—SMD." data-id="CD015448-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 1: LipiFlow versus basic warm compresses, Outcome: 1.3 Mean change from baseline in meibomian gland expression scores at 4 weeks—SMD. </p> </div> </div> </div> </section> <section id="CD015448-sec-0075"> <h6 class="title">Mean change from baseline in meibum quality at one to four weeks</h6> <p>Two trials reported meibum quality at week 4 using a 0‐to‐3 scale, with a total score range of 0 to 45 (<a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a>), or with an unspecified scoring scale system (<a href="./references#CD015448-bbs2-0009" title="MencucciR , MercuriS , CennamoM , MorelliA , FavuzzaE . Efficacy of Vector Thermal Pulsation treatment in reducing post-cataract surgery dry eye disease in patients affected by meibomian gland dysfunction. Journal of Cataract &amp; Refractive Surgery2022;49(4):423-9. NCT05062564. Efficacy of LipiFlow in patients affected by meibomian gland dysfunction in reducing post-cataract surgery dry eye. clinicaltrials.gov/show/NCT05062564 (first received 30 September 2021). ">Mencucci 2022</a>). The single estimate at the participant level suggested that LipiFlow had a slightly decreased meibum quality score by SMD −0.65 (95% CI −1.25 to −0.06; 46 eyes of 46 participants) compared with basic warm compresses and eyelid massages. When reported at the eye level, the single estimate indicated no evidence of a difference in meibum quality when comparing LipiFlow with warm compresses (SMD 0.27, 95% CI −0.12 to 0.67; 100 eyes of 50 participants); there was substantial heterogeneity between the two subgroups (I<sup>2</sup> = 84.7%, P = 0.01) (<a href="#CD015448-fig-0005">Figure 5</a>). We downgraded the certainty of the evidence to very low because of inconsistency (−1) and very serious imprecision (−2). </p> <div class="figure" id="CD015448-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison 1: LipiFlow versus basic warm compresses, Outcome: 1.4 Mean change from baseline in meibum quality scores at 4 weeks—SMD." data-id="CD015448-fig-0005" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 1: LipiFlow versus basic warm compresses, Outcome: 1.4 Mean change from baseline in meibum quality scores at 4 weeks—SMD. </p> </div> </div> </div> </section> <section id="CD015448-sec-0076"> <h6 class="title">Mean change from baseline in meibomian gland atrophy at one to four weeks</h6> <p>No included trial reported this outcome at one to four weeks. <a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a> reported meibomian gland atrophy at month 3. The single‐trial estimate indicated no evidence of a difference in meibomian gland atrophy when comparing LipiFlow with warm compresses (MD 0.03, 95% CI −0.02 to 0.08; 100 eyes of 50 participants; <a href="./references#CD015448-fig-0013" title="">Analysis 1.5</a>). We judged the certainty of the evidence to be low because of very serious imprecision (−2). </p> </section> <section id="CD015448-sec-0077"> <h6 class="title">Mean change from baseline in tear breakup time at one to four weeks</h6> <p>Three trials reported TBUT with sodium fluorescein (<a href="./references#CD015448-bbs2-0001" title="BaumannA , CochenerB . Meibomian gland dysfunction: a comparative study of modern treatments. Journal Français d'Ophtalmologie2014;37(4):303‐12. ">Baumann 2014</a>; <a href="./references#CD015448-bbs2-0005" title="HeJZ , ZhongM . Comparative study between the meibomian pulsation system and the warm compress treatment for MGD. International Eye Science2018;18(7):1324‐8. ">He 2018</a>; <a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a>), and one trial reported NITBUT (<a href="./references#CD015448-bbs2-0009" title="MencucciR , MercuriS , CennamoM , MorelliA , FavuzzaE . Efficacy of Vector Thermal Pulsation treatment in reducing post-cataract surgery dry eye disease in patients affected by meibomian gland dysfunction. Journal of Cataract &amp; Refractive Surgery2022;49(4):423-9. NCT05062564. Efficacy of LipiFlow in patients affected by meibomian gland dysfunction in reducing post-cataract surgery dry eye. clinicaltrials.gov/show/NCT05062564 (first received 30 September 2021). ">Mencucci 2022</a>) at week 4. The single‐trial estimate indicated no evidence of a difference in TBUT when comparing LipiFlow with basic warm compresses, as reported at the participant level (SMD −0.37, 95% CI −0.36 to 1.09; 30 eyes of 30 participants) or the eye level (SMD −0.53, 95% CI −2.67 to 1.60; 190 eyes of 95 participants) (<a href="./references#CD015448-fig-0014" title="">Analysis 1.6</a>). The single‐trial estimate indicated no evidence of a difference in NITBUT when comparing LipiFlow with warm compresses with eyelid massages (MD 0.17, 95% CI −0.68 to 1.02; 46 participants; <a href="./references#CD015448-fig-0015" title="">Analysis 1.7</a>). We downgraded the certainty of the evidence to very low because of inconsistency (−1) and very serious imprecision (−2). </p> </section> <section id="CD015448-sec-0078"> <h6 class="title">Proportion of participants with intervention‐related, vision‐threatening adverse events</h6> <p>Four trials reported no intervention‐related, vision‐threatening adverse events at week 4 (<a href="./references#CD015448-bbs2-0002" title="BooranapongW , PrabhasawatP , ChotikavanichS , TongsaiS , NaranunnP , ThaweerattanasilpW , et al. Comparison of an automated thermodynamic treatment system (LipiFlow) and warm compresses for the treatment of moderate severity of meibomian gland dysfunction. Siriraj Medical Journal2019;72(1):79-86. TCTR20170905001. Comparison of an automated thermodynamic treatment system (LipiFlow®) and eyelid warm compress for the treatment of meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20170905001 (first received 05 September 2017). ">Booranapong 2019</a>; <a href="./references#CD015448-bbs2-0005" title="HeJZ , ZhongM . Comparative study between the meibomian pulsation system and the warm compress treatment for MGD. International Eye Science2018;18(7):1324‐8. ">He 2018</a>; <a href="./references#CD015448-bbs2-0009" title="MencucciR , MercuriS , CennamoM , MorelliA , FavuzzaE . Efficacy of Vector Thermal Pulsation treatment in reducing post-cataract surgery dry eye disease in patients affected by meibomian gland dysfunction. Journal of Cataract &amp; Refractive Surgery2022;49(4):423-9. NCT05062564. Efficacy of LipiFlow in patients affected by meibomian gland dysfunction in reducing post-cataract surgery dry eye. clinicaltrials.gov/show/NCT05062564 (first received 30 September 2021). ">Mencucci 2022</a>; <a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a>). One trial did not report or measure this outcome (<a href="./references#CD015448-bbs2-0001" title="BaumannA , CochenerB . Meibomian gland dysfunction: a comparative study of modern treatments. Journal Français d'Ophtalmologie2014;37(4):303‐12. ">Baumann 2014</a>). We judged the certainty of the evidence to be low because of very serious imprecision (−2). </p> </section> <section id="CD015448-sec-0079"> <h6 class="title">Proportion of participants with progression of dry eye disease</h6> <p>None of the included trials reported this outcome.</p> </section> </section> </section> <section id="CD015448-sec-0080"> <h4 class="title">Comparison 2: LipiFlow versus thermostatic devices</h4> <p>See <a href="./full#CD015448-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD015448-sec-0081"> <h5 class="title">Critical outcome</h5> <section id="CD015448-sec-0082"> <h6 class="title">Mean change from baseline in symptom scores at one to four weeks</h6> <p>Five trials compared LipiFlow with thermostatic devices at week 4 (<a href="#CD015448-fig-0006">Figure 6</a>). Two trials measured this outcome with two different questionnaires, so we analyzed this outcome by questionnaire. The combined estimate favored thermostatic devices over LipiFlow with regard to OSDI scores (MD 4.59, 95% CI 1.23 to 7.95; I<sup>2</sup> = 0; P = 0.007; 553 participants). Neither estimate indicated any evidence of a difference in symptom scores when comparing LipiFlow with thermostatic devices using the SANDE questionnaire (MD −1.22, 95% CI −6.97 to 4.54; I<sup>2</sup> = 0%; 370 participants) or the IDEEL‐SB questionnaire (MD 0.10, 95% CI −0.32 to 0.52; 227 participants). Overall, we judged the certainty of the evidence to be very low because of inconsistency (−1), risk of bias (−1), and imprecision (−1). </p> <div class="figure" id="CD015448-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison 2: LipiFlow versus thermostatic devices, Outcome: 2.1 Mean change from baseline in symptom scores at 4 weeks." data-id="CD015448-fig-0006" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 2: LipiFlow versus thermostatic devices, Outcome: 2.1 Mean change from baseline in symptom scores at 4 weeks. </p> </div> </div> </div> </section> </section> <section id="CD015448-sec-0083"> <h5 class="title">Important outcomes</h5> <section id="CD015448-sec-0084"> <h6 class="title">Mean change from baseline in symptom scores at 6 to 12 months</h6> <p>Only one trial reported this outcome at month 12 (<a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a>). The single‐trial estimate indicated that iLux may reduce symptom scores more than LipiFlow as measured by the IDEEL‐SB questionnaire (MD 0.66, 95% CI 0.21 to 1.11; 227 participants; <a href="./references#CD015448-fig-0017" title="">Analysis 2.2</a>). We downgraded the certainty of the evidence to low because of imprecision (−1) and risk of bias (−1). </p> </section> <section id="CD015448-sec-0085"> <h6 class="title">Mean change from baseline in meibomian gland expression at one to four weeks</h6> <p>Three trials reported meibomian gland expression at week 4 using a 0‐to‐3 scale, with a total score range of 0 to 45 when evaluating 15 glands (<a href="./references#CD015448-bbs2-0012" title="TauberJ . A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction. Cornea2020;39(4):403‐7. ">Tauber 2020b</a>; <a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a>), or with a total score range of 0 to 18 when evaluating 6 glands (<a href="./references#CD015448-bbs2-0008" title="LiS , YangK , WangJ , ZhuL , FengJ , TianL , et al. Effect of a novel thermostatic device on meibomian gland dysfunction: a randomized controlled trial in Chinese patients. Ophthalmology and Therapy2022;11(1):261‐70. NCT04310969. Clinical effect of MiboFlo in dry eye patients. clinicaltrials.gov/show/NCT04310969 (first received 17 March 2020). ">Li 2022</a>). The combined estimate indicated no evidence of a difference in meibomian gland expression when comparing LipiFlow with thermostatic devices, as reported at the eye level (SMD −0.02, 95% CI −0.16 to 0.11; I<sup>2</sup> = 0%; 820 eyes of 410 participants; <a href="#CD015448-fig-0007">Figure 7</a>). Overall, we judged the certainty of the evidence to be low because of high risk of bias (−2). </p> <div class="figure" id="CD015448-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison 2: LipiFlow versus thermostatic devices, Outcome: 2.3 Mean change from baseline in meibomian gland expression scores at 4 weeks—SMD." data-id="CD015448-fig-0007" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 2: LipiFlow versus thermostatic devices, Outcome: 2.3 Mean change from baseline in meibomian gland expression scores at 4 weeks—SMD. </p> </div> </div> </div> </section> <section id="CD015448-sec-0086"> <h6 class="title">Mean change from baseline in meibum quality at one to four weeks</h6> <p>Two trials reported meibum quality at week 4 using a 0‐to‐3 scale, with a total score range of 0 to 18 when evaluating six glands (<a href="./references#CD015448-bbs2-0003" title="GuptaPK , HollandEJ , HovanesianJ , LohJ , JacksonMA , KarpeckiPM , et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea2022;41(4):417‐26. ">Gupta 2022</a>), or with no total score range provided (<a href="./references#CD015448-bbs2-0008" title="LiS , YangK , WangJ , ZhuL , FengJ , TianL , et al. Effect of a novel thermostatic device on meibomian gland dysfunction: a randomized controlled trial in Chinese patients. Ophthalmology and Therapy2022;11(1):261‐70. NCT04310969. Clinical effect of MiboFlo in dry eye patients. clinicaltrials.gov/show/NCT04310969 (first received 17 March 2020). ">Li 2022</a>). The combined estimate indicated no evidence or a difference in meibum quality when comparing LipiFlow with thermostatic devices, as reported at the eye level (SMD 0.11, 95% CI −0.20 to 0.42; I<sup>2</sup> = 43%; 354 eyes of 177 participants; <a href="#CD015448-fig-0008">Figure 8</a>). We downgraded the certainty of the evidence to low because of inconsistency (−1) and imprecision (−1). </p> <div class="figure" id="CD015448-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison 2: LipiFlow versus thermostatic devices, Outcome: 2.4 Mean change from baseline in meibum quality scores at 4 weeks—SMD." data-id="CD015448-fig-0008" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-FIG-08.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 2: LipiFlow versus thermostatic devices, Outcome: 2.4 Mean change from baseline in meibum quality scores at 4 weeks—SMD. </p> </div> </div> </div> </section> <section id="CD015448-sec-0087"> <h6 class="title">Mean change from baseline in meibomian gland atrophy at one to four weeks</h6> <p>No included trials reported this outcome at one to four weeks. <a href="./references#CD015448-bbs2-0008" title="LiS , YangK , WangJ , ZhuL , FengJ , TianL , et al. Effect of a novel thermostatic device on meibomian gland dysfunction: a randomized controlled trial in Chinese patients. Ophthalmology and Therapy2022;11(1):261‐70. NCT04310969. Clinical effect of MiboFlo in dry eye patients. clinicaltrials.gov/show/NCT04310969 (first received 17 March 2020). ">Li 2022</a> reported meibomian gland atrophy at month 2. The single‐trial estimate indicated no evidence of a difference in meibomian gland atrophy when comparing LipFlow with MiboFlo (MD 0.05, 95% CI −0.01 to 0.11; 84 eyes of 42 participants; <a href="./references#CD015448-fig-0020" title="">Analysis 2.5</a>). We judged the certainty of the evidence to be low because of very serious imprecision (−2). </p> </section> <section id="CD015448-sec-0088"> <h6 class="title">Mean change from baseline in tear breakup time at one to four weeks</h6> <p>Two trials reported TBUT with sodium fluorescein (<a href="./references#CD015448-bbs2-0003" title="GuptaPK , HollandEJ , HovanesianJ , LohJ , JacksonMA , KarpeckiPM , et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea2022;41(4):417‐26. ">Gupta 2022</a>; <a href="./references#CD015448-bbs2-0012" title="TauberJ . A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction. Cornea2020;39(4):403‐7. ">Tauber 2020b</a>), and two trials reported NITBUT (<a href="./references#CD015448-bbs2-0008" title="LiS , YangK , WangJ , ZhuL , FengJ , TianL , et al. Effect of a novel thermostatic device on meibomian gland dysfunction: a randomized controlled trial in Chinese patients. Ophthalmology and Therapy2022;11(1):261‐70. NCT04310969. Clinical effect of MiboFlo in dry eye patients. clinicaltrials.gov/show/NCT04310969 (first received 17 March 2020). ">Li 2022</a>; <a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a>) at week 4. The combined trial estimate indicated no evidence of a difference in TBUT (SMD −0.08, 95% CI −0.24 to 0.09; I<sup>2</sup> = 0%; 552 eyes of 276 participants; <a href="./references#CD015448-fig-0021" title="">Analysis 2.6</a>) or NITBUT (MD −0.20, 95% CI −0.62 to 0.22; I<sup>2</sup> = 69%; 538 eyes of 269 participants; <a href="./references#CD015448-fig-0022" title="">Analysis 2.7</a>) when comparing LipiFlow with thermostatic devices reported at the eye level. We downgraded the certainty of the evidence to very low because of risk of bias (−1) and imprecision (−1). </p> </section> <section id="CD015448-sec-0089"> <h6 class="title">Proportion of participants with intervention‐related, vision‐threatening adverse events</h6> <p>Four trials reported no intervention‐related, vision‐threatening adverse events at week 4 (<a href="./references#CD015448-bbs2-0003" title="GuptaPK , HollandEJ , HovanesianJ , LohJ , JacksonMA , KarpeckiPM , et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea2022;41(4):417‐26. ">Gupta 2022</a>; <a href="./references#CD015448-bbs2-0008" title="LiS , YangK , WangJ , ZhuL , FengJ , TianL , et al. Effect of a novel thermostatic device on meibomian gland dysfunction: a randomized controlled trial in Chinese patients. Ophthalmology and Therapy2022;11(1):261‐70. NCT04310969. Clinical effect of MiboFlo in dry eye patients. clinicaltrials.gov/show/NCT04310969 (first received 17 March 2020). ">Li 2022</a>; <a href="./references#CD015448-bbs2-0012" title="TauberJ . A 6-week, prospective, randomized, single-masked study of lifitegrast ophthalmic solution 5% versus thermal pulsation procedure for treatment of inflammatory meibomian gland dysfunction. Cornea2020;39(4):403‐7. ">Tauber 2020b</a>; <a href="./references#CD015448-bbs2-0013" title="NCT03956225. Comparison between iLux and LipiFlow in the treatment of meibomian gland dysfunction (MGD): a 12-month, multicenter study. clinicaltrials.gov/show/NCT03956225 (first received 20 May 2019). WesleyG , BickleK , DowningJ , EchegoyenJ , FisherB , GreeneB , et al. Patient-reported symptoms following SYSTANE iLux and LipiFlow treatment: a 12-month, multicenter study. Investigative Ophthalmology &amp; Visual Science2021;62(8):1242. WesleyG , BickleK , DowningJ , FisherB , GreeneB , HeinrichC , et al. Comparison of two thermal pulsation systems in the treatment of meibomian gland dysfunction: a randomized, multicenter study. Optometry and Vision Science2022;99(4):323‐32. ">Wesley 2022</a>), and one trial did not report or measure this outcome (<a href="./references#CD015448-bbs2-0006" title="BloomensteinM , LohJ , DhamdhereK . Effectiveness of TearCare system in improvement dry eye disease symptoms in meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2022;63(7):1567-A0292. HollandEJ , LohJ , BloomensteinM , ThompsonV , WirtaD , DhamdhereK . A comparison of TearCare and Lipiflow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clinical Ophthalmology (Auckland, NZ)2022;16:2861‐71. NCT03857919. TearCare system to treat dry eye disease. clinicaltrials.gov/show/NCT03857919 (first received 28 February 2019). ">Holland 2022</a>). We judged the certainty of the evidence to be very low because of risk of bias (−1) and very serious imprecision (−2). </p> </section> <section id="CD015448-sec-0090"> <h6 class="title">Proportion of participants with progression of dry eye disease</h6> <p>None of the included trials reported this outcome.</p> </section> </section> </section> <section id="CD015448-sec-0091"> <h4 class="title">Comparison 3: LipiFlow combined with eyelid hygiene product versus eyelid hygiene products alone </h4> <section id="CD015448-sec-0092"> <h5 class="title">Critical outcome</h5> <section id="CD015448-sec-0093"> <h6 class="title">Mean change from baseline in symptom scores at one to four weeks</h6> <p><a href="./references#CD015448-bbs2-0007" title="KasetsuwanN , SuwajanakornD , TantipatC , ReinprayoonU . The efficacy between conventional lid hygiene and additional thermal pulsatile system in meibomian gland dysfunction patients treated with long-term anti-glaucoma medications in a randomized controlled trial. Clinical Ophthalmology (Auckland, NZ)2020;14:2891‐902. TCTR20150919001. Comparison of efficacy between thermal pulsatile system (Lipiflow®) And conventional lid hygiene In anti-glaucoma agent related meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20150919001 (first received 19 September 2015). ">Kasetsuwan 2020</a> was the only trial in this comparison group and reported this outcome at week 1. The single‐trial estimate indicated no evidence of a difference in symptom score when comparing LipiFlow plus eyelid hygiene versus eyelid hygiene alone, as measured by the OSDI (MD 0.53, 95% CI −2.20 to 3.26; 48 participants; <a href="./references#CD015448-fig-0023" title="">Analysis 3.1</a>). We judged the certainty of the evidence to be very low because of the risk of bias associated with biased measurements (−1) and very serious imprecision (−2). </p> </section> </section> <section id="CD015448-sec-0094"> <h5 class="title">Important outcomes</h5> <section id="CD015448-sec-0095"> <h6 class="title">Mean change from baseline in symptom scores at 6 to 12 months</h6> <p><a href="./references#CD015448-bbs2-0007" title="KasetsuwanN , SuwajanakornD , TantipatC , ReinprayoonU . The efficacy between conventional lid hygiene and additional thermal pulsatile system in meibomian gland dysfunction patients treated with long-term anti-glaucoma medications in a randomized controlled trial. Clinical Ophthalmology (Auckland, NZ)2020;14:2891‐902. TCTR20150919001. Comparison of efficacy between thermal pulsatile system (Lipiflow®) And conventional lid hygiene In anti-glaucoma agent related meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20150919001 (first received 19 September 2015). ">Kasetsuwan 2020</a> reported this outcome at month 6. The single‐trial estimate provided no evidence of a difference in symptom scores when LipiFlow plus eyelid hygiene was compared with eyelid hygiene alone, as measured by the OSDI (MD 1.78, 95% CI −0.89 to 4.45; 48 participants; <a href="./references#CD015448-fig-0024" title="">Analysis 3.2</a>). We downgraded the certainty of the evidence to very low because of risk of bias (−1) and very serious imprecision (−2). </p> </section> <section id="CD015448-sec-0096"> <h6 class="title">Mean change from baseline in meibomian gland expression at one to four weeks</h6> <p><a href="./references#CD015448-bbs2-0007" title="KasetsuwanN , SuwajanakornD , TantipatC , ReinprayoonU . The efficacy between conventional lid hygiene and additional thermal pulsatile system in meibomian gland dysfunction patients treated with long-term anti-glaucoma medications in a randomized controlled trial. Clinical Ophthalmology (Auckland, NZ)2020;14:2891‐902. TCTR20150919001. Comparison of efficacy between thermal pulsatile system (Lipiflow®) And conventional lid hygiene In anti-glaucoma agent related meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20150919001 (first received 19 September 2015). ">Kasetsuwan 2020</a> reported meibomian gland expression using a 0‐to‐3 scale, with a total score range of 0 to 45 when evaluating 15 glands at week 1. The single‐trial estimate indicated no evidence of a difference in meibomian gland expression between LipiFlow with eyelid hygiene and eyelid hygiene alone (MD −0.60, 95% CI −3.86 to 2.66; 48 participants; <a href="./references#CD015448-fig-0025" title="">Analysis 3.3</a>). We judged the certainty of the evidence to be very low because of risk of bias (−1) and very serious imprecision (−2). </p> </section> <section id="CD015448-sec-0097"> <h6 class="title">Mean change from baseline in meibum quality at one to four weeks</h6> <p>The only trial in this comparison group did not report this outcome.</p> </section> <section id="CD015448-sec-0098"> <h6 class="title">Mean change from baseline in meibomian gland atrophy at one to four weeks</h6> <p>The only trial in this comparison group did not report this outcome.</p> </section> <section id="CD015448-sec-0099"> <h6 class="title">Mean change from baseline in tear breakup time at one to four weeks</h6> <p>The only trial in this comparison group did not report this outcome.</p> </section> <section id="CD015448-sec-0100"> <h6 class="title">Proportion of participants with intervention‐related, vision‐threatening adverse events</h6> <p>The only trial in this comparison group did not report this outcome.</p> </section> <section id="CD015448-sec-0101"> <h6 class="title">Proportion of participants with progression of dry eye disease</h6> <p>The only trial in this comparison group did not report this outcome.</p> </section> </section> </section> <section id="CD015448-sec-0102"> <h4 class="title">Comparison 4: LipiFlow versus topical DED medications</h4> <section id="CD015448-sec-0103"> <h5 class="title">Critical outcome</h5> <section id="CD015448-sec-0104"> <h6 class="title">Mean change from baseline in symptom scores at one to four weeks</h6> <p><a href="./references#CD015448-bbs2-0011" title="NCT03055832. Comparison Between iLux™ and LipiFlow® in the treatment of meibomian gland dysfunction. clinicaltrials.gov/show/NCT03055832 (first received 16 February 2017). TauberJ , OwenJ , BloomensteinM , HovanesianJ , BullimoreMA . Comparison of the iLUX and the LipiFlow for the treatment of meibomian gland dysfunction and symptoms: a randomized clinical trial. Clinical Ophthalmology (Auckland, NZ)2020;14:405‐18. ">Tauber 2020a</a> was the only trial in this comparison group and reported this outcome on day 42. The single‐trial estimate indicated no evidence of a difference in symptom score when comparing LipiFlow with 5% lifitegrast, as measured using the VAS (MD −6.08, 95% CI −23.77 to 11.61; 50 participants; <a href="./references#CD015448-fig-0026" title="">Analysis 4.1</a>). We judged the certainty of the evidence to be very low because of risk of bias (−1) and very serious imprecision (−2). </p> </section> </section> <section id="CD015448-sec-0105"> <h5 class="title">Important outcomes</h5> <section id="CD015448-sec-0106"> <h6 class="title">Mean change from baseline in symptom scores at 6 to 12 months</h6> <p>The only trial in this comparison group did not report this outcome.</p> </section> <section id="CD015448-sec-0107"> <h6 class="title">Mean change from baseline in meibomian gland expression at one to four weeks</h6> <p><a href="./references#CD015448-bbs2-0011" title="NCT03055832. Comparison Between iLux™ and LipiFlow® in the treatment of meibomian gland dysfunction. clinicaltrials.gov/show/NCT03055832 (first received 16 February 2017). TauberJ , OwenJ , BloomensteinM , HovanesianJ , BullimoreMA . Comparison of the iLUX and the LipiFlow for the treatment of meibomian gland dysfunction and symptoms: a randomized clinical trial. Clinical Ophthalmology (Auckland, NZ)2020;14:405‐18. ">Tauber 2020a</a> reported this outcome on day 42. The single‐trial estimate suggested that LipiFlow slightly increased meibomian gland expression scores compared with 5% lifitegrast, as measured using a 0‐to‐8 scale that evaluated gland patency (MD −1.21, 95% CI −2.37 to −0.05; 50 participants; <a href="./references#CD015448-fig-0027" title="">Analysis 4.2</a>). We judged the certainty of the evidence to be low because of very serious imprecision (−2). </p> </section> <section id="CD015448-sec-0108"> <h6 class="title">Mean change from baseline in meibum quality at one to four weeks</h6> <p><a href="./references#CD015448-bbs2-0011" title="NCT03055832. Comparison Between iLux™ and LipiFlow® in the treatment of meibomian gland dysfunction. clinicaltrials.gov/show/NCT03055832 (first received 16 February 2017). TauberJ , OwenJ , BloomensteinM , HovanesianJ , BullimoreMA . Comparison of the iLUX and the LipiFlow for the treatment of meibomian gland dysfunction and symptoms: a randomized clinical trial. Clinical Ophthalmology (Auckland, NZ)2020;14:405‐18. ">Tauber 2020a</a> reported this outcome on day 42. The single‐trial estimate indicated no evidence of a difference in meibum quality when LipiFlow was compared with 5% lifitegrast, as measured using a 0‐to‐3 scale (MD 0.40, 95% CI −0.06 to 0.86; 50 participants; <a href="./references#CD015448-fig-0028" title="">Analysis 4.3</a>). We downgraded the certainty of the evidence to low because of very serious imprecision (−2). </p> </section> <section id="CD015448-sec-0109"> <h6 class="title">Mean change from baseline in meibomian gland atrophy at one to four weeks</h6> <p>The only trial in this comparison group did not report this outcome.</p> </section> <section id="CD015448-sec-0110"> <h6 class="title">Mean change from baseline in tear breakup time at one to four weeks</h6> <p>The only trial in this comparison group did not report this outcome.</p> </section> <section id="CD015448-sec-0111"> <h6 class="title">Proportion of participants with intervention‐related, vision‐threatening adverse event</h6> <p><a href="./references#CD015448-bbs2-0011" title="NCT03055832. Comparison Between iLux™ and LipiFlow® in the treatment of meibomian gland dysfunction. clinicaltrials.gov/show/NCT03055832 (first received 16 February 2017). TauberJ , OwenJ , BloomensteinM , HovanesianJ , BullimoreMA . Comparison of the iLUX and the LipiFlow for the treatment of meibomian gland dysfunction and symptoms: a randomized clinical trial. Clinical Ophthalmology (Auckland, NZ)2020;14:405‐18. ">Tauber 2020a</a> reported that no intervention‐related, vision‐threatening adverse events occurred during the treatment or follow‐up period. We judged the certainty of the evidence to be low because of very serious imprecision (−2). </p> </section> <section id="CD015448-sec-0112"> <h6 class="title">Proportion of participants with progression of dry eye disease</h6> <p>The only trial in this comparison group did not report this outcome.</p> </section> </section> </section> <section id="CD015448-sec-0113"> <h4 class="title">Comparison 5: LipiFlow versus oral interventions</h4> <section id="CD015448-sec-0114"> <h5 class="title">Critical outcome</h5> <section id="CD015448-sec-0115"> <h6 class="title">Mean change from baseline in symptom scores at one to four weeks</h6> <p><a href="./references#CD015448-bbs2-0004" title="HagenKB , BediR , BlackieCA , Christenson-AkagiKJ . Comparison of a single-dose vectored thermal pulsation procedure with a 3-month course of daily oral doxycycline for moderate-to-severe meibomian gland dysfunction. Clinical Ophthalmology (Auckland, NZ)2018;12:161‐8. ">Hagen 2018</a> was the only trial in this comparison group and reported this outcome at month 3. The single‐trial estimate suggested that LipiFlow may slightly reduce symptom scores when compared with oral doxycycline, as measured by the SPEED questionnaire (MD −4.00, 95% CI −7.33 to −0.67; 24 participants; <a href="./references#CD015448-fig-0029" title="">Analysis 5.1</a>). We judged the certainty of the evidence to be very low because of risk of bias (−1) and very serious imprecision (−2). </p> </section> </section> <section id="CD015448-sec-0116"> <h5 class="title">Important outcomes</h5> <section id="CD015448-sec-0117"> <h6 class="title">Mean change from baseline in symptom scores at 6 to 12 months</h6> <p>The only trial in this comparison group did not report this outcome.</p> </section> <section id="CD015448-sec-0118"> <h6 class="title">Mean change from baseline in meibomian gland expression at one to four weeks</h6> <p><a href="./references#CD015448-bbs2-0004" title="HagenKB , BediR , BlackieCA , Christenson-AkagiKJ . Comparison of a single-dose vectored thermal pulsation procedure with a 3-month course of daily oral doxycycline for moderate-to-severe meibomian gland dysfunction. Clinical Ophthalmology (Auckland, NZ)2018;12:161‐8. ">Hagen 2018</a> reported this outcome at month 3. The single‐trial estimate indicated no evidence of a difference in meibomian gland expression when comparing LipiFlow with oral doxycycline (MD −2.90, 95% CI −6.09 to 0.29; 50 eyes of 24 participants; <a href="./references#CD015448-fig-0030" title="">Analysis 5.2</a>). We judged the certainty of the evidence to be very low because of risk of bias (−1) and very serious imprecision (−2). </p> </section> <section id="CD015448-sec-0119"> <h6 class="title">Mean change from baseline in meibum quality at one to four weeks</h6> <p>The only trial in this comparison group did not report this outcome.</p> </section> <section id="CD015448-sec-0120"> <h6 class="title">Mean change from baseline in meibomian gland atrophy at one to four weeks</h6> <p>The only trial in this comparison group did not report this outcome.</p> </section> <section id="CD015448-sec-0121"> <h6 class="title">Mean change from baseline in tear breakup time at one to four weeks</h6> <p><a href="./references#CD015448-bbs2-0004" title="HagenKB , BediR , BlackieCA , Christenson-AkagiKJ . Comparison of a single-dose vectored thermal pulsation procedure with a 3-month course of daily oral doxycycline for moderate-to-severe meibomian gland dysfunction. Clinical Ophthalmology (Auckland, NZ)2018;12:161‐8. ">Hagen 2018</a> reported this outcome at month 3. The single‐trial estimate indicated no evidence of a difference in TBUT when comparing LipiFlow with oral doxycycline (MD 0.85, 95% CI −0.22 to 1.92; 50 eyes of 24 participants; <a href="./references#CD015448-fig-0031" title="">Analysis 5.3</a>). We downgraded the certainty of the evidence to very low because of risk of bias (−1) and very serious imprecision (−2). </p> </section> <section id="CD015448-sec-0122"> <h6 class="title">Proportion of participants with intervention‐related, vision‐threatening adverse event</h6> <p>The only trial in this comparison group did not report this outcome.</p> </section> <section id="CD015448-sec-0123"> <h6 class="title">Proportion of participants with progression of dry eye disease</h6> <p>The only trial in this comparison group did not report this outcome.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD015448-sec-0124" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD015448-sec-0124"></div> <section id="CD015448-sec-0125"> <h3 class="title" id="CD015448-sec-0125">Summary of main results</h3> <p>LipiFlow is an approved treatment for people who suffer from MGD, yet it is has been unclear if LipiFlow was more efficacious than other available treatments for MGD. When we analyzed symptom scores based on questionnaires, with the OSDI or SPEED completed by participants in the included trials, results showed conflicting evidence of a difference between LipiFlow and basic warm compresses after four weeks. The other metrics (meibomian gland expression, meibum quality, meibomian gland atrophy, TBUT, NITBUT) used to compare LipiFlow and warm compresses failed to find a clinically meaningful difference between these treatments. When we compared LipiFlow with thermostatic devices, thermostatic device usage may result in significantly better OSDI scores than LipiFlow treatment at week 4, yet this significant difference failed to meet the level of being clinically meaningful (<a href="./references#CD015448-bbs2-0066" title="MillerKL , WaltJG , MinkDR , Satram-HoangS , WilsonSE , PerryHD , et al. Minimal clinically important difference for the Ocular Surface Disease Index. Archives of Ophthalmology2010;128(1):94-101.">Miller 2010</a>). No other statistically significant differences in signs or symptoms were found between LipiFlow and thermostatic devices at four weeks. When comparing LipiFlow plus eyelid hygiene to eyelid hygiene alone, there were no statistically significant differences in signs or symptoms at any time point evaluated. When we compared LipiFlow to a topical DED medication (lifitegrast 5%) at day 42, there were no significant differences in symptom scores between groups. LipiFlow may slightly reduce meibomian gland expression scores when compared to 5% lifitegrast; however, there was only about one gland difference in expression, which may not be a clinically meaningful between‐group difference. When we compared LipiFlow with an oral intervention (doxycycline), LipiFlow‐treated participants had significantly better SPEED scores than doxycycline‐treated participants. No other statistically significant differences in signs or symptoms were found between LipiFlow and doxycycline at three months. Overall, no trial reported any intervention‐related, vision‐threatening adverse events. </p> <p>When reviewing individual trial reports, there was a tendency for participants who were treated with LipiFlow to show an improvement in ocular signs and symptoms; however, we failed to find convincing evidence that LipiFlow is superior to other commonly used MGD treatments. An overall lack of significant findings may be attributed to the overall low‐ or very low‐certainty evidence, lack of a common regimen of clinical testing, and heterogeneity among studies. </p> </section> <section id="CD015448-sec-0126"> <h3 class="title" id="CD015448-sec-0126">Overall completeness and applicability of evidence</h3> <p>In this systematic review we evaluated outcomes reported from 13 trials with a total of 1155 randomized participants. While enough participants were included in the review to begin to understand the effectiveness of LipiFlow compared with other treatments, the included trials failed to represent the demographic characteristics of the patient group of interest (e.g. limited data by race and ethnicity) and the full arsenal of MGD treatments (e.g. only one topical DED medication compared to LipiFlow). Each included trial utilized a different testing protocol, which resulted in high trial heterogeneity and a low certainty of evidence in the outcome effect estimates. Specifically, the included trials failed to consistently use the same questionnaire for evaluating DED symptoms, which made it challenging to discern whether there was a true between‐interventions difference for our primary outcome. Furthermore, the included trials failed to use a consistent grading scale for evaluating meibomian gland expressibility and meibum quality (e.g. trials evaluated a different number of glands), which made it challenging to synthesize these data. Among other design weaknesses, the sample size of most of the trials was small, leading to imprecise estimates of outcome estimates. This review also highlights the limited number of long‐term randomized trials that have compared LipiFlow with other treatment options, which is problematic given that MGD is typically a chronic, lifelong condition. These issues, along with the lack of proper masking of participants or investigators, or both, suggest that additional, long‐term, appropriately masked, adequately powered trials with a consistent testing methodology are needed before the eye care community can reliably determine if LipiFlow is better at treating the signs and symptoms of DED than other common DED and MGD interventions. </p> </section> <section id="CD015448-sec-0127"> <h3 class="title" id="CD015448-sec-0127">Certainty of the evidence</h3> <p>All the included trials reporting symptom scores at one to four weeks suffered from some concerns (four trials) or high (seven trials) potential for bias. We downgraded the certainty of the evidence to low or very low for the review outcomes because of inconsistency, imprecision, and risk of bias related to inadequate description of the randomization procedure, missing outcome data, or biased outcome measurement. This conclusion was based upon all 13 trials that reported on symptoms (primary outcome) evaluated by unmasked trial participants. Other common quality issues included lack of availability of a published statistical analysis plan or trial protocol. The <a href="./references#CD015448-bbs2-0001" title="BaumannA , CochenerB . Meibomian gland dysfunction: a comparative study of modern treatments. Journal Français d'Ophtalmologie2014;37(4):303‐12. ">Baumann 2014</a> trial also had between‐group differences in baseline assessments, and the <a href="./references#CD015448-bbs2-0003" title="GuptaPK , HollandEJ , HovanesianJ , LohJ , JacksonMA , KarpeckiPM , et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea2022;41(4):417‐26. ">Gupta 2022</a> and <a href="./references#CD015448-bbs2-0006" title="BloomensteinM , LohJ , DhamdhereK . Effectiveness of TearCare system in improvement dry eye disease symptoms in meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2022;63(7):1567-A0292. HollandEJ , LohJ , BloomensteinM , ThompsonV , WirtaD , DhamdhereK . A comparison of TearCare and Lipiflow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clinical Ophthalmology (Auckland, NZ)2022;16:2861‐71. NCT03857919. TearCare system to treat dry eye disease. clinicaltrials.gov/show/NCT03857919 (first received 28 February 2019). ">Holland 2022</a> trials failed to use a robust statistical approach for data analysis. </p> </section> <section id="CD015448-sec-0128"> <h3 class="title" id="CD015448-sec-0128">Potential biases in the review process</h3> <p>We followed standard Cochrane methodology throughout the planning and execution of this review in order to minimize bias. An experienced Information Specialist collaborated with the clinical authors to perform a thorough literature search of multiple electronic databases with no limits on language. Two review authors independently performed data extraction from each included trial. We also performed an additional handsearch through the references of trials included in the review and reached out to study authors or trial investigators for clarification on study design, trial results, and outcome measures. The main issue related to risk of bias in this review is with the primary outcome (patient‐reported symptom score), which can be heavily influenced in this instance by participant awareness of the intervention assigned. </p> </section> <section id="CD015448-sec-0129"> <h3 class="title" id="CD015448-sec-0129">Agreements and disagreements with other studies or reviews</h3> <p>There is currently only one other published systematic review evaluating the efficacy of the LipiFlow (<a href="./references#CD015448-bbs2-0049" title="HuJ , ZhuS , LiuX . Efficacy and safety of a vectored thermal pulsation system (Lipiflow®) in the treatment of meibomian gland dysfunction: a systematic review and meta-analysis. Graefe's Archive for Clinical and Experimental Ophthalmology2022;260(1):25-39.">Hu 2022</a>). <a href="./references#CD015448-bbs2-0049" title="HuJ , ZhuS , LiuX . Efficacy and safety of a vectored thermal pulsation system (Lipiflow®) in the treatment of meibomian gland dysfunction: a systematic review and meta-analysis. Graefe's Archive for Clinical and Experimental Ophthalmology2022;260(1):25-39.">Hu 2022</a> concluded that LipiFlow was effective in treating MGD and did not increase the incidence of adverse events. While the primary goal of our review was to examine the relative efficacy of LipiFlow compared with other treatments for DED, some of our outcome variables were shared with <a href="./references#CD015448-bbs2-0049" title="HuJ , ZhuS , LiuX . Efficacy and safety of a vectored thermal pulsation system (Lipiflow®) in the treatment of meibomian gland dysfunction: a systematic review and meta-analysis. Graefe's Archive for Clinical and Experimental Ophthalmology2022;260(1):25-39.">Hu 2022</a> (e.g. symptom scores, meibomian gland scores). Our review generally agrees with <a href="./references#CD015448-bbs2-0049" title="HuJ , ZhuS , LiuX . Efficacy and safety of a vectored thermal pulsation system (Lipiflow®) in the treatment of meibomian gland dysfunction: a systematic review and meta-analysis. Graefe's Archive for Clinical and Experimental Ophthalmology2022;260(1):25-39.">Hu 2022</a> that LipiFlow improves symptoms and meibomian gland function, even though LipiFlow outcomes were not significantly different from other DED treatments. Furthermore, our review agrees with <a href="./references#CD015448-bbs2-0049" title="HuJ , ZhuS , LiuX . Efficacy and safety of a vectored thermal pulsation system (Lipiflow®) in the treatment of meibomian gland dysfunction: a systematic review and meta-analysis. Graefe's Archive for Clinical and Experimental Ophthalmology2022;260(1):25-39.">Hu 2022</a> in that LipiFlow does not appear to induce adverse events. <a href="./references#CD015448-bbs2-0049" title="HuJ , ZhuS , LiuX . Efficacy and safety of a vectored thermal pulsation system (Lipiflow®) in the treatment of meibomian gland dysfunction: a systematic review and meta-analysis. Graefe's Archive for Clinical and Experimental Ophthalmology2022;260(1):25-39.">Hu 2022</a> noted similar issues such as unit of analysis errors and heterogeneity that weaken the certainty of the evidence. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD015448-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD015448-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/full#CD015448-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: symptom scores at one to four weeks." data-id="CD015448-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-FIG-02.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: symptom scores at one to four weeks.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/full#CD015448-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-FIG-02.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 1: LipiFlow versus basic warm compresses, Outcome: 1.1 Mean change from baseline in symptom scores at 4 weeks." data-id="CD015448-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison 1: LipiFlow versus basic warm compresses, Outcome: 1.1 Mean change from baseline in symptom scores at 4 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/full#CD015448-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 1: LipiFlow versus basic warm compresses, Outcome: 1.3 Mean change from baseline in meibomian gland expression scores at 4 weeks—SMD." data-id="CD015448-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison 1: LipiFlow versus basic warm compresses, Outcome: 1.3 Mean change from baseline in meibomian gland expression scores at 4 weeks—SMD. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/full#CD015448-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 1: LipiFlow versus basic warm compresses, Outcome: 1.4 Mean change from baseline in meibum quality scores at 4 weeks—SMD." data-id="CD015448-fig-0005" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison 1: LipiFlow versus basic warm compresses, Outcome: 1.4 Mean change from baseline in meibum quality scores at 4 weeks—SMD. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/full#CD015448-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 2: LipiFlow versus thermostatic devices, Outcome: 2.1 Mean change from baseline in symptom scores at 4 weeks." data-id="CD015448-fig-0006" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison 2: LipiFlow versus thermostatic devices, Outcome: 2.1 Mean change from baseline in symptom scores at 4 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/full#CD015448-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 2: LipiFlow versus thermostatic devices, Outcome: 2.3 Mean change from baseline in meibomian gland expression scores at 4 weeks—SMD." data-id="CD015448-fig-0007" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison 2: LipiFlow versus thermostatic devices, Outcome: 2.3 Mean change from baseline in meibomian gland expression scores at 4 weeks—SMD. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/full#CD015448-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 2: LipiFlow versus thermostatic devices, Outcome: 2.4 Mean change from baseline in meibum quality scores at 4 weeks—SMD." data-id="CD015448-fig-0008" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-FIG-08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison 2: LipiFlow versus thermostatic devices, Outcome: 2.4 Mean change from baseline in meibum quality scores at 4 weeks—SMD. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/full#CD015448-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-FIG-08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: LipiFlow versus basic warm compresses, Outcome 1: Mean change from baseline in symptom scores at 4 weeks" data-id="CD015448-fig-0009" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: LipiFlow versus basic warm compresses, Outcome 1: Mean change from baseline in symptom scores at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: LipiFlow versus basic warm compresses, Outcome 2: Mean change from baseline in symptom scores at 6 months" data-id="CD015448-fig-0010" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: LipiFlow versus basic warm compresses, Outcome 2: Mean change from baseline in symptom scores at 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: LipiFlow versus basic warm compresses, Outcome 3: Mean change from baseline in meibomian gland expression scores at 4 weeks—SMD" data-id="CD015448-fig-0011" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: LipiFlow versus basic warm compresses, Outcome 3: Mean change from baseline in meibomian gland expression scores at 4 weeks—SMD </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: LipiFlow versus basic warm compresses, Outcome 4: Mean change from baseline in meibum quality scores at 4 weeks—SMD" data-id="CD015448-fig-0012" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: LipiFlow versus basic warm compresses, Outcome 4: Mean change from baseline in meibum quality scores at 4 weeks—SMD </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: LipiFlow versus basic warm compresses, Outcome 5: Mean change from baseline in meibomian gland atrophy at 3 months" data-id="CD015448-fig-0013" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: LipiFlow versus basic warm compresses, Outcome 5: Mean change from baseline in meibomian gland atrophy at 3 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: LipiFlow versus basic warm compresses, Outcome 6: Mean change from baseline in tear film breakup time at 4 weeks—SMD" data-id="CD015448-fig-0014" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: LipiFlow versus basic warm compresses, Outcome 6: Mean change from baseline in tear film breakup time at 4 weeks—SMD </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: LipiFlow versus basic warm compresses, Outcome 7: Mean change from baseline in non‐invasive tear film breakup time at 4 weeks" data-id="CD015448-fig-0015" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: LipiFlow versus basic warm compresses, Outcome 7: Mean change from baseline in non‐invasive tear film breakup time at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: LipiFlow versus thermostatic device, Outcome 1: Mean change from baseline in symptom scores at 4 weeks" data-id="CD015448-fig-0016" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: LipiFlow versus thermostatic device, Outcome 1: Mean change from baseline in symptom scores at 4 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: LipiFlow versus thermostatic device, Outcome 2: Mean change from baseline in symptom scores at 12 months" data-id="CD015448-fig-0017" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: LipiFlow versus thermostatic device, Outcome 2: Mean change from baseline in symptom scores at 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: LipiFlow versus thermostatic device, Outcome 3: Mean change from baseline in meibomian gland expression scores at 4 weeks—SMD" data-id="CD015448-fig-0018" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: LipiFlow versus thermostatic device, Outcome 3: Mean change from baseline in meibomian gland expression scores at 4 weeks—SMD </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: LipiFlow versus thermostatic device, Outcome 4: Mean change from baseline in meibum quality scores at 4 weeks—SMD" data-id="CD015448-fig-0019" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: LipiFlow versus thermostatic device, Outcome 4: Mean change from baseline in meibum quality scores at 4 weeks—SMD </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: LipiFlow versus thermostatic device, Outcome 5: Mean change from baseline in meibomian gland atrophy at 2 months" data-id="CD015448-fig-0020" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: LipiFlow versus thermostatic device, Outcome 5: Mean change from baseline in meibomian gland atrophy at 2 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: LipiFlow versus thermostatic device, Outcome 6: Mean change from baseline in tear film breakup time at 4 weeks—SMD" data-id="CD015448-fig-0021" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: LipiFlow versus thermostatic device, Outcome 6: Mean change from baseline in tear film breakup time at 4 weeks—SMD </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: LipiFlow versus thermostatic device, Outcome 7: Mean change from baseline in non‐invasive tear film breakup time at 4 weeks—SMD" data-id="CD015448-fig-0022" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: LipiFlow versus thermostatic device, Outcome 7: Mean change from baseline in non‐invasive tear film breakup time at 4 weeks—SMD </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: LipiFlow + eyelid hygiene versus eyelid hygiene product alone, Outcome 1: Mean change from baseline in symptom scores at 1 week" data-id="CD015448-fig-0023" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: LipiFlow + eyelid hygiene versus eyelid hygiene product alone, Outcome 1: Mean change from baseline in symptom scores at 1 week </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: LipiFlow + eyelid hygiene versus eyelid hygiene product alone, Outcome 2: Mean change from baseline in symptom scores at 6 months" data-id="CD015448-fig-0024" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: LipiFlow + eyelid hygiene versus eyelid hygiene product alone, Outcome 2: Mean change from baseline in symptom scores at 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: LipiFlow + eyelid hygiene versus eyelid hygiene product alone, Outcome 3: Mean change from baseline in meibomian gland expression scores at 1 week" data-id="CD015448-fig-0025" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: LipiFlow + eyelid hygiene versus eyelid hygiene product alone, Outcome 3: Mean change from baseline in meibomian gland expression scores at 1 week </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: LipiFlow versus topical DED medication, Outcome 1: Mean change from baseline in symptom scores at 42 days" data-id="CD015448-fig-0026" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: LipiFlow versus topical DED medication, Outcome 1: Mean change from baseline in symptom scores at 42 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: LipiFlow versus topical DED medication, Outcome 2: Mean change from baseline in meibomian gland expression scores at 42 days" data-id="CD015448-fig-0027" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: LipiFlow versus topical DED medication, Outcome 2: Mean change from baseline in meibomian gland expression scores at 42 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: LipiFlow versus topical DED medication, Outcome 3: Mean change from baseline in meibum quality scores at 42 days" data-id="CD015448-fig-0028" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: LipiFlow versus topical DED medication, Outcome 3: Mean change from baseline in meibum quality scores at 42 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: LipiFlow versus oral interventions, Outcome 1: Mean change from baseline in symptom scores at 3 months" data-id="CD015448-fig-0029" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: LipiFlow versus oral interventions, Outcome 1: Mean change from baseline in symptom scores at 3 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: LipiFlow versus oral interventions, Outcome 2: Mean change from baseline in meibomian gland expression scores at 3 months" data-id="CD015448-fig-0030" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: LipiFlow versus oral interventions, Outcome 2: Mean change from baseline in meibomian gland expression scores at 3 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015448-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/urn:x-wiley:14651858:media:CD015448:CD015448-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: LipiFlow versus oral interventions, Outcome 3: Mean change from baseline in tear film breakup time at 3 months" data-id="CD015448-fig-0031" src="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_t/tCD015448-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: LipiFlow versus oral interventions, Outcome 3: Mean change from baseline in tear film breakup time at 3 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/media/CDSR/CD015448/image_n/nCD015448-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD015448-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">LipiFlow compared with basic warm compresses</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>LipiFlow compared with basic warm compresses for dry eye disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with dry eye </p> <p><b>Settings:</b> hospitals or eye clinic </p> <p><b>Intervention:</b> LipiFlow </p> <p><b>Comparison:</b> local eyelid manipulation (EyeGiene, MeiboPatch, warm compresses, warm compresses with eyelid massages) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Local eyelid manipulation</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>LipiFlow</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mean change from baseline in symptom scores at 1 to 4 weeks</b> </p> <p>(lower is favored)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>OSDI questionnaire</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mean change in symptom scores in LipiFlow groups was on average 16.62 (29.41 to 3.83) lower than in the basic warm compresses groups at week 4. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD −16.62</b> </p> <p>(−29.41 to −3.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 eyes/30 participants</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015448-bbs2-0005" title="HeJZ , ZhongM . Comparative study between the meibomian pulsation system and the warm compress treatment for MGD. International Eye Science2018;18(7):1324‐8. ">He 2018</a> (90 eyes in 45 participants) reported this outcome at the eye level, with an MD of −0.43 (95% CI −2.39 to 1.53) at week 4. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>SPEED questionnaire</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mean change in symptom scores in LipiFlow groups was on average 2.12 (4.09 to 0.14) lower than in the basic warm compresses groups at week 4. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD −2.12</b> </p> <p>(−4.09 to −0.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 eyes/76 participants</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015448-bbs2-0002" title="BooranapongW , PrabhasawatP , ChotikavanichS , TongsaiS , NaranunnP , ThaweerattanasilpW , et al. Comparison of an automated thermodynamic treatment system (LipiFlow) and warm compresses for the treatment of moderate severity of meibomian gland dysfunction. Siriraj Medical Journal2019;72(1):79-86. TCTR20170905001. Comparison of an automated thermodynamic treatment system (LipiFlow®) and eyelid warm compress for the treatment of meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20170905001 (first received 05 September 2017). ">Booranapong 2019</a> (56 eyes in 56 participants; paired‐eye design) and <a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a> (100 eyes in 50 participants) reported this outcome at the eye level, with an MD of −0.12 (95% CI −0.21 to −0.03) at week 4. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change from baseline in meibomian gland expression scores at 1 to 4 weeks</b> </p> <p>(higher is favored)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mean change in meibomian gland expression scores in LipiFlow groups was on average 1.31 SMD (−0.21 to 2.83) higher than in the basic warm compresses groups at week 4. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD 1.31</b> </p> <p>(−0.21 to 2.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 eyes/76 participants</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015448-bbs2-0005" title="HeJZ , ZhongM . Comparative study between the meibomian pulsation system and the warm compress treatment for MGD. International Eye Science2018;18(7):1324‐8. ">He 2018</a> (90 eyes in 45 participants), <a href="./references#CD015448-bbs2-0002" title="BooranapongW , PrabhasawatP , ChotikavanichS , TongsaiS , NaranunnP , ThaweerattanasilpW , et al. Comparison of an automated thermodynamic treatment system (LipiFlow) and warm compresses for the treatment of moderate severity of meibomian gland dysfunction. Siriraj Medical Journal2019;72(1):79-86. TCTR20170905001. Comparison of an automated thermodynamic treatment system (LipiFlow®) and eyelid warm compress for the treatment of meibomian gland dysfunction. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20170905001 (first received 05 September 2017). ">Booranapong 2019</a> (56 eyes in 56 participants; paired‐eye design), and <a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a> (100 eyes in 50 participants) reported this outcome at the eye level, with an SMD of 0.17 (95% CI −0.08 to 0.42) at week 4. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change from baseline in meibum quality scores at 1 to 4 weeks</b> </p> <p>(higher is favored)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mean change in meibum quality scores in LipiFlow groups was on average 0.65 SMD (1.25 to 0.06) lower than in the basic warm compresses groups at week 4. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD −0.65</b> </p> <p>(−1.25 to −0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 eyes/46 participants</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a> (100 eyes in 50 participants) reported this outcome at the eye level, with an SMD of 0.27 (95% CI −0.12 to 0.67) at week 4. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change from baseline in meibomian gland atrophy scores at 1 to 4 weeks</b> </p> <p>(lower is favored)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015448-bbs2-0010" title="MengZ , ChuX , ZhangC , LiuH , YangR , HuangY , et al. Efficacy and safety evaluation of a single thermal pulsation system treatment (Lipiflow®) on meibomian gland dysfunction: a randomized controlled clinical trial. International Ophthalmology2022;16:16. ">Meng 2022</a> (100 eyes in 50 participants) reported mean change from baseline in meibomian gland atrophy scores at 3 months, with an MD of 0.03 (95% CI −0.02 to 0.08). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with intervention‐related, vision‐threatening adverse events at 1 to 4 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000 at week 4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000 at week 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>197 participants</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean baseline risk from the studies in the meta‐analysis; the total number of events in the control group divided by the total number of participants in the control groups, scaled to 1000. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>MD</b> : mean difference; <b>OSDI</b> : Ocular Surface Disease Index; <b>RCT:</b> randomized controlled trial; <b>SMD</b> : standardized mean difference; <b>SPEED</b>: Standard Patient Evaluation of Eye Dryness </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for inconsistency (−1).<br/><sup>b</sup>Downgraded for risk of bias (−1).<br/><sup>c</sup>Downgraded for imprecision (−1).<br/><sup>d</sup>Downgraded for very serious imprecision (−2). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">LipiFlow compared with basic warm compresses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/full#CD015448-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015448-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">LipiFlow compared with thermostatic devices</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>LipiFlow compared with thermostatic devices for dry eye disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with dry eye </p> <p><b>Settings:</b> hospitals or eye clinics </p> <p><b>Intervention:</b> LipiFlow </p> <p><b>Comparison:</b> thermostatic device (iLux, MiBoFlo, TearCare) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Thermostatic device</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>LipiFlow</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Mean change from baseline in symptom scores at 1 to 4 weeks</b> </p> <p>(lower is favored)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>OSDI questionnaire</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mean change in symptom scores in LipiFlow groups was on average 4.59 (1.23 to 7.95) higher than in the thermostatic device groups at week 4. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 4.59</b> </p> <p>(1.23 to 7.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>553 participants</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>SANDE questionnaire</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mean change in symptom scores in LipiFlow groups was on average 1.22 lower (6.97 lower to 4.54 higher) than in the thermostatic device groups at week 4. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD −1.22</b> </p> <p>(−6.97 to 4.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>370 participants</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p><b>IDEEL‐SB questionnaire</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mean change in symptom scores in LipiFlow group was on average 0.10 higher (0.32 lower to 0.52 higher) than in the thermostatic device group at week 4. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.10</b> </p> <p>(−0.32 to 0.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227 participants</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change from baseline in meibomian gland expression scores at 1 to 4 weeks</b> </p> <p>(higher is favored)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mean change in meibomian gland expression scores in LipiFlow groups was on average 0.02 SMD lower (0.16 lower to 0.11 higher) than in the thermostatic device groups at week 4. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD −0.02</b> </p> <p>(−0.16 to 0.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>820 eyes/410 participants</p> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All included trials reported at the eye level.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change from baseline in meibum quality scores at 1 to 4 weeks</b> </p> <p>(higher is favored)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Mean change in meibum quality scores in LipiFlow groups was on average 0.11 SMD higher (0.20 lower to 0.42 higher) than in the thermostatic device groups at week 4. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD 0.11</b> (−0.20 to 0.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>354 eyes/177 participants</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All included trials reported at the eye level.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change from baseline in meibomian gland atrophy scores at 1 to 4 weeks</b> </p> <p>(lower is favored)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015448-bbs2-0008" title="LiS , YangK , WangJ , ZhuL , FengJ , TianL , et al. Effect of a novel thermostatic device on meibomian gland dysfunction: a randomized controlled trial in Chinese patients. Ophthalmology and Therapy2022;11(1):261‐70. NCT04310969. Clinical effect of MiboFlo in dry eye patients. clinicaltrials.gov/show/NCT04310969 (first received 17 March 2020). ">Li 2022</a> (84 eyes) reported mean change from baseline in meibomian gland atrophy scores to 2 months, with an MD of 0.05 (95% CI −0.01 to 0.11) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants with intervention‐related, vision‐threatening adverse events at 1 to 4 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000 at week 4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000 at week 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>445 participants</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean baseline risk from the studies in the meta‐analysis; the total number of events in the control group divided by the total number of participants in the control groups, scaled to 1000. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IDEEL‐SB:</b> Impact of Dry Eye on Everyday Life—Symptom Bother; <b>MD:</b> mean difference; <b>OSDI:</b> Ocular Surface Disease Index; <b>RCT:</b> randomized controlled trial; <b>SANDE:</b> Symptom Assessment iN Dry Eye; <b>SMD</b>: standardized mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for inconsistency (−1)<br/><sup>b</sup>Downgraded for risk of bias (−1)<br/><sup>c</sup>Downgraded for high risk of bias (−2)<br/><sup>d</sup>Downgraded for imprecision (−1)<br/><sup>e</sup>Downgraded for very serious imprecision (−2) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">LipiFlow compared with thermostatic devices</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/full#CD015448-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015448-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">LipiFlow versus basic warm compresses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Mean change from baseline in symptom scores at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 OSDI; participant‐level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.62 [‐29.41, ‐3.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 OSDI; eye‐level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.43 [‐2.39, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 SPEED; participant‐level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.12 [‐4.09, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 SPEED; eye‐level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.21, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Mean change from baseline in symptom scores at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Mean change from baseline in meibomian gland expression scores at 4 weeks—SMD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Participant‐level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [‐0.21, 2.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Eye‐level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [‐0.08, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Mean change from baseline in meibum quality scores at 4 weeks—SMD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Participant‐level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Eye‐level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Mean change from baseline in meibomian gland atrophy at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Mean change from baseline in tear film breakup time at 4 weeks—SMD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Participant‐level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [‐0.36, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Eye‐level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐2.67, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Mean change from baseline in non‐invasive tear film breakup time at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">LipiFlow versus basic warm compresses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015448-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">LipiFlow versus thermostatic device</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Mean change from baseline in symptom scores at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 OSDI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.59 [1.23, 7.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 SANDE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.22 [‐6.97, 4.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 IDEEL‐SB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.32, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Mean change from baseline in symptom scores at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Mean change from baseline in meibomian gland expression scores at 4 weeks—SMD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.16, 0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Mean change from baseline in meibum quality scores at 4 weeks—SMD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.20, 0.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Mean change from baseline in meibomian gland atrophy at 2 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Mean change from baseline in tear film breakup time at 4 weeks—SMD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.24, 0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Mean change from baseline in non‐invasive tear film breakup time at 4 weeks—SMD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.62, 0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">LipiFlow versus thermostatic device</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015448-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">LipiFlow + eyelid hygiene versus eyelid hygiene product alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Mean change from baseline in symptom scores at 1 week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Mean change from baseline in symptom scores at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Mean change from baseline in meibomian gland expression scores at 1 week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">LipiFlow + eyelid hygiene versus eyelid hygiene product alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015448-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">LipiFlow versus topical DED medication</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Mean change from baseline in symptom scores at 42 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Mean change from baseline in meibomian gland expression scores at 42 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Mean change from baseline in meibum quality scores at 42 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">LipiFlow versus topical DED medication</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015448-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">LipiFlow versus oral interventions</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Mean change from baseline in symptom scores at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Mean change from baseline in meibomian gland expression scores at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Mean change from baseline in tear film breakup time at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">LipiFlow versus oral interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#CD015448-tbl-0007">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-1"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 Mean change from baseline in symptom scores at 4 weeks</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.1.1 OSDI; participant‐level</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Baumann 2014</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-high col2" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The only information about randomization methods is a statement that the study is randomized. "In our study, the two groups of the study are not homogeneous at the base although randomized. Before any treatment, the impairment was more severe in the LipiFlow group". </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and personnel could not be masked due to the nature of interventions. It was not reported if the analysis was followed by intention‐to‐treat, but all randomized participants were included in the analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There were no missing outcome data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>OSDI score and SPEED scores were used to measure the subjective symptoms.<br/>Patient‐reported outcome (symptom scores) could be influenced by the knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No statistical analysis plan and protocol are publicly available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was judged as high risk in randomization process as well as some concerns in outcome measurement and selective outcome reporting. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.1.2 OSDI; eye‐level</b> </p> </td> </tr> <tr class="study-data"> <td> <p>He 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Details not reported but stated that participants were randomly assigned. Comparison results were not reported but based on post‐hoc t‐test on mean age, there were no differences between group. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and personnel could not be masked due to the nature of interventions. No deviation was reported, but there was no evidence of such possibility. The authors used available (complete) case analysis to estimate the effect of assignment to intervention. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were only available for 84% and 92% of the participants randomized, but there is no evidence that the result was biased by the missing outcome data. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>OSDI questionnaire has been validated and routinely used in the clinical setting. Patient‐reported outcome (symptom scores) could be influenced by the knowledge of intervention received. Due to the open‐label nature of the trials, patients known about the other treamtents. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No study protocol or analytic plan available for assessment. However, the trial randomized individual participants but analyzed and reported results for eyes. It was unclear if the authors accounted for non‐independence of the eye level data in the analysis. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was judged as high risk in outcome measurement as well as some concerns in randomization process and selective outcome reporting. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.1.3 SPEED; participant‐level</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Baumann 2014</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-high col2" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The only information about randomization methods is a statement that the study is randomized. "In our study, the two groups of the study are not homogeneous at the base although randomized. Before any treatment, the impairment was more severe in the LipiFlow group". </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and personnel could not be masked due to the nature of interventions. It was not reported if the analysis was followed by intention‐to‐treat, but all randomized participants were included in the analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There were no missing outcome data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>OSDI score and SPEED scores were used to measure the subjective symptoms.<br/>Patient‐reported outcome (symptom scores) could be influenced by the knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No statistical analysis plan and protocol are publicly available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was judged as high risk in randomization process as well as some concerns in outcome measurement and selective outcome reporting. </p> </td> </tr> <tr class="study-data"> <td> <p>Mencucci 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The only information about randomization methods is a statement that the study is randomized. "All the baseline characteristics were comparable between groups, without any significant difference". </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and personnel could not be masked due to the nature of interventions. It was not reported if the analysis was followed by intention‐to‐treat, but all randomized participants were included in the analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There were no missing outcome data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>SPEED scores were used to measure the subjective symptoms. Patient‐reported outcome (symptom scores) could be influenced by the knowledge of intervention received. Due to the nature of the trial design, patients were aware of the treatment being administered to the other group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No statistical analysis plan and protocol are publicly available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was judged as high risk in outcome measurement as well as some concerns in randomization process, and selective outcome reporting. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.1.4 SPEED; eye‐level</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Booranapong 2019</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The only information about randomization methods is a statement that the study is randomized. Baseline characteristic were compatible between two groups (Table 1, 2, 3). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and personnel could not be masked due to the nature of interventions. It was not reported if the analysis was followed by intention‐to‐treat, but randomized participants were included in the analysis excepted participants with missing outcome data. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Symptom scores was available for 28 (84.8%) out of 33 randomized participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>SPEED scores were used to measure the subjective symptoms. Patient‐reported outcome (symptom scores) could be influenced by the knowledge of intervention received. Patient received different treatments in both eyes. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No statistical analysis plan and protocol are publicly available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was judged as high risk in outcome measurement as well as some concerns in randomization process, missing outcomes, and selective outcome reporting. </p> </td> </tr> <tr class="study-data"> <td> <p>Meng 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>"Fifty participants who met the criteria at the Tianjin Medical University Eye Hospital were recruited and randomized into single LipiFlow treatment group (n = 50 eyes) and warm compress treatment group (n = 50 eyes) using a randomized digital table by the randomization manager." "Parameters of baseline evaluation were comparable between two groups (Table 1)." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and personnel could not be masked due to the nature of interventions. It was not reported if the analysis was followed by intention‐to‐treat, but all randomized participants were included in the analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There were no missing outcome data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>SPEED score was used to measure the subjective symptoms. Patient‐reported outcome (symptom scores) could be influenced by the knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No statistical analysis plan and protocol are publicly available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was judged as some concern in outcome measurement, randomization process, and selective outcome reporting. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 Mean change from baseline in symptom scores at 4 weeks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#riskOfBias2Table-1">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-2"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.1 Mean change from baseline in symptom scores at 4 weeks</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.1.1 OSDI</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Gupta 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The only information about randomization methods is a statement that the study is randomized. "The demographics' data of all study subjects were similar between the treatment groups (Table 1)." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and personnel could not be masked due to the nature of interventions. This is a 'per‐protocol' analysis; used both eyes in the analysis, but used random‐effects model. Participants did not attend follow‐up section were excluded, but no evidence showed there were substantial impact on the result between two groups. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Symptom scores was available for 135 (96%) out of 141 randomized participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>OSDI score and SANDE scores were used to measure the subjective symptoms. Patient‐reported outcome (symptom scores) could be influenced by the knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The primary analysis population was the per‐protocol (PP) population that included all subjects who completed the study and had no major protocol deviations, specifically related to use of dry eye medications such as Restasis and Xiidra, medications interfering with the ocular surface, or other medications interfering with outcome measures. The secondary effectiveness outcomes for the PP population were measured on either a per‐eye basis (corneal staining, conjunctival staining, and meibomian gland scores) or per‐subject basis (OSDI score, SANDE scores, and EDS), as appropriate. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was judged as some concerns in randomization process, outcome measurement and deviation from the intervention. </p> </td> </tr> <tr class="study-data"> <td> <p>Holland 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The only information about randomization methods is a statement that the study is randomized. "There were no distinguished differences between the study groups as well as the subgroups stratified by MGSS (Table 1)." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and personnel could not be masked due to the nature of interventions. It didn't mention if they use ITT effect or PP effect. Also, they didn't clearly mention how many participants they have randomized. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Study does not state how many were discontinued. The enrollment number does not appear consistent with clinicaltrials.gov. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>OSDI score and SANDE scores were used to measure the subjective symptoms. Patient‐reported outcome (symptom scores) could be influenced by the knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No statistical analysis plan and protocol are publicly available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was judged as high risk in missing outcome and outcome measurement as well as some concerns in randomization process, deviations from the intervention, and selective results reporting. </p> </td> </tr> <tr class="study-data"> <td> <p>Li 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>"The subjects were randomized 1:1 to the MiBoFlo treatment group (54 eyes) and LipiFlow treatment group (54 eyes) using a randomized digital table by the randomization manager." "No significant difference was found at baseline levels of OSDI score, MGYLS score, CFS score, NIKBUT, TMH, and area of MG loss in both groups." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and personnel could not be masked due to the nature of interventions. It was not reported if the analysis was followed by intention‐to‐treat, but randomized participants were included in the analysis excepted participants with appropriate missing outcome data. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Total 12 subjects (16%) were excluded but didn't provide clear exclusion reason. "In the end, there were 22 subjects in the MiBoFlo group who completed the final follow‐up and 20 subjects in the LipiFlow group in total." </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>OSDI score was used to measure the subjective symptoms. Patient‐reported outcome (symptom scores) could be influenced by the knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No statistical analysis plan and protocol are publicly available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was judged as some concerns risk of bias in randomization process, missing outcomes, outcome measurement and selective results reporting. </p> </td> </tr> <tr class="study-data"> <td> <p>Tauber 2020b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>"Sequentially numbered envelopes containing the assigned treatment procedure were provided to each site. Before treatment, the personnel assigned to perform the treatment opened the lowest numbered envelope." There were no distinguished differences between the study groups (baseline comparison from Table 1 and 2). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and personnel could not be masked due to the nature of interventions. It was not reported if the analysis was followed by intention‐to‐treat, but "one subject in the LipiFlow treatment arm had one eye that could not be treated because the device’s activator was too large to fit the subject’s eye" the patients didn't get treated, should be appropriate to be excluded; "one subject in the iLUX treatment arm withdrew from the study 1 week after treatment due to resumption of contact lens wear during the study period", post‐randomization exclusions of ineligible participants was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Symptom scores was available for 141(99%) out of 142 randomized participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>OSDI score was used to measure the subjective symptoms.Patient‐reported outcome (symptom scores) could be influenced by the knowledge of intervention received. Due to the nature of the trial design, patients were aware of the treatment being administered to the other group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial protocol and statistical analysis plan are available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was judged as high risk in outcome measurement.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.1.2 SANDE</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Gupta 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The only information about randomization methods is a statement that the study is randomized. "The demographics' data of all study subjects were similar between the treatment groups (Table 1)." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and personnel could not be masked due to the nature of interventions. This is a 'per‐protocol' analysis; used both eyes in the analysis, but used random‐effects model. Participants did not attend follow‐up section were excluded, but no evidence showed there were substantial impact on the result between two groups. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Symptom scores was available for 135 (96%) out of 141 randomized participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>OSDI score and SANDE scores were used to measure the subjective symptoms. Patient‐reported outcome (symptom scores) could be influenced by the knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The primary analysis population was the per‐protocol (PP) population that included all subjects who completed the study and had no major protocol deviations, specifically related to use of dry eye medications such as Restasis and Xiidra, medications interfering with the ocular surface, or other medications interfering with outcome measures. The secondary effectiveness outcomes for the PP population were measured on either a per‐eye basis (corneal staining, conjunctival staining, and meibomian gland scores) or per‐subject basis (OSDI score, SANDE scores, and EDS), as appropriate. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was judged as some concerns in randomization process, outcome measurement and deviation from the intervention. </p> </td> </tr> <tr class="study-data"> <td> <p>Holland 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The only information about randomization methods is a statement that the study is randomized. "There were no distinguished differences between the study groups as well as the subgroups stratified by MGSS (Table 1)." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and personnel could not be masked due to the nature of interventions. It didn't mention if they use ITT effect or PP effect. Also, they didn't clearly mention how many participants they have randomized. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Study does not state how many were discontinued. The enrollment number does not appear consistent with clinicaltrials.gov. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>OSDI score and SANDE scores were used to measure the subjective symptoms. Patient‐reported outcome (symptom scores) could be influenced by the knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No statistical analysis plan and protocol are publicly available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was judged as high risk in missing outcome and outcome measurement as well as some concerns in randomization process, deviations from the intervention, and selective results reporting. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.1.3 IDEEL‐SB</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Wesley 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The only information about randomization methods is a statement that the study is randomized. "No substantial difference was observed in baseline values for the clinical characteristics between the two treatment groups (Table 1)." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and personnel could not be masked due to the nature of interventions. It was not reported if the analysis was followed by intention‐to‐treat, but it mentioned, "a mixed‐effects repeated measures model was used to test non‐inferiority for the change from baseline for each of the primary and key exploratory end points." </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Symptoms score was available for 227 (96%) out of 236 participants, 8 were withdrawn or discontinued, and 1 was lost to follow‐up. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>IDEEL‐SB scores were used to measure the subjective symptoms.Patient‐reported outcome (symptom scores) could be influenced by the knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Trial protocol and statistical analysis plan are available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was judged as some concern in randomization process and outcome measurement.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.1 Mean change from baseline in symptom scores at 4 weeks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#riskOfBias2Table-2">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-3"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.1 Mean change from baseline in symptom scores at 1 week</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Kasetsuwan 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>After informed consent was obtained and baseline data were collected, patients were allocated to either the study group or the control group by block randomization, concealed to the investigator in an envelope. "Baseline characteristic were compatible between two groups (Table 1)." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and personnel could not be masked due to the nature of interventions. It was not reported if the analysis was followed by intention‐to‐treat, but randomized participants were included in the analysis excepted participants with appropriate missing outcome data. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The missing 12 patients (20%) were withdrawn from the study due to inconvenience or health problems unrelated to the ocular disease. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>OSDI score was used to measure the subjective symptoms. Patient‐reported outcome (symptom scores) could be influenced by the knowledge of intervention received. Due to the nature of the trial design, patients were aware of the treatment being administered to the other group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No statistical analysis plan and protocol are publicly available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was judged as high risk in outcome measurement as well as some concerns in missing outcomes and selective results reporting. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.1 Mean change from baseline in symptom scores at 1 week</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#riskOfBias2Table-3">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-4"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.1 Mean change from baseline in symptom scores at 42 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Tauber 2020a</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>"Patients were randomized using a computer‐generated randomization schedule to receive lifitegrast ophthalmic solution 5% (Xiidra; Shire, Lexington, MA) twice daily for 42 days or one treatment at day 0 with TPP (LipiFlow; Johnson &amp; Johnson Vision/TearScience, Morrisville, NC)." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and personnel could not be masked due to the nature of interventions.It was not reported if the analysis was followed by intention‐to‐treat, but randomized participants were included in the analysis excepted participants with appropriate missing outcome data. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Symptom scores was available for 47 (94%) out of 50 randomized participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>VAS were used to measure the subjective symptoms. Patient‐reported outcome (symptom scores) could be influenced by the knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No statistical analysis plan and protocol are publicly available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was judged as some concern risk of bias in randomization process, outcome measurement and selective results reporting. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.1 Mean change from baseline in symptom scores at 42 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#riskOfBias2Table-4">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-5"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.1 Mean change from baseline in symptom scores at 3 months</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Hagen 2018</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The only information about randomization methods is a statement that the study is randomized. "Table 1 shows baseline data which is comparable between groups." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and personnel could not be masked due to the nature of interventions. It was not reported if the analysis was followed by intention‐to‐treat, but randomized participants were included in the analysis excepted participants with appropriate missing outcome data. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Symptom scores was available for 25 (89%) out of 28 randomized participants. But one outlier was removed from the analysis of SPEED score in the Lipiflow treatment group. Reported reasons for missing outcome data differ between the intervention groups. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>SPEED scores were used to measure the subjective symptoms. Patient‐reported outcome (symptom scores) could be influenced by the knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No statistical analysis plan and protocol are publicly available.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial was judged as high risk in missing outcome and as well as some concerns in randomization process, outcome measurement, and selective results reporting. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.1 Mean change from baseline in symptom scores at 3 months</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015448.pub2/references#riskOfBias2Table-5">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD015448.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD015448-note-0008">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD015448-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD015448-note-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD015448-note-0013">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD015448-note-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD015448-note-0010">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD015448-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD015448-note-0019">Polski</a> </li> <li class="section-language"> <a class="" href="ro#CD015448-note-0020">Română</a> </li> <li class="section-language"> <a class="" href="ru#CD015448-note-0009">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD015448-note-0017">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD015448-note-0015">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD015448-note-0016">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015448\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015448\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015448\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015448\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015448\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015448\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015448\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015448\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015448\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015448\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015448\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015448\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015448\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015448\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015448\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015448\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015448\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015448\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=EBp84H4P&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015448.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015448.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD015448.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD015448.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015448.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728744155"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015448.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728744159"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015448.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ecbf3ed05f56f',t:'MTc0MDcyODc0NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 